NATURAL PRODUCTS AS BUILDING BLOCKS AND LEAD COMPOUNDS FOR API PRODUCTION by C. Marucci
 Doctorate School in Chemical Science - XXIX Cycle 
 
 
 
Natural products as building blocks and lead 
compounds for API production 
 
 
PhD Thesis of 
Cristina MARUCCI 
R10607 
 
 
 
Tutor: Prof. Daniele Passarella 
Cotutor: Dott. Marcello Luzzani 
 
Academic Year: 2015/2016
 
  
 
 
 
 
Ai miei genitori 
  
 
 
  
 
 
Summary 
1. Natural products in drug discovery ................................................................... 10 
1.1. Role of nature in drug discovery ................................................................... 11 
2. Natural products as building blocks for production of API ............................ 17 
2.1. Industrial synthesis of vincamine .................................................................. 18 
2.1.1. Introduction ........................................................................................... 18 
2.1.2. Biosynthesis ........................................................................................... 21 
2.1.3. Total synthesis of vincamine ................................................................. 23 
2.1.4. Synthesis of vincamine with tabersonine as starting material ............... 28 
2.1.5. Impurities derived from the synthesis of vincamine .............................. 35 
2.2. Design of experiment (DOE) ......................................................................... 37 
2.2.1. Full factorial design ............................................................................... 40 
2.2.2. Reactivity of 3-oxo-tabersonine and 3-oxo-vincadifformine ................ 46 
2.3. Lignans .......................................................................................................... 50 
2.3.1. Introduction ........................................................................................... 50 
2.4. Lignans derivatives ........................................................................................ 55 
2.4.1. Synthesis of oxomatairesinol ................................................................. 55 
2.4.2. Synthesis of (-)-7(R)-HMR .................................................................... 58 
2.5. Experimental part .......................................................................................... 65 
2.5.1. General information ............................................................................... 65 
3. Isolation and structural characterization of natural products ........................ 77 
3.1. Indole alkaloids from Vocanga africana ....................................................... 78 
3.1.1. Voacanga africana ................................................................................ 78 
3.1.2. Isolation and structure elucidation of Voacanga alkaloids .................... 80 
 
 
3.2. (-)-Cytisine: natural sources .......................................................................... 87 
3.2.1. Introduction ........................................................................................... 87 
3.2.2. Biosynthesis ........................................................................................... 91 
3.2.3. Total synthesis of the lupin alkaloid cytisine ........................................ 93 
3.2.4. (-)-Cytisine derivatives: synthesis of N-formyl and N-methyl derivatives
 96 
3.3. Experimental part ........................................................................................ 101 
3.3.1. General information ............................................................................. 101 
4. Natural products as lead compounds ............................................................... 112 
4.1. Synthesis of an analogue of the natural product doliculide ......................... 113 
4.1.1. Introduction ......................................................................................... 113 
4.1.2. Aim of the project and retrosynthetic plan .......................................... 115 
4.2. Result and discussion................................................................................... 117 
4.2.1. Synthesis of dipeptide .......................................................................... 117 
4.2.2. Synthesis of secondary alcohol fragment ............................................ 119 
4.2.3. Fragment coupling and completation of the synthesis......................... 122 
4.3. Pironetin-dumetorine hybrid compounds .................................................... 124 
4.3.1. Introduction ......................................................................................... 124 
4.3.2. Docking studies of pironetin ................................................................ 128 
4.3.3. Aim of the project and retrosynthetic plan .......................................... 129 
4.3.4. Hybrid compounds docking ................................................................. 131 
4.4. Result and discussion................................................................................... 132 
4.4.1. Synthesis of hybrid compounds ........................................................... 132 
4.4.2. Biological evaluation ........................................................................... 136 
 
 
4.5. Bivalent compounds toward -tubulin interaction ................................... 137 
4.5.1. Introduction ......................................................................................... 137 
4.5.2. Aim of the work ................................................................................... 139 
4.5.3. Synthetic strategy ................................................................................ 141 
4.5.4. Biological evaluation and future work ................................................ 143 
4.6. Experimental part ........................................................................................ 144 
4.6.1. General information ............................................................................. 144 
4.6.2. Doliculide fragments synthesis ............................................................ 145 
4.6.3. Pironetin-dumetorine hybrid compounds ............................................ 155 
4.6.4. Bivalent compounds ............................................................................ 173 
4.7. Biological assay ........................................................................................... 176 
4.8. Docking Studies ........................................................................................... 177 
5. Natural products and cancer stem cells ........................................................... 178 
6. Conclusions ........................................................................................................ 198 
7. Acknowledgments .............................................................................................. 199 
 
 
 
 
 
8 
 
Abstract 
This dissertetion describes the relevance of natural products as building blocks for 
production of active pharmaceutical ingredients (API) and as lead compounds.  
Chapter 1 offers an introduction on the use of natural products as an effective therapeutic 
and its role on inspiring the discovery of new drugs. 
Chapter 2 focuses on the importance of natural products as lead compounds for active 
pharmaceutical ingredients (API) production. In the first part of this chapter the synthesis 
of vincamine, the major indole alkaloid presents in Vinca minor L., will be discussed. In 
particular the design of experiment (DOE) applied to the synthesis of vincamine starting 
from vincadifformine will be described. In the second part of this chapter the semi-
synthesis of two lignan derivatives, oxomatairesinol and (-)-7-(R)-hydroxymatairesinol, 
will be reported.  
Chapter 3 will focus on the isolation and structural characterization of natural products. 
The first part describes the isolation and structural characterization of ten indole 
alkaloids from Voacanga africana (Apocynaceae) seeds. Then the semisynthesis of two 
cytisine derivatives, N-formyl and N-methyl cytisine, will be described. 
Chapter 4 describes the role of natural products as lead compounds. The first section 
illustrate a project that was performed in the laboratory of Prof. Karl-Heinz Altmann 
(ETH-Zurich, Switzerland) in the frame of COST Action CM1407 (Challenging Organic 
Synthesis Inspired By Nature: From Natural Product Chemistry To Drug Discovery). It 
is related to the synthesis of an analogue of the natural product doliculide, a 16-
membered depsipeptide, that has been isolated in 1994 from the Japanese sea hare 
Dolabella auricularia. The second section will focus on the design and synthesis of 
hybrid compounds. Particularly it will describe the synthesis of pironetin-dumetorine 
hybrid compounds whose structures are representative of an optimizable lead scaffold 
for the discovery of new tubulin binders. Another topic here discussed will be the 
production of bivalent compounds linking two different units, a pironetin-dumetorine 
hybrid compound and a drug able to bind -tubulin, in order to have a duble action with 
the aim to limit the the protein-protein interaction between  and -tubulin.  
9 
 
Chapter 5 offers an overview on the role of natural products in drug discovery, in 
particular related to cancer stem cells (CSCs). In a recent review we summarized the 
natural products that demonstrate activity against CSCs. Forty-nine different natural 
products grouped into several structural classes (such as flavonoids, polyketides, 
terpenes, alkaloids and many others) will be described. Their structure diversity could 
suggest the synthesis of libraries of new compounds for a huge exploration of the 
chemical space of CSCs inhibitors. 
 
 
1. Natural products in drug discovery  
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1.1. Role of nature in drug discovery  
Nature is continually providing interesting inspirations for the discovery, design and 
synthesis of novel drugs.1 In fact, it offers a tremendous variety of small molecules that 
possess fascinating structure and potent medicinal properties. The biological origin of 
these small molecules is as diverse as their chemical composition (Figure 1). 
 
Figure 1: Examples of natural product sources 
The term natural products refers to: (a) pure bioactive compounds (alkaloids, lignans, 
flavonoids, sugars, etc.) isolated from plants, microorganisms or animals; (b) an entire 
organism, for example plant or microorganism, that has not been submitted to any kind 
of treatment or processing except a simple process of preservation, such as drying; (c) 
an extract of an organism or part of an organism; (d) part of an organism (leaves or seeds 
of a plant).  
The importance of natural products in the treatment of different human diseases is well 
documented. This is a demonstration of the continuing and valuable contributions of 
nature as a source not only of potential therapeutic agents but also of lead compounds 
that inspire the semisynthesis or total synthesis of effective new drugs.  
                                                          
1 (a) Martin, M. E. Org. Biomol.Chem. 2015, 13, 5302–5343; (b) Cordier, C.; Morton, D.; Murrison, 
S.;Nelson, A.; O'Leary-Steele, C. Nat. Prod.Rep. 2008, 25, 719–737; (c) Grabowski, K.; Baringhaus,K.-H.; 
Schneider, G. Nat. Prod. Rep. 2008, 25, 892–904; (d) Vasilevich, N. I.; Kombarov, R. V.; Genis, D. V.; 
Kirpichenok, M. A. J. Med. Chem. 2012, 55, 7003–7009. 
Plant sources
• Paclitaxel
Animal sources  
• Epibatidine 
Marine sources
• Phorboxazole 
Bacterial sources
• Cephalosporins 
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In a recent review, Cragg et al.2 reported an extensively analysis of the role of natural 
products in the drug discovery and development process, covered the period from 1981 
to 2014. In this paper, the drugs were classified as N (natural product); NB (natural 
product “botanical drug”); ND (a modified natural product); S (totally synthetic drug); 
S* (a synthetic compound with a natural product pharmacophore); S*/NM (a synthetic 
compound with a natural product pharmacophore showing competitive inhibition of the 
natural product substrate); V (vaccine); and S/NM (a synthetic compound showing 
competitive inhibition of the natural product substrate). 
They reported that for example, in the area of cancer, the 13% of the 174 anticancer 
drugs approved or in clinical trials from 1981 to 2014 are classifiable into the “S” 
category (totally synthetic drug), while the 38.22% of the anticancer drugs  are derived 
from a natural product using generally a semisynthetic modification (Figure 2). 
 
Figure 2: All anticancer drugs covering the years 1981-2014 
In 2012 the Food and Drug Administration (FDA) approved two plant-derived agents, 
omacetaxine mepesuccinate, formerly named as homoharringtonine or HHT, for the 
treatment of chronic myeloid leukemia, and ingenol mebutate, named also Picato, for 
the topical treatment of  actinic keratosis, a precancerous condition, that if untreated may 
turn into a type of cancer called squamous cell carcinoma (Figure 3). As natural products 
derivatives (“ND” category), abiraterone was approved in 2011 under the trade names 
Zytiga, Abiratas, Abretone, Abirapro, together with Adcetris, a dolastatin 10 derivative, 
which was approved in the same year. In 2012, the aminolevulinic acid hydroclochloride 
                                                          
2 Newman, D.J.; Cragg, G. M.  J. Nat. Prod. 2016, 79, 629−661. 
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Ameluz was approved for photodynamic therapy and in the same year was also approved 
carfilzomib under the trade name Kyprolis, for use in patients with multiple myeloma 
(Figure 3). 
 
 
 
Figure 3: Novel drugs inspired by natural products 
In other areas, the influence of natural product structures is quite marked, wit the anti-
infective area being dependent on natural products and their structures. 
Concerning the new drugs approved by FDA from 1981 until 2014, the 27% of the drugs 
are totally synthetic compounds, while the 21% of the drugs are natural products 
analogues (Figure 4).  
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Figure 4: All new drugs from 1981 till 2014 
In addition in this review it is possible to find a list of antibacterial, antifungal, antiviral, 
anticancer and antidiabetic drugs (filled up to 2014) arising from natural sources, 
illustrating in this way the continuing contribution of natural products to the expansion 
of the chemotherapeutic space. 
Metabolomics and metagenomics are useful tools to indentify new classes of natural 
products. 
The term metabolomics refers to the qualitative and quantitative analysis of all 
metabolites contained in an organism under a given set of conditions and at a specific 
time.3 This stategy provides indirect monitoring of the biochemical and genetic status of 
an organism by examining its biochemical profile. A combination of metabolomics and 
genomics can be used to optimize a biosynthetic pathway to selectively produce 
biologically active secondary metabolites. 
While metabolite analysis has been conducted for decades, recent improvements in 
metabolomics technologies reveal the unequivocal role of metabolomics tools in gene-
function systems biology, analysis and diagnostic platforms.  
Metabolomic may have diverse applications. For example, it could be used during the 
isolation, purification and structural elucidation of bioactive secondary metabolites for 
identifying the fractions for further purification, leading to save time and resources in 
isolating the target compounds. 
                                                          
3 Hur, M.; Campbell, A. A.; Almeida-de-Macedo, M.; Li, L.; Ransom, N.; Jose, A.; Crispin, M.; Nikolau, 
B.J.; Wurtele, E.S. Nat. Prod. Rep. 2013, 30, 565–583. 
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Metabolomics can also be applied to recognize and sustain the production of interesting 
secondary metabolites during cultivation and production processes, and to optimize 
fermentation, thus assisting in improving the biosynthesis of desired products. 
Along with the OSMaC (one strain, many compounds, an approach to activate metabolic 
pathways that can be combined with genomics scanning) approach, metabolomics can 
be used to explore and statistically validate relationships between culture methods, diver-
sity, bioactivity and metabolome evolution in a microbial isolate. 
Continued advancements in metabolomic technologies will give additional 
improvements in the utility of metabolomics tools as applied toward both medical and 
scientific research. With advanced spectroscopic and mass analysis, rapid accurate 
metabolite profiles will continue to enhance metabolomics data repositories and lead to 
new drug therapies, more effective diagnostics and improved disease prognosis. 
Genomics and metagenomics are also interesting tools in the target-directed search of 
new bioactive secondary metabolites and microorganisms from different geographical 
areas.4 Metagenomics approaches have now become important tools for defining, 
elucidating, and controlling biosynthetic pathways. The aim of these approaches is to 
develop an efficient heterologous gene expression platform that will facilitate the 
production of particular target secondary metabolites or various new natural product. 
An example of the usefulness of this approach is related to the epothilones, naturally 
occurring polyketide macrolides originally isolated from Sorangium cellulosum. They 
posses anticancer activity and are able to act as microtubule disruptors, similarly to 
taxanes. Several epothilone analogues (Figure 5) are currently undergoing clinical trials: 
patupilone (also named as EPO-906 or epothilone B) has been through Phase III trials in 
the United States, and Phase III trials are ongoing in Spain, United Kingdom and Greece 
for the treatment of ovarian cancer.  
Ixabepilone (Ixempra; Bristol-Myers Squibb), an analogue of epothilone B, has been 
approved by the FDA in 2007 for the treatment of breast cancer.5 The biosynthetic gene 
                                                          
4 Wilson, M. C.; Piel, J. Chem. Biol. 2013, 20, 636–647. 
5 Alvarez, R. H.; Valero, V.; Hortobagyi, G. N. Ann. Med. 2011, 43, 477–486. 
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clusters of epothilones have been extensively studied.6 Recently, a 56-kb epothilone 
biosynthetic gene cluster was reassembled using unique restriction sites (which allowed 
for future module interchangeability) in the guanine- and cytosine-rich host Myxococcus 
xanthus. 
 
Figure 5: Epothilone B and Ixabepilone structures 
To increase production yield, and to efficiently derivatize a variety of analogues with 
improved bioactivity, the epothilone biosynthetic gene cluster from Sorangium 
cellulosum was redesigned and reassembled for expression in Myxococcus xanthus.7 
Although natural products have been extensively used in traditional medicine, there are 
still many resources that need to be investigated in modern natural-product research. 
In addition, microorganisms demonstrate a large biodiversity that exceedes those of 
eukaryotes, and can have exceptional metabolic adaptability. Nevertheless, less than 1% 
of this huge biodiversity has been investigated, mainly due to non-cultivability in the 
laboratory. Using metagenomic and heterologous-expression techniques, we can 
increase the diverse microbial community and so potentially, we can have the advantage 
to access to a source of novel bioactive compounds. 
 
 
                                                          
6  Molnar, I.; Schupp, T.; Ono, M.; Zirkle, R. E.; Milnamow, M.; Nowak-Thompson, B.; Engel, N.; Toupet, 
C.; Stratmann, A.; Cyr, D. D.; Gorlach, J.; Mayo, J. M.; Hu, A.; Goff, S.; Schmid, J.; Ligon, J. M. Chem. 
Biol. 2000, 7, 97–109. 
7 Osswald, C.; Zipf, G.;  Schmidt, G.; Maier, J.;  Bernauer, HS.; Müller, R.; Wenzel, SC. ACS Synth. Biol. 
2012, 3, 759–772. 
2. Natural products as building blocks for production of API 
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2.1. Industrial synthesis of vincamine  
2.1.1. Introduction  
The genus Vinca (Apocynaceae), also referred as Lochnera, Pervinca, Catharanthus and 
Ammocallis, is distributed in Europe, Northwest Africa, and South-west Asia. The most 
important species are Vinca major L. and Vinca minor L. (Figure 
6). Vinca minor was first investigated by Lucas in 1859, but the 
first Vinca alkaloids whose structure became known, were 
reserpine, sarpagine and akuammine, which had previously been 
isolated from Rauvolfia and Catharanthus species. After the 
isolation of reserpine many research groups examined 
apocynaceaous plants in order to find new alkaloids and now 
over 90 Vinca alkaloids are known.  
The Apocynaceae plant family includes a great number of so-
called eburnamine–vincamine alkaloids. The same 
foundamental C9-C10 unit characterizes this family of alkaloids. Variation of this unit, in 
combination with tryptamine, formally elaborate the three significantly different groups of 
complex indole alkaloids: Coryananthe, Iboga and Aspidosperma (Figure 7). With three 
exception (vincoridine, vincamidine and pleiocarpiamine chloride), all of the other Vinca 
minor alkaloids contain the carbon skeleton type II and III in Figure 7. 
 
Figure 7: Terpenoid skeleton of Vinca alkaloids 
Very different are the Vinca major alkaloids, where the majority of compounds derive from 
“unrearranged” ten-carbon units (structure I in Figure 7), such as ajmaline and sarpagine 
Figure 6: Vinca minor L. 
Natural products as building blocks for production of API 
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alkaloids type. The Vinca major alkaloids, which contain a rearranged non-tryptophan unit 
(structure II and III in Figure 7), are represented by vincamine, vincadifformine and vincine. 
Pharmacological investigation on Vinca alkaloids and their derivatives, such as vincristine, 
vinorelbine, vinblastine and vindesine, mainly regard their anticancer properties. 
Among Vinca alkaloids, vincamine (Figure 8) is the most frequently observed alkaloids in 
this genus plants. It was first isolated from Vinca minor L. (Apocyanaceae) by Zabolotnaya8 
and independently by Schilitter and Furlenmeyer.9 However, only in 1961 its structure was 
elucidated by Trojanek.10 
Vincamine, a monoterpenoid indole alkaloid, is an attractive synthetic 
target, because it showed to be pharmacologically active in both 
cardiovascular and central nervous system. Nevertheless, its activity 
is mainly on the vessels of the brain. By increasing the cerebral blood 
flow vincamine is able to improve the metabolism of essential 
nutrients and oxygen utilization in the brain. The above properties make vincamine of 
particular interest for the treatment of some important neurodegenerative conditions such as 
Parkinson’s and Alzheimer diseases.11 
Vincamine is sold as drug in Europe under the trade name Oxybral SR, for the treatment of 
primary degenerative and vascular dementia, while in US it is sold as “smart drug” or 
nootropics to support cerebral metabolism and cognitive function and to improve memory 
and concentration. 
Vincamine (98.0%) is commercially available from Sigma-Aldrich and some companies 
supply vincamine (≥ 98.5%) to the pharma industry.  
 
 
 
 
                                                          
8 Zabolotnaya, E.S. Moscow 1950, 10, 29–33. 
9 Schlittler, E.; Furlenmeier, R. Helv. Chim. Acta 1953, 36, 2017.  
10 Trojànek, J.; Ŝtrouf, O.; Holubeck, J.;Ĉekan, Z. Tetrahedron Lett. 1961, 20, 702–706. 
11 (a) Karpati, E.; Biro K.; Kukorelli, T. Acta Pharma. Hung. 2002, 72, 25-36; (b) Vas, A.; Gulyas, B. 
Med.Res.Rev.2005, 25, 737-757; (c) Vereczkey, L. Drug. Metab. Pharmacokinet. 1985, 10, 89-103. 
Figure 8: Vincamine 
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Chemical identification of vincamine: 
 
CAS registry No. 1617-90-9 
Iupac name 
Methyl(316)-14,15-Dihydro-
14hydroxyeburnaminenine-14-
carboxylate 
 
Other name 
(+)-vincamine; vincamine (6CI,8CI); 
1H-Indolo [3,2,1de] pyrido [3,2,1-
ij][1,5] naphthyridine, eburnamenine-
14-carboxylic acid deriv.; (+)-cis-
Vincamine 
 
Molecular formula C21H26N2O3 
Molecular weight 354.44 g/mol 
Melting point 231.5 °C 
Appearance White crystalline powder 
Specific optical rotation Between +39.0 and +43.5 (dry basis) 
Solubility 
Soluble in chloroform, slightly soluble 
in alcohol, insoluble in water 
Storage 
Sealed container and protected from 
light 
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2.1.2. Biosynthesis 
The eburnamine-vincamine group of alkaloids12 is an interesting family that has received 
considerable attention concerning the biosynthetic pathway. Structural analysis of different 
members shows that these alkaloids may be related biosynthetically to the Aspidosperma 
family.13 
In 1965, Wenkert14 proposed a simple mechanism for the biosynthesis of vincamine E that 
takes into account the implication of the Aspidosperma intermediate A and its rearrangement 
via B, C, and D (Scheme1). 
 
Scheme 1: Biomimetic conversion of vincadifformine into vincamine  
Kutney and co-workers reported an extensively investigation on eburnamine-vincamine 
alkaloids biosynthesis.15 They observed the incorporation of various intermediates, such as 
tryptophan, stemmadenine, tabersonine and secodine, into V. minor L. However, these results 
suggested but did not prove that the eburnamine-vincamine group of alkaloids may be 
derived from the corynantheinoid family via the strychnos and aspidosperma bases as 
outlined in Scheme 1. 
                                                          
12 W. I. Taylor, Alkaloids 1968, 11,125. 
13 A. I. Scott , Accounts Chem. Res.1970, 3, 151. 
14 E. Wenkert and B. Wickberg, J.Amer. Chem. Soc.1965, 87, 1580. 
15 (a) Kutney, J. P.; Ehret, C.; Nelson, V. R.; Wigfield, D. C. J.Amer.Chem.Soc. 1968, 90, 5929; (b) Kutney, J. 
P.; Ehret, C.; Nelson, V. R.; Wigfield, D. C. J. Amer. Chem. Soc. 1971, 93, 255-257. 
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Recently, O’Konnor’s group,16 discovered the cytochrome P450 16T3O (16-
methoxytabersonine 3-oxygenase) which is required for the biosynthesis of vindoline. This 
enzyme catalyzes the formation of epoxide F, which first opens to imine alcohol G and then 
can undergo rearrangement to give the vincamine–eburnamine backbone.The evidence of 
the action of 16T3O in inducing a rearrangement of F to H suggests that a16T3O homolog 
is implicated in the biosynthesis of vincamine and related alkaloids (Scheme 2). Therefore, 
the discovery of this enzyme can be useful in order to elucidate the biosynthetic pathway of 
vincamine starting from tabersonine. 
Scheme 2: Rearrangement of epoxide F to form vincamine type compounds  
                                                          
16 Kellner, F.; Geu-Flores, F.; Sherden,N.H.; Brown,S.; Foureau, E.; Courdavault, V.;O’Connor, S.E. Chem. 
Commun. 2015, 51, 7626-7628. 
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2.1.3. Total synthesis of vincamine 
Several strategies for the synthesis of (+)-vincamine and analogs have been developed17 with 
the aim to find pharmacologically active compounds better characterized and safer to be 
administered as the natural alkaloids occurring in the plants. 
The common aspect in these strategies was to establish first the [ABCD]-type 
octahydroindolo [2, 3 a]-quinolizine ring system (Scheme 3), starting from an indole subunit. 
The final step of the synthesis lead to the creation of the last ring E. As a consequence, 
strategically, the elaboration of vincamine and related alkaloids reduced to four major 
strategies for building up the required gem-disubstituted tetracyclic skeleton 2: the Bischler-
Napieralski cyclization,18 the Michael-type alkylation of the so-called “Wenkert’s 
enamine”,19 the Pictet-Spengler cyclization20 and the annulation reaction of a dihydro--
carboline derivative.21 Moreover, the intermediate 1 is characterized by the presence of two 
controlled stereogenic carbon atom, namely the crucial quaternary center at C-20 and the 
adjacent center at C-21. 
 
Scheme 3: Common synthetic strategies toward the vinca framework 
                                                          
17 (a) Hugel, G.; Lèvy, J. Tethraedron 1984, 40, 1067; (b) Hakam, K.; Thielmann, M.; Thielmann, T.; Winterfeldt, 
E. Tetrahedron 1987, 43, 2035; (c) Gènin, D.; Andriamialisoa, R.Z.; Langlois, N.; Langlois, Y. 
J.Org.Chem.1987, 52, 353; (d) Kaufman, M. D.; Grieco, P.A. J. Org. Chem. 1994, 59,7197; (e) Wenkert, E.; 
Hudlicky, T.; Showalter, H.D. J.Am.Chem. Soc. 1978, 100, 4893; (f) Lavilla, R.; Coll, O.; Bosch, J.; Orozco, M.; 
Luque, F. J. Eur. J. Org. Chem. 2001, 19, 3719-3729. 
18 Herrmann, J. L.; Cregge, R. J.; Richman, J. E.; Semmelhack, C. L.; Schlessinger, R. H. J. Am. Chem. Soc. 
1974, 96, 3702-3703. 
19 (a) Rossey, G.; Wick, A.; Wenkert, E. J. Org. Chem.1982, 47, 4745; (b) Wenkert, E.; Wickberg, B. J. Am. 
Chem. Soc. 1965, 87, 1580; (c) Szabo, L.; Sapi, J.; Kalaus, G.; Argay, G.; Kalman, A.; Baitz-Gacs, E.; Tamas, 
J.; Szantay, C. Tetrahedron 1983, 39, 3737; (d) Nemes, A.; Czibula, L.; Visky, G.; Farkas, M.; Kreidl, J. 
Heterocycles 1991, 32, 2329. 
20 Gmeiner, P.; Feldman, P. L.; Chu- Moyer, M. Y.; Rapoport, H. J. Org. Chem. 1990, 55, 3068-3074. 
21 (a) Oppolzer, W.; Hauth, H.; Pfäffli, P.; Wenger, R. Helv. Chim. Acta 1977, 60, 1801-1809; (b) Genin, D.; 
Andriamialisoa, R. Z.; Langlois, N.; Langlois, Y. J. Org. Chem. 1987, 52, 353-356. 
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Wenkert et al. reported a five-step procedure for the preparation of alkaloid vincamine 
(Scheme 4). The key step involved the introduction of a side chain, 
which then became the functionalized part of the fifth ring of the base, 
by way of the alkylation of an enamine with methyl bromopyruvate 2,4-
dinitrophenylhydrazone 5. Wenkert’s enamine is the key intermediate 
of the synthetic pathway (Figure 9). 
 
Scheme 4: Synthesis of vincamine proposed by Wenkert et al. 
(±)-Vincamine were obtained from reduction of the salt 3 with zinc in acetic acid. Aqueous 
cleavage of the side chain of compound 4 led to salt 3. Intermediate 4 derived from treatment 
of hydrazone 5 with Wenkert’s enamine and trimethylamine in ethyl acetate solution. 2,4-
Dinitrophenylhydrazone 5 was prepared by the interaction of pyruvic acid 2,4-
dinitrophenylhydrazone with thionyl chloride in methanol, followed by bromination of the 
resultant ester. 
In 1997, D’Angelo et al. described the synthesis of vincamine22 starting from tryptamine and 
using as key step the stereocontrolled creation of the quaternary carbon center by using 
asymmetric Michael reaction involving chiral imine/secondary enamines. The synthetic 
strategy is outlined in the retrosintetic pathway in Scheme 5. 
 
                                                          
22 Alves, J.C. F.;  Simas, A. ; Costa, P.; D'Angelo, J. J. Org. Chem. 1997, 62, 3890-3901. 
Figure 9: Wenkert's 
enamine 
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Scheme 5: Asymmetric synthesis of vincamine 
Vincamine was obtained from a known precursor 6, which derived from a base-induced 
cyclization of 7. Wolff-Kishner reduction of the additional keto group of 8, followed by 
Bischler-Napieralski cyclitazion, led to indoquinolizidine derivate 7. 
Finally, the synthesis of precursor 8, involved the asymmetric Michael addition of the chiral 
enaminolactam, obtained from 9 and (S)-1-phenylethylamine, to methyl acrylate.  
In 1975 Oppolzer and co-workers21a illustrated a general methodology for the conversion of 
apovincamine to vincamine using the aldehyde shows in Figure 10, named Oppolzer’s 
aldehyde. This aldehyde has been the key intermediate in many vincamine syntheses. Since 
its discovery, Danieli et al.,23 Govindachari and Rajeswari,24 and 
Langlois et al.25 reported three other approaches. 
Tolvanen and Lounasmaa reported the synthesis of vincamine using 
as key intermediate compound 12 obtained from the Oppolzer’s 
aldehyde 13 (Scheme 6). 
 
                                                          
23 Danieli, B.; Lesma, G.; Palmisano, G. Gazz. Chim. Ital. 1981, 111, 257. 
24 Govindachari, T. R.; Rajeswari, S. Indian J. Chem., Sect. B 1983, 22, 531. 
25 Langlois, Y.; Pouilhẽs, A.; Gẽnin, D.; Andriamialisoa, R. Z.; Langlois, N. Tetrahedron 1983, 39, 3755. 
Figure 10: Oppolzer's 
aldehyde 
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Scheme 6: Retrosynthetic pathway proposed by Tolvanen 
Vincamine was obtained from a treatment of oxolactame 10 with a base in methanol. This 
type of conversion is well documented in literature.26 
Compound 10 derived from a hydrolysis of the intermediate enamine 11, which was obtained 
from a dehydration of lactam 12 using acetic anhydride/DMAP in pyridine at room 
temperature. Finally, the reaction of aldehyde 13 with the LDA enolate of glycine ester 
furnished directly the cyclized product 12. 
The synthetic strategy for the synthesis of vincamine proposed by Schultz and co-workers27 
is based on the conversion of apovincamine 14 into vincamine using the reaction conditions 
reported by Oppolzer. The retrosynthetic pathway is depicted in Scheme 7. 
 
                                                          
26 (a) Szantay, C.; Szabo, L.; Kalaus, G. Tetrahedron1977, 33, 1803; (b) Szabo, L.; Kalaus, G.; Szantay, C. Arch. 
Pharm. (Weinheim, Ger.) 1983, 316, 629-638. 
 27Schultz, A.; Malachowski, P.W. J. Org. Chem. 1997, 62, 1223-1229. 
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Scheme 7: Retrosynthetic pathway for the preparation of vincamine  
Compound 14 was obtained from the conversion of (+)-apovincaminal 15a to the acetal 15b 
followed by a free radical bromination using NBS/AIBN in CCl4. 15a derived by the 
treatment of 16 with AgBF4, DMSO and Et3N followed by an aqueous work-up procedure. 
Electrophilic bromination of the double bond in 17 with N-bromoacetamide led to dibromide 
16. Reduction of the diene lactam 18 by the method of Shamma28 et al. provided the 
intermediate 17. The strategy for production of 18 involved coupling of tryptamine with the 
chiral enantiomerically pure butyrolactone, followed by acid-catalyzed tricyclization and 
elimination of MeOH from an amido keto aldehyde intermediate. Butyrolactone resulted 
from a chiral benzamide by a novel process29 that affords a practical “asymmetric linkage” 
between chiral acyclic substrates and aromatic carboxylic acids. 
  
                                                          
28 Shamma, M.; Rosenstock, P. O. J. Org. Chem.1961, 26, 718. 
29 Schultz, A. G.; Hoglen, D. K.; Holoboski, M. A.Tetrahedron Lett.1992, 33, 6611. 
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2.1.4. Synthesis of vincamine with tabersonine as starting material 
Methods for obtaining vincamine and other indolic alkaloids on an industrial scale can be 
grouped into three different types of strategies:  
a) Extractive method 
b) Total synthesis 
c) Semi-synthesis 
Method of direct extraction from vegetal species have limited applications because 
vincamine is contained in different species of the genus Vinca in a very low amount (0.l-
0.2%). Thus, the extraction processes and the purification processes are significantly costly 
and complicated, and this is the reason of the high disproportion existing between the 
quantity of starting vegetal product, reagents and solvents necessary, and the amount of 
substance obtained with suitable purity level.  
Total synthesis possesses the advantage to use commercially available chemical compounds 
as starting material. Nevertheless, these total syntheses involve a large number of steps, due 
to the complexity of the chemical structure of vincamine and it presents the critical problem 
of the stereoselctively. 
Semi-synthesis is a type of strategy which used compounds isolated from natural sources as 
starting material. This strategy has the characteristics of low cost, high yield, short time and 
simple and safe operation and is completely suitable for an industrialized mass production. 
In addition this approach has the advantage to overcome problem of stereoselectivity because 
of the starting material has a specif configuration. 
Different processes of semi-synthesis of vincamine or related alkaloids have been proposed, 
more particularly aiming at simplifying the operative steps and reducing duration thereof. 
Considering that tabersonine is a biosynthetic precursor of vincamine, it is considered as a 
suitable starting material for the semi-synthesis of vincamine. 
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Tabersonine 
Tabersonine is an indole alkaloid extracted from Voacanga africana. Alkaloids of the 
Aspidosperma type, e.g. tabersonine and vindoline, and Iboga type, e.g. catharanthine, 
derived from the biosynthetic pathway reported in Scheme 8.30 
The strictosidine derivative preakuammicine is the general precursor for the strychnos, 
aspidosperma and iboga alkaloids. Even though several mechanisms have been reported in 
order to elucidate the formation of preakuammicine from geissoschizine,31 the physiological 
precursor and mechanism for preakuammicine continues to be unknow. 
 
Scheme 8: Biosynthetic pathway of strychnos, iboga and aspidosperma alkaloids. 
                                                          
30 (a) Battersby, A. R.; Burnett, A. R.; Hall E. S.; Parsons, P. G. Chem. Commun., 1968, 1582–1583; Scott, A. I.; 
(b) Cherry,P. C.; Qureshi,. A. A. J. Am. Chem. Soc., 1969, 91, 4932–4933; (c) Scott, A. I. J. Am. Chem. Soc., 
1972, 94, 8262. 
31 Scott, A. I.; Qureshi, A. A. J. Am. Chem. Soc., 1969, 91, 5874–5876; (b) Wenkert, E.; Wickberg, B. J. Am. 
Chem. Soc., 1965, 87, 1580–1589. 
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Reduction of preakuammicine generates stemmadenine, which rearranges to form the acrylic 
ester dehydrosecodine. This is a common intermediate for both the Iboga and the 
Aspidosperma skeletons. It is possible that the catharanthine and tabersonine are formed from 
a Diels–Alder reaction of dehydrosecodine, but there is no indication for this reaction in the 
plant.32 Tabersonine is used as the biosynthetic precursor to several members of the 
Aspidosperma family, especially vindoline (Scheme 9).33 In the first step, tabersonine is 
hydroxylated at the C-16 position by tabersonine-16-hydroxylase (T16H). The hydroxyl 
group is then methylated by the enzyme 16-hydroxytabersonine-16-O-methyltransferase 
(HTOM) to yield 16-methoxy-tabersonine. Subsequently, hydration of a double bond by an 
unknown enzyme produces 16-methoxy-2,3-dihydro-3-hydroxytabersonine. 
 
Scheme 9: Vindoline biosynthesis from tabersonine. 
                                                          
 32S. Laschat, Angew. Chem., Int. Ed. Engl., 1996, 35, 289–291. 
33 (a) Danieli, B.; Lesma, G.; Palmisano, G.; Riva, R.J. Chem. Soc., Chem.Commun. 1984, 909-911; (b) Danieli, 
B.; Lesma, G.; Palmisano, G.; Riva,R. J. Chem. Soc., Perkin Trans. 1 1987, 155-161. 
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Transfer of a methyl group to the indole nitrogen by an N-methyl transferase (NMT) leads 
to desacetoxyvindoline. The action of the 2-oxoglutarate-dependent dioxygenase 
desacetoxyvindoline 4-hydroxylase (D4H) produces the intermediate deacetylvindoline 
which is, finally, acetylated by deacetylvindoline O-acetyltransferase (DAT) to give 
vindoline. Tabersonine is important not only for its biosynthetic relationship to the Vinca 
alkaloids but also because it is the chemical progenitor of these alkaloids. The chemical 
conversion of tabersonine to various bisindole alkaloids is widely documented.34 
For these reasons, tabersonine represented an attractive target for synthesis.35 
 
In 1978, Paracchini et al. reported a new method of partial synthesis of vincamine starting 
from tabersonine (Scheme 10). 36 
Scheme 10: Synthesis of vincamine 2 starting from tabersonine 
First of all tabersonine 19 was catalitically reduced to vincadifformine 20, which was 
subsequentelly oxidizetohydroxy-[3H]- indole N(4) oxide 21. Intermediate 21 was reduced 
                                                          
34 (a) Scott, A. I. Acc. Chem. Res.1970, 3, 151-157; (b) Basha, A.; Atta-Ur-Rahman, Biosynthesis of Indole 
Alkaloids; Clarendon Press: Oxford, 1983. 
35 (a) Ziegler, F. E.; Bennett, G. B. J. Am. Chem. Soc.1971, 93, 5930-5931; (b) Ziegler, F. E.; Bennett, G. B.J. 
Am. Chem. Soc.1973, 95, 7458-7464; (c) Takano, S.; Hatakeyama, S.; Ogasawara, K.J. Am. Chem. Soc.1979, 
101, 6414-6420; (d) Lèvy, J.; Laronze, J.-Y.; Laronze, J.; Le Men, J.Tetrahedron Lett.1978, 1579-1580. 
36 Paracchini, S.; Pesce, E. Farmaco, 1978, 33, 573-582. 
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and after a rearrangement induced by acidic conditions, vincamine 2, 16-epivincamine 22 
and apovincamine 23 were formed (Scheme10). 
Scheme 11 illustrates the mechanism of the rearrangement of hydroxy-[3H]- indole N(4) 
oxide 21 to vincamine 2 and epivincamine 22. 
 
Scheme 11: Rearrangement of 21 to vincamine 2 and epivincamine 22. 
It is important to note that the induction of rearrangement requires the oxidation of 
vincadifformine 20 to intermediate 21 using peroxy acids (Scheme12). 
 
Scheme 12: Conversionof vincadifformine 20 to intermediate 21. 
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The semi-synthesis of vincamine starting from tabersonine is a strategy widely used in 
industry because of it results economic. Therefore, a large number of patent have been 
published in the last years. 37 
We took into consideration the obtainment of vincamine starting from (-)-tabersonine 19, an 
indole alkaloid extracted from Voacanga Africana (Scheme 13). 
Applying the reaction sequence of Nemes38 tabersonine is submitted to catalytic 
hydrogenation in the presence of Ni-Raney to give vincadifformine 20. The subsequent 
treatment with 3-chloroperbenzoic acid in toluene generated the intermediate 21. Treatment 
of 21 with triphenylphosphine and acetic acid induced formation of a mixture of (+)-
vincamine 2 and epivincamine 22. The use of a base permitted the epimerization at C20 of 
epivincamine to give (+)-vincamine 2 as main product. 
Scheme 13: General procedure for the preparation of vincamine 
The complete conversion of tabersonine into (+)-vincamine takes place with a total yield 
over than 30%. 
                                                          
37 (a) Xuedong, P.; Xiaobo, W.; Jinshao, Z.; Zhenglian, W. CN 102108082 A 20110629; (b) Wen, S.; Yi, W.; 
Peng, L.; Jun, L.; Guohui, Y.;Shijiang, L. CN 102276599 A 20111214; (c) Xuedong, P. 
CN 103232452 A 20130807; (d) Xuedong, P.; Mei, Z.; Jinshao, Z.; Yongyi, Y. CN 104788447 A 20150722. 
38 Nemes, A.; Szàntay, C.; Czibula, L.; Reiner, I. Heterocycles, 2007, 71, 2347-2362. 
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The formation of the desired product 2 was evaluated through mass spectroscopy (MS) and 
nuclear magnetic resonance (NMR) analysis. 
Mass spectrum (EI) showed the molecular peak (M) at 354 m/z together with the peaks of 
characteristic fragments at 339 (M-Me), 325 (M-Et), 307 (M-Et-H2O), 295 (M-COOMe), 
267 (M-COOMe-CO). 
1H-NMR analysis of vincamine 2 shows the signal at δ 4.60 ppm related to the OH proton 
and it does not show correlation with any carbon signal. The signal at δ 3.95 ppm is 
characeristic of the proton at position 21. COSY spectrum evidences a correlation between 
the signal of the proton at position 9 at δ 7.50 ppm and the proton at position 21 at δ 3.95 
ppm.  
Moreover, the signals of the protons at position 17 presents a decreased difference in 
chemical shift (δ 2.15 e 2.25 ppm, AB system) respect to the corresponding signals of the 
protons in epivincamine (δ 2.05 and 2.73 ppm, AB system). This is due to the opposite 
configuration at position 16 and to the effect of COOMe (Figure 10). In addition, the signal 
of the proton at position 12 presents a highfield shift (δ 7.05-7.15 ppm, multiplet) if compared 
with the corresponding signal in epivincamine (δ 7.50-7.85 ppm, multiplet). 
 
                  
 
Figure 11: 3D structure of vincamine (on the left) and epivincamine (on the right). 
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2.1.5. Impurities derived from the synthesis of vincamine 
The HPLC analysis of the obtained vincamine shows the presence of crucial impurities 
(Figure 12), which occur in a range of 0.03-1.89%.  
We isolated different byproducts with the aim to identify their chemical structures and to 
define the reason of their formation. 
Name Retention time (min.) 
ImpurityA 0.8 
Impurity B (epivincamine) 0.9 
Vincamine  9.3 
Impurity C (-14-vincamine) 1.35 
Impurity D (apovincamine) 2.5 
 
Figure 12: Retention time of different impurities 
The assignment of the impurities structure was based on the EIMS and NMR analysis (Figure 
13). 
 
Figure 13: Structure of compounds deriving from industrial synthesis of vincamine 
For what regard compound 22, the mass spectrum (EI) shows the molecular peak at 354 m/z 
(M) together with the peaks of characteristic fragments at 307 (M-Et-H2O), 295 (M-
COOMe). 
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1H-NMR spectrum shows the signals of the protons at position 12 and 9 at δ 7.45 and 7.55 
ppm, respectively, as doublets together with a multiplet in the region δ 7.0-7.1 ppm due to 
H-10 and H-11. The signal of H-21 appears at δ 3.90 ppm. The protons at position 17 present 
an increased difference in chemical shift (δ 2.05 and 2.75 ppm, AB system) if compared with 
the corresponding signals in vincamine. This is due to the opposite configuration at position 
16 and to the effect of COOMe. The proton at position 12 suffers of downfield effect and 
moves at δ 7.4 ppm (vincamine δ 7.05-7.15 ppm). 
Compound 23 presents (EI) a molecular peak (M) at 336 accompanied by other peaks at 307               
(M-Et) and 266 that is due to the fragment reported in the Figure 14. 
The presence of the double bond between the carbons 16 and 17 is 
confirmed by the signal of the proton at position 17 at δ 6.15 ppm as a 
singlet and the corresponding signal at 128.2 in the 13C-NMR 
spectrum. 
The mass spectrum (EI) of compound 30 shows the molecular peak 
at 384 m/z. The 1H-NMR spectrum shows three signals in the aromatic region for the 
presence of a substituent on the indole portion. Multiplicity of those signals (d, d and dd) 
with two different coupling constants (J= 2 and 9 Hz) confirms the presence of the substituent 
at position 10 or 11. COSY spectrum evidences two correlations between the signal at δ 6.93 
(J = 2 Hz) and the signal at δ 6.72 ppm (J= 2 and 9 Hz) with the one at δ 3.91 ppm (H-21). 
NOESY spectrum shows an interaction between the signal at 6.93 ppm (dd) and the signal 
at δ 2.5-2.6 ppm (H-6).  
Compound 31 presents (EI) the molecular peak at 352 (M) accompanied by other peaks at 
323 (M-Et), 319 (M-Me-H2O), 305 (M-Et-H2O), 293 (M-COOMe) and 
the one at 284 due to the fragment reported in the Figure 15.  
 In the 1H-NMR spectrum the region of the aliphatic signals results 
simplified with the disappearance of the signals due to the protons at 
position 14 and 15. Same trends is detectable in 13C-NMR spectrum. 
Two signals at δ 5.78 and 5.62 ppm confirm the presence of two vicinal olefinic protons. 
These signals results coupled to the signals due to the protons at position 3. 
  
Figure 15: 
Fragment at 282 
Figure 14: 
Fragment at 266 
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2.2. Design of experiment (DOE)  
The design of new products or the improvement of existing ones, together with the design 
and development of manufacturing processes to synthesize them, are critical activities in 
most industrial organizations.  
Statistically designed experiments have a key role for product and process design and 
development. In the last years, many new developments in experimental design have been 
made and they have been found broad application in many disciplines. Typical experimental 
design application areas embrace process and product characterization, control and stability, 
process optimization, achieving variability reduction, and designing products and processes 
to accomplish robustness.  
Within the theory of optimization, an experiment is a sequence of tests in which the input 
variables are changed according to a given rule in order to identify the reasons for the changes 
in the output response. According to Montgomery:39 
“Experiments are performed in almost any field of enquiry and are used to study the 
performance of processes and systems. […] The process is a combination of machines, 
methods, people and other resources that transforms some input into an output that has one 
or more observable responses. Some of the process variables are controllable, whereas other 
variables are uncontrollable, although they may be controllable for the purpose of a test. 
The objectives of the experiment include: determining which variables are most influential 
on the response, determining where to set the influential controllable variables so that the 
response is almost always near the desired optimal value, so that the variability in the 
response is small, so that the effect of uncontrollable variables are minimized.” 
DOE (Design Of Experiment), or experimental design, is the name given to the techniques 
used for guiding the choice of the experiments to be performed in an efficient way. 
Due to the close link between statistics and DOE, it is quite common to find in literature 
terms like statistical experimental design, or statistical DOE.  
                                                          
39 Douglas C. Montgomery, Design and Analysis of Experiments, John Wiley & Sons Inc, 2012. 
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Statistical experimental design, together with the fundamental ideas underlying DOE, was 
born in the 1920s from the work of Sir Ronald Aylmer Fisher. He developed the insights that 
lead to the three basic principles of experimental design: randomization, replication and 
blocking. In the 1930s, Box and Wilson applied the idea of statistical design to industrial 
experiments and developed the response surface methodology (RSM), a method that 
explores the relationships between several explanatory variables and one or more response 
variables. Finally, the work of Genichi Taguchi in the 1980s had a significant effect on 
making statistical experimental design popular and stressed the importance it can have in 
terms of quality improvement. 
In order to perform a DOE first it is necessary to identify the problem and choose the 
variables, which are called factors or parameters. A design space, or region of interest, have 
to be defined, that is, a range of variability must be set for each variable. The amount of 
values the variables can assume in DOE is restricted and usually small. The DOE technique 
and the number of levels are to be chosen according to the number of experiments that can 
be afforded. The term levels refers to the number of different values a variable can assume 
according to its discretization. The number of levels usually is the same for all variables, 
however some DOE techniques allow the differentiation of the number of levels for each 
variable. In experimental design, the objective function and the set of the experiments to be 
performed are called response variable and sample space respectively. 
As already said, the three basic principles of experimental design are: randomization, 
replication and blocking. Randomization implies that both the allocation of the 
experimental material and the order in which the scientists runs or trials of the experiments 
are to be performed are randomly determined. Replication refers to an independent repeat of 
each factor combination, while blocking is the arranging of experimental units in groups 
(blocks) that are similar to one another. 
Several DOE techniques are available to the experimental designer (Table 1): Randomized 
Complete Block Design (RCBD), Latin Square, Fractional Factorial, Central Composite, 
Box-Behnken, Plackett-Burman, Taguchi, Random, Halton - Faure- Sobol, Latin Hypercube, 
Optimal design and Full Factorial design. The choice of the best experimental design 
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depends on the problem to be investigated and on the aim of the experimentation. Items to 
be consider are: 
1. the number of experiments N which can be given 
2. the number of parameters k of the experiment 
3. the number of levels L for each parameter 
4. the aim of the DOE. 
Method Number of experiment Suitability 
RCBD N (Li) = ∏ 𝐿𝑖
𝑘
𝑖=1  
Focusing on a primary factor 
using blocking techniques 
Latin squares N (L) = L2 
Focusing on a primary factor 
economically 
Full factorial N (L, k) = Lk 
Computing the main and the 
interaction effects, building 
response surfaces 
Fractional factorial N (L, k, p) = Lk−p 
Estimating the main and the 
interaction effects 
Central composite N (k) = 2k + 2k + 1 Building response surfaces 
Box-Behnken N (k) from tables 
Building quadratic response 
surfaces 
Plackett-Burman 
N (k) = k + 4 − mod 
𝑘
4
 
 
Estimating the main effects 
Taguchi 
N (kin , kout , L) = NinNout , 
Nin (kin , L), Nout (kout , L) 
from tables 
Addressing the influence of noise 
variables 
Random chosen by the experimenter Building response surfaces 
Halton, Faure, 
Sobol 
chosen by the experimenter Building response surfaces 
Latin hypercube chosen by the experimenter Building response surfaces 
Optimal design chosen by the experimenter Building response surfaces 
 
Table 1: DOE methods table 
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2.2.1. Full factorial design 
For our purpose, we used a full factorial design. The most simple form is two-levels full 
factorial, in which there are k factors and L = 2 levels per factor. The samples are given by 
every possible combination of the factors values. Thus, the sample size is N = 2k. The two 
levels are called high (“h”) and low (“l”) or, “+1” and “−1”. Starting from any sample within 
the full factorial scheme, the samples in which the factors are changed one at a time are still 
part of the sample space.  
In some full factorial designs also the central point of the design space is added to the 
samples. The central point is the sample in which all the parameters have a value that is the 
average between their low and high level and in 2k full factorial tables can be individuated 
with “m” (mean value) or “0”. 
We applied the DOE on the synthesis of vincamine starting from vincadifformine (Scheme 
14), in order to evaluate the effect of some parameters (set on two values) on the profile of 
the impurities and to increase the yield of the reaction. 
Scheme 14: Synthesis of vincamine from vincadifformine 
We considered to change 5 parameters, one parameter each time, for a total of 32 trials: 
A. Volume of solvent 
B. Temperature 
C. Oxidant concentration 
D. Reducing agent 
E. Reaction time 
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To these, four experiments have been added as central point “0”, in order to estimate the 
natural variance of the process. (Table 2) 
Run A B C D E Run A B C D E 
1 1 1 1 1 -1 20 1 1 1 1 1 
2 1 1 1 -1 1 21 1 1 1 -1 -1 
3 1 1 -1 1 1 22 1 1 -1 1 -1 
4 1 1 -1 -1 -1 23 1 1 -1 -1 1 
5 1 -1 1 1 1 24 1 -1 1 1 -1 
6 1 -1 1 -1 -1 25 1 -1 1 -1 1 
7 1 -1 -1 1 -1 26 1 -1 -1 1 1 
8 1 -1 -1 -1 1 27 1 -1 -1 -1 -1 
9 -1 1 1 1 1 28 -1 1 1 1 -1 
10 -1 1 1 -1 -1 29 -1 1 1 -1 1 
11 -1 1 -1 1 -1 30 -1 1 -1 1 1 
12 -1 1 -1 -1 1 31 -1 1 -1 -1 -1 
13 -1 -1 1 1 -1 32 -1 -1 1 1 1 
14 -1 -1 1 -1 1 33 -1 -1 1 -1 -1 
15 -1 -1 -1 1 1 34 -1 -1 -1 1 -1 
16 -1 -1 -1 -1 -1 35 -1 -1 -1 -1 1 
17 0 -1 0 0 0 36 0 -1 0 0 0 
18 0 -1 0 0 0 37 0 -1 0 0 0 
19 0 -1 0 0 0 
Table 2: Encoding tests 
Graphics and considerations below derived from statistical analysis using the Minitab40 
program and they were made considering a 95% confidence limit (= 0.05). Then it was 
also taken into account the 90% limit ( = 0.10), to check if there was a significant influence 
of one more factor. 
Figure 16 shows the effect of solvent, temperature, oxidant, reducing agent and the reaction 
time: it is positevely influenced by the increase of the reducing agent, while increasing 
temperature and concentration of the oxidant we have no effect on the yield. Solvent quantity 
and time of addition of acid does not show an effect on the yield of the reaction, too. 
                                                          
40 (a)Meyer, Ruth K.; David D. Krueger (2004). A Minitab Guide to Statistics (3rd ed.). Upper Saddle River, NJ: 
Prentice-Hall Publishing; (b) Hardwick, Colin (2013). Practical Design of Experiments: DoE Made Easy! (1st 
ed.). United Kingdom: Liberation Books Ltd. 
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Figure 16: Effect of A (volume), B (temperature), C (oxidant concentration), D (reducing agent), E 
(time of reaction) on total yield. 
As regards the formation of the impurity C (-14-vincamine) (Figure 17), the significant 
parameter is the amount of reducing agent. In fact, the quantity of the impurities decrease 
with increasing the amount of the reducing agent. The other factors are not significant. 
 
                      
Figure 17: Effect of volume of solvent (A), temperature (B), oxidant concentration (C), reducing 
agent (D) and  time of reaction (E) on some impurities. 
In conclusion, the Design of Experiment applied to the synthesis of vincamine from 
vincadifformine has allowed to obtain some useful information: increasing the stoichiometry 
of the reducing agent (from “+1” to “-1”), the yield increases. At the same time, the reducing 
agent leads to the increase of total impurities. Increasing the temperature, the amount of total 
impurities also increase. The increase in the volume of the reaction affects the formation of 
dimers, reducing the amount. 
Pareto Chart Of The Standardized Effects 
(response is total yield) 
Pareto Chart Of The Standardized Effects 
(response is impurity A) 
Pareto Chart Of The Standardized Effects 
(response is 14-vincamine) 
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We repeated the DOE using an additive in order to evaluate if some impurities could derived 
from parallel reactions.  
We considered to change 4 parameters, one parameter each time, for a total of 20 trials: 
A. Volume of solvent 
B. Temperature 
C. Oxidant concentration 
D. Time of reaction 
Run A B C D 
1 +1 +1 +1 +1 
2 +1 +1 +1 -1 
3 +1 +1 -1 +1 
4 +1 +1 -1 -1 
5 +1 -1 +1 +1 
6 +1 -1 +1 -1 
7 +1 -1 -1 +1 
8 +1 -1 -1 -1 
9 -1 +1 +1 +1 
10 -1 +1 +1 -1 
11 -1 +1 -1 +1 
12 -1 +1 -1 -1 
13 -1 -1 +1 +1 
14 -1 -1 +1 -1 
15 -1 -1 -1 +1 
16 -1 -1 -1 -1 
17 0 -1 0 0 
18 0 -1 0 0 
19 0 -1 0 0 
20 0 -1 0 0 
Table 3: Encoding tests 
Graphics and considerations below derived from statistical analysis using the Minitab 
program and they have been made considering a 95% confidence limit (α = 0.05). 
Figure 18 shows the effect of solvent volume, temperature, oxidant and time of reaction on 
the molar yield of the reaction: it is positevely influenced by the increase of time reaction, 
while the other parameters and the combination of them are not statistically significant. In 
the case of the previous work without the additive (DOE full 5 factors volume, temperature, 
oxidant and time of addition), it was notice the same effect but the decrease of the yield was 
even more marked. 
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Figure 18: Effect of A (volume), B (temperature), C (oxidant concentration), D (time of reaction) on 
total yield. 
The formation of the impurity A (Figure 19), is no effected by the experimental factors 
chosen differing from what observed in the DOE without the additive, in which the amount 
of the impurity decreases with increasing the reducing agent. 
 
 
Figure 19: Effect of A (volume), B (temperature), C (oxidant concentration), D (time of reaction) on 
impurity A. 
As regard the formation of impurity C (14-vincamine) (Figure 20), the significant parameter 
is the time of reaction. In the previous DOE without the additive, no factors effected the 
formation of the impurity. 
 
 
 
Pareto Chart Of The Standardized Effects 
(response is total yield) 
Pareto Chart Of The Standardized Effects 
(response is impurity A) 
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Figure 20: Effect of A (volume), B (temperature), C (oxidant concentration), D (time of addition) on 
impurity C. 
In conclusion, the DOE in the presence of an additive give us some useful information about 
the formation of the impurities. The volume of solvent showed positive effects on the total 
impurities, while the temperature had no effect on the impurities formation. The time of 
addition is an important parameter: increasing the time the total impurities decreases.  
Pareto Chart Of The Standardized Effects 
(response is 14-vincamine) 
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2.2.2. Reactivity of 3-oxo-tabersonine and 3-oxo-vincadifformine 
In this chapter, the reactivity of both 3-oxo-tabersonine and 3-oxo-vincadifformine is 
discussed.  
3-Oxo-tabersonine and tabersonine are both components of Voacanga africana. Since 
tabersonine is used for the industrial synthesis of vincamine, we decided to synthesize 3-oxo-
tabersonine and to apply the same synthetic strategy used to obtain vincamine. The aim of 
this procedure is to evaluate if impurities formed during the transformation of the tabersonine 
into vincamine, derive from 3-oxo-tabersonine. Moreover, considering that the preparation 
of vincamine requires the conversion of tabersonine to vincadifformine, we decided to 
synthesize 3-oxo-vincadifformine and to submit it to the synthetic condition used to obtain 
vincamine. 
Tabersonine, a terpene indole alkaloid, plays a central role in the biosynthesis of 
Aspidosperma alkaloids. It was first isolated in 1954 by Le Men et al.41 from Amsonia 
tabernaemontana. Shortly after the initial report, the alkaloid was isolated from different 
other natural sources, demonstrating its relative biological abundance.  
In 1978, Aimi and Haginiwa first reported the isolation of 3-oxo-tabersonine from the seeds 
of Amsonia elliptica.42 Among the alkaloids that they were able to extract and separate from 
the plant, they were able to obtain a compound with a mass of 350 m/z corresponding to the 
molecular formula C21H22O3N2. This data suggested that a methylene group of tabersonine 
was replaced by a carbonyl group, and an IR absorption band at 1665 cm-1, characteristic of 
an amide carbonyl group, confirmed this hypothesis. However, from NMR data the signals 
of AB system were observed at  5.94 and  6.44 ppm with a coupling constant of 9 Hz, 
referable to the vicinal olefinic protons on C-14 and C-15, respectively. This information 
suggested that no proton is present on carbon C-3 and the chemical schift of the olefinic 
protons suggest a functionalization at C-3. Therefore, this compound was deduced to be 3-
oxo-tabersonine. (Figure 21) 
                                                          
41 Janot, M.-M.; Pourrat, H., Le Men, J. Bull. Soc. Chim. Fr.1954, 707-708. 
42 Aimi, N.; Asada Y.; Sakai, S.I.; Haginiwa J.Chem.Pharm.Bull. 1978, 26, 1182-1187. 
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Figure 21: Structure of 3-oxo-tabersonine 
To confirm the structure, 3-oxo-tabersonine was catalytically reduced with PtO2 to the 
dehydro derivative 3-oxo-vincadifformine (Scheme 15).  
 
Scheme 15: Catalytic reduction of 3-oxo-vincadifformine 
Given that Le Men et al.43 reported the synthesis of 3-oxo-vincadifformine, they sent to Prof. 
Le Men a sample of their product supposed to be 3-oxo-vincadifformine. Le Men confirmed 
the identity of the sample, proving that Aimi and Haginiwa were able to isolate 3-oxo-
tabersonine from the seeds of Amsonia elliptica. Then 3-oxo-tabersonine was synthesize by 
Aimi and Haginiwa on direct oxidation of tabersonine using KMnO4, in order to further 
support the structure.  
Recently, 3-oxo-tabersonine was first isolated also in cultivated Vinca major in Kunming 
botanical garden in China.44,45 In chapter 4, the isolation and structural characterization of 
this impurities from the seeds of Voacanga africana will be discussed.  
In Scheme 16 is reported the synthetic condition for the obtainement of 3-oxo-tabersonine 
starting from tabersonine. 
                                                          
43 Laronze, J.Y.; Fontaine, J.L.; Lèvy, J.; Le Men, J. Tetrahedron Lett.1974, 491. 
44 Cheng, G.G. et al.Tetrahedron 2014, 70, 8723-8729. 
45 Achenbach, H.; Benirschke, M.; Torrenegra, R. Phytochemistry 1997, 45, 325-335. 
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Scheme 16: Synthesis of 3-oxo-tabersonine 
Then 3-oxo-tabersonine was submitted to the same sequence to produce vincamine using the 
same oxidant, solvent, reducing agent and base. 
HPLC-MS analysis of the raw material demonstrated that 3-oxo-tabersonine did not react 
under the reported conditions and the starting material was recovered (Figure 22). 
 
Figure 22: HPLC-MS analysis of the raw material 
Le Men et al. reported the synthesis of 3-oxo-vincadifformine as an intermediate in their 
total synthesis of (±) vincadifformine. 
3-Oxo-tabersonine has been reduced to 3-oxo-vincadifformine by hydrogenation in the 
presence of PtO2 (Scheme 17). 
 
Scheme 17: Synthesis of 3-oxo-vincadifformine 
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Then 3-oxo-vincadifformine was submitted to the same sequence to produce vincamine 
using the same reagents. 
HPLC-MS analysis of the raw material demonstrated that 3-oxo-vincadifformine did not 
react under the reported conditions and the starting material was recovered (Figure 23). 
 
Figure 23: HPLC-MS analysis of the raw material 
These analyses revealed that 3-oxo-tabersonine and 3-oxo-vincadifformine did not lead to 
the formation of crucial impurities.  
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2.3. Lignans 
2.3.1. Introduction  
Lignans are naturally occurring plant polyphenols that are derived biosynthetically from 
phenylpropanoids and they are classified as phytoestrogens due to their structural similarities 
with mammalian estrogens.46 
Lignans, which are found in all morphological parts of the plants including roots, leaves, 
flowers, fruits, and seeds, are secondary metabolites with low molecular weight. 
The major dietary sources of lignans are whole vegetables, seeds and legumes, with 
exceptionally high concentrations of lignans occurring in flaxseed. 
Lignans possess numerous pharmacological features including anticancer, antimicrobial, 
antioxidant, anti-inflammatory and immunomodulating activities, and are largely studied due 
to their potential usefulness in many hormonal-related conditions such as prostate and breast 
cancer, cardiovascular disease and conditions associated with the menopause.47 
Nowadays, their wide use in traditional medicine makes lignans an important family of lead 
compounds for the development of new therapeutic agents based on structural 
modifications.48 Lignans can be classified in five main groups according to their structures: 
lignans, neolignans, norlignans, hybrid lignans, and oligomeric lignans.  
Most lignans are phenylpropanoid dimers, in which the phenylpropane units are linked by 
the central C-atom, C-8, of their side chains. They differ substantially in substitution pattern, 
oxidation level, and chemical structure of their basic C-framework. 
In addition, lignans are classified in six subgroups based upon the way in which the O-atom 
is incorporated in the skeleton and cyclization pattern: dibenzylbutyrolactones, 
dibenzylbutanes, arylnaphthalenes, furofurans, terahydrofurans and dibenzocyclooctadienes 
(Figure 24). 
                                                          
46 Dixon, R.A. Annu Rev Plant Biol. 2004, 55, 225–61. 
47 (a) Knight, D.C.; Eden, J.A. Obstet Gynecol. 1996, 87 ,897–904; (b) Tham, D.M.; Gardner, C.D.; Haskell, 
W.L. J. Clin. Endocrinol. Metab.1998, 83, 2223–5. 
48 Gordaliza, M.; Garcia, P. A.; Miguel del Corral, J. M.; Castro, M. A.; Gomez-Zurita, M. A. Toxicon.2004, 44, 
441. 
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Figure 24: General skeleton of lignans 
Among lignans, 7-hydroxymatairesinol (HMR) is the major lignan in Norway spruce (Picea 
abies). 
In 1957, Freudenberg and Knof 49 first isolated HMR as a mixture of two isomers in the ratio 
of ca. 1:3. The two isomers were shown to be diastereomers, since they differ in the relative 
stereochemistry at position C-7. These isomers were separated, characterized and named by 
Freudenberg et al. as (-)-allo-HMR and (-)-HMR, respectively. The stereochemistry of the 
hydroxymatairesinol isomers has been largely studied by NMR spectroscopy,50 but only in 
2002 Patrik Eklund and Rainer Sjöholm have proved the absolute configurations. They 
published a paper51 in which they unambiguously determined that the configurations at C-7 
in (-)-allo-HMR and (-)-HMR are R and S, respectively (Figure 25). 
                                                          
49 Freudenberg, K.; Knof, L.Chem. Ber.1957, 90, 2857. 
50 (a) Kawamura, F.; Ohashi, H.; Kawai, S.; Teratani, F.; Kai, Y. Mokuzai Gakkaishi 1996, 42, 301; (b) Mattinen, 
J. ; Sjöholm, R.; Ekman, R. ACH Models Chemistry 1998, 135 (4), 583.  
51 Eklund, P.; Sillanpää, R.; Sjöholm, R.J. Chem. Soc., Perkin Trans. 1 2002, 19, 1906. 
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Moreover in 200352 they separated the two isomers by chromatography and comparing 
optical rotation and NMR spectroscopic with previously published data,13,14 they were able 
to determine that (-)-allo-HMR is the minor while (-)-HMR is the major isomer present in 
Norway spruce wood. 
 
Figure 25: Hydroxymatairesinol isomers  
HMR is structurally closely related to the natural plant lignin matairesinol (Figure 26), and 
it has been shown to metabolise to the known mammalian lignan enterolactone (EL), which 
possesses antitumourigenic properties for hormone dependent cancer forms.53 Mammalian 
lignans bind with low affinity to the estrogen receptors  and , and are supposed to act as a 
weak phytoestrogens. However, the mechanism of action for mammalian lignans is not 
completely understood and other mechanisms than those directly involving estrogen 
receptors may be involved. 
During metabolisation, HMR goes through demethylation and dehydroxylation by intestinal 
bacteria, forming EL. 
Jacobs et al.54 have revealed that enterolactone undergoes further oxidative metabolisation 
by hepatic microsomes, resulting in hydroxylated compounds by modifications in the 
aromatic as well as in the aliphatic portions of the molecule.  
Conversely, very little is known about the biotransformation of HMR and the biological 
effects of its metabolites. 
                                                          
52 Eklund, P. C.; Sjoholm, R. E.Tetrahedron 2003, 59, 4515-4523. 
53 Saarinen, N. M.; Wärri, A.; Mäkelä, S. I.; Eckerman, C.; Reunanen, M.; Ahotupa, M.; Salmi, S. M.; Franke, 
A. A.; Kangas, L.; Santti, R. Nutr. Cancer 2000, 36, 207. 
54 Jacobs, E.; Metzler, M.J. Agric. Food Chem.1999, 47, 1071. 
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Figure 26: Chemical structures of matairesinol,7-hydroxymatairesinol (HMR) and enterolactone (EL) 
HMR is designed for use as a functional food ingredient to decrease the risk of developing 
certain forms of cancer and the risk of cardiovascular diseases. Moreover, some evidence 
has been provided that HMR may be a powerful antioxidant. 
An important characteristic of HMR is that it could be extracted in large scale from the 
heartwood of the Norway spruce, Picea abies.55 The spruce knots, that are part of the 
branches embedded in the stem, contain 6–16% of lignans, and HMR is 65–80% of the total 
lignan content.56 
Due to its biological properties and excellent availability, HMR has been proposed as a 
chemopreventive agent against hormone dependent diseases, cancers and cardiovascular 
diseases. 
                                                          
55 Saarinen, N.M.; Warri, A.; Makela, S.I.; Eckerman, C.; Reunanen, M.; Ahotupa, M. et al. Nutr. Cancer 2000, 
36, 207–16. 
56 Hemming, J.; Reunanen, M.; Eckerman, C.; Holmbom, B. Holtzforschung 2003, 57, 27–36. 
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The synthesis of oxomatairesinol and (-)-7(R)-HMR are reported in the next two sections, 
3.4.1 and 3.4.2. We planned the synthesis of these two lignans in order to have standard 
reference material for further biological studies. (-)-7(S)-HMR is used as starting material, 
since the potential large-scale isolation from Norway spruce knots makes it readily available 
(Scheme 18).  
Scheme 18: Transformations of (-)-7(S)-HMR 
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2.4. Lignans derivatives 
2.4.1. Synthesis of oxomatairesinol  
This chapter is focused on the synthesis of oxomatairesinol starting from (-)-7-(S)-HMR 34 
via the strategy depicted in Scheme 19.57 
 
Scheme 19: Transformation of 7(S)-HMR in oxomatairesinol 
The first reaction was the protection of the hydroxyl groups at position 4 and 4’ of HMR 
using tert-butyldimethylsilyl chloride (TBSCl) and imidazole (Scheme 20). 
  
                                                          
57 Fischer, J. A.; Reynolds, J.; Sharp, L. A.; Sherburn, M. S. Org. Lett. 2004, 6, 1345-1348. 
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Scheme 20: Synthesis of (-)-bis-TBS-7(S)-HMR  
The formation of the desired product 35 was evaluated through NMR analysis: it is possible 
to note the appearance of signals at δ 0.97, 0.95, 0.13, 0.11 ppm related to the tert-butyl and 
methyl protons of the introduced protecting group and the signal at δ 4.58 ppm which refers 
to the proton at position 7, proving that the protecting groups were introduced only in the 
desired position 4 and 4’. 
The second step (Scheme 21) was the oxidation of the hydroxyl group at position 7 to ketone 
using Dess-Martin periodinane (DMP) instead of pyridinium chlorochromate (PCC) as 
reported in literature. 
 
Scheme 21: Synthesis of (+)-bis-TBS-oxomatairesinol 36 
1H-NMR spectrum showed the disappearance of the signal of the proton at position 7 at δ 
4.58 ppm, confirming the formation of the desired product 36.  
Finally the deprotection reaction using tetra-n-butylammonium fluoride (TBAF), led to the 
formation of oxomatairesinol in good yield (Scheme 22).  
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Scheme 22: Synthesis of oxomatairesinol 
In literature this reaction was performed at room temperature, but in our case we observed 
low yield (around 20%). Therefore, we decided to change the reaction conditions decreasing 
the temperature till 0°C. This trick led us to obtain compound 37 with a very good yield.  
NMR analysis of 37 showed the absence of the protecting groups TBS signals. Instead two 
signals from the hydroxyl group protons appeared at δ 6.15 e 5.47 ppm, respectively. 
Moreover, spectroscopic data for synthetic oxomatairesinol were compared with those 
reported in literature, and they were in good agreement with each other. 
It is important to note that the configuration at C-8 and C-8’ is maintained during the 
synthethic pathway. 1H-NMR spectrum confirmed that no epimerization occurred, despite 
the use of mild basic conditions: the proton at position 8’ showed a signal at δ 2.90-2.98 
ppm as a multiplet in both oxomatairesinol (37) and (-)-7-(S)-HMR (34), while the 
downfield shift of proton H-8 signal (δ 3.55-3.50 ppm, multiplet) is only due to the presence 
of a carbonyl group in C-7. 
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2.4.2. Synthesis of (-)-7(R)-HMR 
The need to use (-)-7(R)-HMR (39) as standard reference sample for further biological 
studies propted us to synthesize this lignan derivative (Scheme 23). 
The synthesis involved an inversion of configuration of C-7 using modified Mitsunobu 
conditions.58 
 
Scheme 23: Conversion of (-)-7(S)-HMR in (-)-7(R)-HMR  
Scheme 24 reported the procedure for the preparation of compound 39: 
 
Scheme 24: Synthetic strategy for preparation of (-)-7(R)-HMR 
                                                          
58 Martin, S. F.; Dodge, J. A. Tetrahedron Lett.1991, 32, 3017-3020. 
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Starting from (-)-7(S)-HMR 34 the first reaction is the protection of the hydroxyl groups at 
C4 and C4’ (Scheme 25). 
 
Scheme 25: Synthesis of (-)-bis-TBS-7(S)-HMR  
The second step involves the inversion of the C-7-hydroxy group of 35 under Mitsunobu 
conditions (Scheme 26). This reaction was carried out with diisopropyl azodicarboxylate 
(DIAD) instead of diethyl azodicarboxylate (DEAD) because the former was considered a 
safer compound and was more readly available. 
 
Scheme 26: Synthesis of (+)-bis-TBS-7(R)-HMR 38 
The Mitsunobu reaction is one of the most useful reactions in organic synthesis, particularly 
for the inversion of configuration of secondary alcohols under mild and essentially neutral 
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reaction conditions.59,60 In addition, the reaction has proven basically sensitive to the steric 
environment of the alcohol.61 
Mitsunobu inversions of encumbered alcohols has proven problematic usually resulting in 
low yields or recovered starting material. Martin and Dodge reported a simple modification 
of this reaction that showed an improved yield for the inversion of sterically hindered 
alcohols. They discovered that simple replacement of benzoic acid with p-nitrobenzoic acid62 
occurred in considerably improved yields in the inversion process. The use of p-nitrobenzoic 
acid as the nucleophile in Mitsunobu reaction leads to two other advantages:  
1. the p-nitrobenzoate esters are readily deprotected through saponification compared 
to the corresponding benzoates; 
2. the p-nitrobenzoate esters are frequently crystalline and may be purified without 
difficulty. 
Moreover, the reaction could be performed in anhydrous tetrahydrofuran as an alternative to 
the commonly used benzene. 
Several solvents are suitable for the Mitsunobu reaction. Recently, it was found that the rate 
of the Mitsunobu esterification reaction is much higher in non-polar solvents.63 This provides 
an elucidation as to why the yield in the Mitsunobu reaction, in particular with sterically 
hindered alcohols, is often higher in non-polar solvents: side reactions, such as acylation of 
the hydrazine, are much slower in non-polar solvents.64 
The general mechanism for this reaction is reported in Scheme 27: 
                                                          
59 (a) Mitsunobu, O. Synthesis1981, 1-28; (b) Kato, K.; Mitsunobu, O. J.Org. Chem.1970, 35, 4227-4229; (c) 
Mitsunobu, O.; Yamada, M.Bull.Chem. Soc. Jpn.1967, 40, 2380. 
60 (a) Jenkins, I. D.; Mitsunobu, O. In Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A., Ed.; 
Wiley: New York, 1995; Vol. 8, pp 5379 -5390; (b) Hughes, D. L. Org. React.1992, 42, 335-656. 
61 Bose,A.K.; Lal, B.; Hoffman, W.A.; Manhas, M.S. Tetrahedron Lett. 1973, 1619. 
62 (a)Eaton, P.; Jobe, P.G.; Reingold, I.D. J.Am.Chem.Soc.1984, 106, 6437; (b)Jarosz, S.; Glodek, J.; Zamojski,A. 
Carb. Res.1987, 163, 289. 
63 Camp, D.;Harvey, P.J.; Jenkins I. D. Tetrahedron 2015, 71, 3932-3938. 
64 Hughes, D. L.; Reamer, R. A. J. Org. Chem.1996, 61, 2967-2971. 
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Scheme 27: Mechanism of the Mitsunobu reaction 
The first step is the nucleophilic attack of a triphenyl phosphine I upon diethyl 
azodicarboxylate II producing a relatively stable betaine intermediate III.65 The anion 
produced by this first stage is basic enough to remove a proton from the carboxylic acid, 
generating the nucleophile ready for reaction. Then the positively charged phosphorus is 
attacked by the alcohol to give compound V. The nitrogen anion generated in this step rapidly 
removes the proton from the alcohol to give intermediate VII and a by-product VIII, the 
reduced form of DEAD. Finally, the anion of the nucleophile attacks the phosphorous 
derivative of the alcohol in a SN2 reaction at carbon with the posphine oxide as the leaving 
group.  
The formation of intermediate IX was evaluated by NMR analysis. The number of 1H-NMR 
signals indicated that it is a single compound. In particular it was observed a downfield shift 
of proton H-7 signal (δ 5.82 ppm, doublet) proving the inversion of configuration at C-7.  
The hydrolisys of compound IX using basic conditions lead to the desired product 38. 
                                                          
65 (a) Crich, D.; Dyker, H.; Harris, R. J. J. Org. Chem.1989, 54, 257-259; (b) Guthrie, R. D.; Jenkins, I. D.Aust. 
J. Chem.1982, 35, 767-774; (c) Brunn, E.; Huisgen, R.Angew. Chem., Int. Ed. Engl.1969, 8, 513-515; Angew. 
Chem.1969, 81, 534-536. 
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Mitsunobu reaction 
The mechanism of the Mitsunobu reaction has been the subject of various investigations.66 
A detailed mechanism for this reaction is reported in Scheme 28: 
The first step is the nucleophilic attack of a triphenyl phosphine I upon diethyl 
azodicarboxylate II producing a relatively stable betaine intermediate III. 
Scheme 28: General mechanism of the Mitsunobu reaction 
The second step is not completely clear and many mechanisms were proposed.67 Betaine III 
can react through two different competing pathways a and b.29,68 In path a the betaine III is 
                                                          
66 (a)Hughes, D. L.Org. Prep. Proced. Int.1996, 28,127-164; (b) Dandapani, S.; Curran, D. P. Chem.Eur. J.2004, 
10,3130-3138; (c) Dembrinski, R. Eur. J. Org. Chem.2004, 69,2763-2772. 
67 (a) Watanabe, T.; Gridnev, I. D.; Imamoto, T. Chirality 2000, 12, 346-351; (b) Hughes, D. L.; Reamer, R. A.; 
Bergan, J. J.; Grabowski, E. J. J. J. Am. Chem. Soc.1988, 110, 6487-6491. 
68 (a) Kumar, N. S.; Kumar, K. P.; Kumar, K. V. P. P.; Kommana, P.; Vittal, J.J.; Swamy, K. C. K. J. Org. 
Chem.2004, 69, 1880-1889; (b) Wilson, S. R.; Perez, J.; Pasternak, A. J. Am. Chem. Soc.1993, 115, 1994-1997 
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protonated given compound IV.69 After the addition of an equivalent of alcohol, compound 
IV decomposed and a hydrazine VI and an alkoxyphosphonium salt VII are formed. 
In the opposing path b the betaine III initially reacts with two equivalent of alcohol to 
produce a dialkoxyphosphorane V and a hydrazine VI. Subsequently, an acid-induced 
decomposition of V allows the oxyphosphonium salt VII under regeneration of one 
equivalent of alcohol.  
In literature there are quite works which shows that the reaction conditions, particularly the 
order in which the alcohol and acid are added, help to define which pathway is favored.70 On 
the contrary, some studies reveal that both pathways are in equilibrium with each other 
independently of the order of reagent addition.71 
The nature, in particular the pKa value, of the carboxylic acid used in the latter step of the 
Mitsunobu reaction has an important influence on the product yield.72 This has been 
identified by a competition between the alcohol and the carboxylate anion for compound IV. 
With acids stronger than acetic acid, for example p-nitrobenzoic acid, this degradation side 
reaction can be avoid. 73 
In addition, also the pKa of the acid is an important parameter in the reaction pathway. In 
particular, Jenkins has shown via 31P-NMR that using acids having lower pKa’s than benzoic 
acid results in equilibria favoring formation of the requisite activated oxyphosphonium 
intermediate VII that undergoes the inversion process. 
                                                          
69 Varasi, M.; Walker, K. A. M.; Maddox, M. L. J. Org. Chem.1987, 52, 4235-4238. 
70 (a) Camp, D.; Jenkins, I. D. Aust. J. Chem.1992, 45,47-55; (b) Von Itzstein, M.; Jenkins, I. D. J. Chem. Soc., 
Perkin Trans. 11987, 2057-2060; (c) Von Itzstein, M.; Jenkins, I. D.J. Chem. Soc., Perkin Trans. 11986, 437-
445; (d) Adam, W.; Narita, N.; Nishizawa, Y.J. Am. Chem. Soc.1984, 106, 6, 1843-1845; (e) Von Itzstein, M.; 
Jenkins, I. D.Aust. J. Chem.1983, 36, 557-563. (f) Grochowski, E.; Hilton, B. D.; Kupper, R. J.; Michejda, C. J.J. 
Am. Chem. Soc.1982, 104, 6876-6877. 
71 (a) Camp, D.; Jenkins, I. D. J.Org. Chem.1989,54,3045-3049; (b) Camp, D.; Jenkins, I. D. J. Org. 
Chem.1989,54, 3049-3054; (c) Pautard-Cooper, A.; Evans, S. A. Jr.J. Org. Chem.1989, 54, 2485-2488. (d) Von 
Itzstein, M.; Jenkins, I. D. Aust. J. Chem.1984, 37, 2447-2451. 
72 (a) Dodge, J. A.; Trujillo, J. I.; Presnell, M.J. Org. Chem.1994, 59, 234-236; (b) Caine, D.; Kotian, P. L.J. Org. 
Chem.1992, 57, 6587-6593; (c) Saiah, M.; Bessodes,M.; Antonakis, K.TetrahedronLett.1992,33, 4317-4320; (d) 
Martin, S. F.; Dodge, J. A.Tetrahedron Lett.1991, 32, 3017-3020. 
73 Hughes, D. L.; Reamer, R. A.J. Org. Chem.1996, 61, 2967-2971. 
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The last step involves a substitution reaction of the alkoxyphosphonium salt VII with a 
carboxylate ion to produce phosphine oxide and the ester IX. To elucidate the second-order 
kinetics identified for this reaction step in addition to the great excess of inversion product 
obtained, SN2 attack by the carboxylate ion on the C-O bond of the activated alcohol has 
been suggested. At this point if a very weak acid is used and the alcohol is sterically hindered, 
the Mitsunobu reaction can be diverged into an anhydride channel. The carboxylate anion 
present in the reaction competes with the alcohol for VII, and an acyloxyalkoxyphosphorane 
X is formed. 
Moreover, the Mitsunobu procedure can occur with retention of configuration and usually 
this is due to large mechanistic deviations. 
The final step for the synthesis of the desired (-)-7(R)-HMR is the deprotection reaction using 
the same procedure previously described for the synthesis of oxomatairesinol (Scheme 29). 
 
Scheme 29: Synthesis of (-)-7(R)-HMR 
Spectroscopic data for synthetic (-)-7(R)-HMR were in good agreement with those reported 
in literature. In particular the proton H-7 in (-)-7(S)-HMR showed a signal at 4.63 ppm as a 
doublet (J = 6.5 Hz), while in (-)-7(R)-HMR the signal of proton H-7 appears at 4.38 ppm as 
a doublet (J = 7.8 Hz). 
  
(continued)  
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2.5. Experimental part 
2.5.1. General information  
Thin-layer chromatography (TLC) was performed on Merck precoated 60F254 plates. 
Reactions were monitored by TLC on silica gel, with detection by Uv light ( = 254 nm) or 
by charring with 1% permanganate solution. Flash chromatography was performed using 
Silica gel (240-400 Mesh, Merck). NMR spectra were recordered with Brucker 300 and 400 
MHz spectrometers. Chemical shifts are reported in parts per million () downfield from 
tetramethylsilane (TMS). EI mass spectra were recorded at an ionizing voltage of 6 kEv on 
a VG 70-70 EQ. ESI mass spectra were recorded on FT-ICR APEXII. Specific rotations were 
measured with a P-1030-Jasco polarimeter with 10 cm optical path cells and 1 ml capacity 
(Na lamp,  = 589 nm). 
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Vincamine  
 
 
 
1H-NMR (400 MHz, CDCl3):  7.50 (d, J = 6.4 Hz, 1H), 7.19 (dd, J = 6.4 and 2.0 Hz,1H), 
7.19 (dd, J = 6.2 and 2.0 Hz,1H), 7.15 (d, J = 6.2 Hz, 1H), 4.60 (bs, 1H), 3.95 (s, 1H), 3.82 
(s, 3H), 3.45-3.25 (m, 2H), 3.05-2.97 (m, 1H), 2.85-2.70 (m, 1H), 2.70-2.50 (m, 3H), 2.25 
(d, J = 14 Hz,1H), 2.15 (d, J = 14 Hz,1H), 1.85-1.55 (m, 3H), 1.50-1.40 (m, 2H), 0.95 (t, J= 
7.2 Hz, 3H) ppm. 
13C-NMR (100 MHz, CDCl3):  175.1, 134.7, 131.9, 129.6, 122.2, 120.9, 119.2, 111.0, 
106.6, 82.5, 59.8, 55.0, 51.6, 45.2, 45.0, 35.7, 29.6, 25.7, 21.4, 17.5, 8.3 ppm. 
EIMS: m/z= 354 (M), 339 (M-Me), 325 (M-Et), 307 (M-Et-H2O), 295 (M-COOMe), 267 
(M-COOMe-CO). 
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Epivincamine (Impurity B) 
 
 
 
1H-NMR (400 MHz, CDCl3):  7.07 (d, J = 9 Hz, 1H), 6.93 (d, J = 2 Hz, 1H), 6.72 (dd, J = 
9 and 2 Hz, 1H),  4.80 (bs, 1H), 3.91 (s, 1H), 3.83 (s, 3H), 3.77 (s, 3H),  3.40-3.20 (m, 2H), 
3.05-2.85 (m, 1H), 2.55-2.45 (m, 3H), 2.30-2.10 (m, 3H), 2.25 (d, J = 14 Hz,1H), 2.15 (d, J 
= 14 Hz,1H), 1.88-1.35 (m, 5H), 0.95 (t, J= 7 Hz, 3H) ppm. 
13C-NMR (100 MHz, CDCl3):  173.9, 155.1, 131.7, 130.1, 129.8, 112.0, 11.4, 105.2, 101.0, 
82.4, 59.7, 55.5, 53.0, 51.2, 44.7, 44.4, 35.6, 28.6, 25.6, 20.9, 16.9, 7.06 ppm. 
EIMS: m/z= 354 (M), 307 (M-Et-H2O), 295 (M-COOMe). 
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Apovincamine (Impurity D) 
 
 
 
 
1H-NMR (400 MHz, CDCl3):  7.44 (d, J= 8 Hz, 1H), 7.20-7.02 (m, 3H), 6.15 (s, 1H), 3.90 
(bs, 1H), 3.35-3.18 (m, 2H), 3.09-2.95 (m, 1H), 2.65-2.59 (m, 3H), 2.00-1.80 (m, 2H), 1.80-
50 (m, 2H), 1.60-1.50 (m, 1H), 1.00-0.90 (m, 1H), 0.05 (t, J= 7 Hz, 3H) ppm. 
13C-NMR (100 MHz, CDCl3):  165.0, 135.0, 130.8, 129.4, 128.9, 128.2, 122.3, 120.6, 
118.4, 112.6, 109.0, 55.9, 52.3, 51.5, 45.0, 38.4, 29.2, 27.4, 20.4, 16.4, 8.2 ppm. 
EIMS: m/z= 336 (M), 307 (M-Et), 266. 
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14,15-vincamine (Impurity C) 
 
 
 
1H-NMR (400 MHz, CDCl3):  7.50 (d, J= 7.5 Hz, 1H), 7.05-7.15 (m, 3H), 5.78 (s, 1H), 
5.62 (s, 1H),  4.85 (bs, 1H), 4.13 (s, 1H), 3.90 (s, 3H), 3.50-3.35 (m, 2H), 3.20-3.03 (m, 3H), 
2.65-2.55 (m, 1H), 2.43-2.35 (m, 2H), 2.09-1.95 (m, 1H), 1.70-1.60 (m, 1H), 1.05 (t, J= 7.5 
Hz, 3H) ppm. 
13C-NMR (100 MHz, CDCl3):  173.1, 134.3, 131.6, 129.2, 128.1, 125.6, 121.7, 120.3, 
118.4, 110.5, 106.3, 82.2, 57.5, 54.0, 49.6, 43.8, 43.7, 63.9, 34.9, 16.7, 8.46 ppm. 
EIMS: m/z= 352 (M), 323 (M-Et), 319 (M-Me-H2O), 305 (M-Et-H2O), 293 (M-COOMe), 
284. 
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Synthesis of 3-oxo-tabersonine (32) 
 
To a solution of tabersonine (0.200 g, 0.6 mmol) in dry acetone (15 mL), powdered KMnO4 
(0.112 g, 0,71 mmol) was added at – 25°C. Within three hours 0.037 g of KMnO4 were added. 
The reaction mixture was filtered and then was washed with saturated aqueous NaHSO3, 
alkalized till pH 10 and extracted with CH2Cl2. The organic extracts were combined and the 
solvent was removed in vacuo. The residue was purified by flash chromatography (AcOEt), 
giving 3-oxo-tabersonine as a colourless oil (0.065 g, 30%). 
1H-NMR (400 MHz, CDCl3):  9.03 (bs, 1H), 7.32-6.92 (m, 4H), 6.41 (d, J= 10.6 Hz, 1H), 
5.92 (d, J= 10.6 Hz,1H), 4.32-4.27 (m, 1H), 3.76 (s, 3H), 3.52-3.23 (m, 1H), 2.66 (d, J = 15 
Hz,1H), 2.06 (d, J = 15 Hz,1H), 1.98-1.56 (m, 2H), 1.15-0.9 (m, 2H), 0.69 (t, J= 7 Hz, 3H) 
ppm. 
13C-NMR (100 MHz, CD3OD):  169.0, 166.7, 163.4, 139.1, 144.8, 136.5, 129.4, 122.8, 
122.6, 122.0, 11.3, 90.8, 68.0, 58.3, 51.7, 44.8, 44.6, 41.7, 28.0, 27.5, 7.5 ppm. 
ESIMS: m/z= 351 [M+H]+ 
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Synthesis of 3-oxo-vincadifformine (33) 
 
3-Oxo-tabersonine (0.05 g, 0.14 mmol) was reduced catalytically in MeOH (4 mL) with PtO2 
(0.005 g) at room temperature. After 1 hour, the reaction mixture was filtered over celite and 
the solvent was removed in vacuo giving 3-oxo-vincadifformine as white solid (quantitative 
yield). 
1H-NMR (400 MHz, CDCl3):  9.01 (bs, 1H), 7.30-6.82 (m, 4H), 4.25 (dd, J = 12, 8 Hz,1H), 
3.75 (s,3H), 3.50 (bs, 1H), 3.42 (dd, J = 12, 6 Hz,1H),  2.66 (dd, J = 15.5, 1.5 Hz,1H),  1.98 
(d, J = 15.5 Hz,1H), 1.82-1.56 (m, 4H), 1.40-1.35 (m, 1H), 1.00 (q, J= 6.8 Hz, 2H), 0.71 (t, 
J= 6.8 Hz, 3H) ppm. 
13C-NMR (100 MHz, CD3OD):  170.1, 166.5, 163.0, 139.5, 144.5, 129.2, 122.6, 122.0, 
11.3, 91.1, 68.0, 58.3, 51.8, 44.8, 44.5, 41.8, 32.5, 28.5, 28.0, 27.5, 8.1 ppm. 
ESIMS m/z: 353 [M+H] + 
Natural products as building blocks for production of API 
 
72 
 
Synthesis of (-)-bis-TBS-7(S)-HMR (35) 
 
To a solution of (-)-7(S)-HMR 34 (0.250 g, 0.66 mmol) in DMF (2.5 mL) at rt was added 
TBSCl (0.211 g, 1.42 mmol) and imidazole (0.226 g, 3.34 mmol).  
The reaction mixture was stirred for 2 hours then washed with saturated aqueous NaHCO3 
and brine and dried over anhydrous sodium sulfate. The solvent was removed in vacuo and 
the crude material was purified by flash chromatography (Hexane/EtOAc 8:2) to give 35 as 
colourless oil (0.186 g, 46% overall yield). 
1H-NMR (400 MHz, CDCl3): δ 6.81 (d, J = 8.1 Hz, 1H), 6.78-6.44 (m, 5H), 4.58 (d, J = 6.8 
Hz, 1H), 3.92-3.83 (m, 2H), 3.78 (s, 3H), 3.75 (s, 3H), 3.13 (dd, J = 13.2, 4.9 Hz, 1H), 3.07-
2.97 (m,1H), 2.94-2.78 (m,1H), 2.62-2.54 (m, 1H), 0.97 (s, 9H), 0.95 (s, 9H), 0.13 (s, 6H), 
0.11 (s, 6H) ppm. 
13C-NMR (100 MHz,CDCl3): δ 179.4, 150.9, 150.1, 1454.6, 144.0, 135.1, 131.1, 122.5, 
120.9 120.5, 117.5, 113.1, 110.2, 74.9, 68.8, 55.8, 55.0, 45.5, 43.0, 35.0, 26.2, 18.8, -4.5 
ppm. 
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Synthesis of (+)-bis-TBS-Oxomatairesinol (36) 
 
To a solution of the protected HMR 35 (0.186 g, 0.31 mmol) in CH2Cl2 (5 mL) was added 
DMP (0.144 g, 0.99 mmol). The reaction mixture was stirred at rt for 1 hour, then washed 
with saturated aqueous NaHCO3 and extracted with CH2Cl2. The combined organic phases 
were dried over anhydrous Na2SO4, and the solvent was removed in vacuo. The residue was 
purified by flash chromatography (Hexane/EtOAc 8:2) to give 36 as oil (0.156 g, 84% overall 
yield). 
1H-NMR (400 MHz, CDCl3): δ 7.33 (s, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.79 (d, J = 8.1 Hz, 
1H), 6.66 (d, J= 8.1 Hz, 1H), 6.58 (s, 1H), 6.50 (d, J = 8.1 Hz, 1H), 4.40-4.28 (m, 1H), 4.11-
3.98 (m, 2H), 3.82 (s, 3H), 3.63 (s, 3H), 3.55-3.48 (m,1H), 3.06-2.94 (m, 2H), 0.98 (s, 9H), 
0.95 (m, 9H), 0.17 (s, 6H), 0.05 (s, 6H) ppm. 
13C-NMR (100 MHz, CDCl3): δ 195.0, 177.2, 150.9, 151.3, 151.0, 144.0, 130.4, 129.5, 
122.6, 121.5, 121.0, 120.2, 112.9, 111.1, 68.3, 55.4, 55.2, 46.8, 44.6, 34.4, 26.0, 25.6, 18.5, 
18.4, -4.6, -4.7 ppm. 
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Synthesis of oxomatairesinol (37) 
 
To a solution of the (+)-bis-TBS-oxomatairesinol 36 (0.150 g, 0.25 mmol) in THF (1 mL) 
and acetic acid (5 µL, 0.99 mmol) was added TBAF (0.2 mL, 1M in THF, 0.99 mmol) at 
0°C. The reaction mixture was stirred at 0°C for 2 hours, then washed with saturated aqueous 
NH4Cl and extracted with diethyl ether. The organic extracts were combined and the solvent 
was removed in vacuo. The residue was purified by flash chromatography (Hexane/AcOEt 
1:1), giving the oxomatairesinol 37 as a colourless oil (0.082 g, 88% overall yield). 
1H-NMR (400 MHz, CDCl3): δ 7.32 (d, J = 2.0 Hz, 1H), 7.19 (dd, J = 8.3, 2.0 Hz, 1H), 6.89 
(d, J = 8.3 Hz, 1H), 6.72 (d, J = 7.8 Hz, 1H), 6.59 (d, J =2.0 Hz, 1H), 6.52 (dd, J = 7.8, 2.0 
Hz, 1H), 6.16 (s, 1H), 5.48 (s, 1H), 4.39-4.32 (m,1H), 4.15-4.08 (m, 2H), 3.91 (s, 3H), 3.73 
(s, 3H), 3.54-3.48 (m, 1H), 2.98-2.90 (m,1H),3.06-2.90 (m, 1H) ppm. 
13C-NMR (100 MHz, CDCl3): δ 194.6, 177.0, 151.5, 146.9, 146.5, 144.5, 128.8, 128.6, 
123.5, 122.0, 114.3, 113.8, 112.0, 109.9, 68.3, 56.3, 55.7, 46.4, 45.0, 34.3 ppm. 
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Synthesis of (+)-bis-TBS-7(R)-HMR (38) 
 
To a solution of the TBS protected HMR 35 (0.180 g, 0.31 mmol), p-nitrobenzoic acid (0.150 
g, 0.93 mmol) and triphenylphosphine (0.236 g, 0.93mmol) in anhydrous THF (8 mL) at rt 
was added DIAD (0.2 mL, 0.93 mmol). The mixture was stirred at rt overnight then the 
solvent was removed in vacuo. The p-nitrobenzoate was purified by flash chromatography 
(Hexane/AcOEt 8:2) then dissolved in methanol (4 mL) and treated with an aqueous solution 
of K2CO3(0.2 mL, 20% w/v). After 1 hour the mixture was diluted with diethyl ether and 
washed with saturated aqueous NH4Cl. The organic phase was separated and the aqueous 
phase was extracted with diethyl ether. The combined organic phases were dried over 
anhydrous sodium sulfate and the solvent was removed in vacuo. The product was purified 
by flash chromatography (Hexane/AcOEt 8:2) to give 38 as a colourless oil (0.561g, 43%). 
1H-NMR (300 MHz, CDCl3): δ 6.79 (d, J= 8.1 Hz, 1H), 6.72 (d, J= 7.8 Hz, 1H), 6.65 (d, J= 
2.0 Hz, 1H), 6.60-6.58 (m, 2H), 6.47 (dd, J= 8.1, 2.0 Hz, 1H), 4.39 (dd, J= 6.6, 2.2 Hz, 1H), 
4.29 (dd, J= 9.3, 7.1 Hz, 1H), 3.98 (dd, J= 8.1, 8.1Hz, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 2.85-
2.67 (m, 3H), 2.58-2.47 (m, 1H), 0.98 (s, 9H), 0.97 (s, 9H), 0.12 (s, 6H), 0.11 (s, 6H) ppm. 
13C-NMR (100 MHz, CDCl3): δ 180.0, 151.3, 151.0, 145.1, 143.9, 135.1, 130.9, 121.5, 
121.0, 120.7, 118.1, 112.9, 109.5, 74.1, 67.9, 55.4, 46.1, 43.3, 34.7, 25.7, 18.4, -4.7 ppm. 
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Synthesis of (-)-7(R)-HMR (39) 
 
To a solution of the (+)-bis-TBS-7(R)-HMR 38 (1.12 g, 1.86 mmol) in THF (50 mL) and 
acetic acid (0.41 mL, 7.44 mmol) was added TBAF (7.44 mL, 1M in THF, 7.44 mmol) at 
0°C. The reaction mixture was stirred at 0°C for 2 hours, then washed with saturated aqueous 
NH4Cl and extracted with diethyl ether. The organic extracts were combined and the solvent 
was removed in vacuo. The residue was purified by flash chromatography (Hexane/AcOEt 
1:1), giving 7(R)-HMR 39 as a colourless oil (0.500 g, 72%). 
1H-NMR (400 MHz, CDCl3): δ 6.82 (d, J= 8.0 Hz, 1H), 6.76 (d, J= 7.9 Hz, 1H), 6.63 (dd, 
J= 8.1, 1.9 Hz, 1H), 6.54 (d, J= 1.9 Hz,1H), 6.47 (dd, J= 8.0, 1.9 Hz, 1H), 6.42 (d, J= 1.9 
Hz, 1H), 4.43 (dd, J= 9.5, 5.6 Hz, 1H), 4.38 (d, J= 7.8 Hz, 1H), 4.22 (dd, J= 9.5, 7.6 Hz,1H), 
3.79 (s, 3H), 3.74 (s, 3H), 2.79-2.72 (m, 2H), 2.65-2.59 (m, 1H), 2.54-2.47 (m, 1H) ppm. 
[𝑎]𝐷
20 = - 3.45 (c 0.10, CHCl3) 
13C-NMR (100 MHz, CDCl3): δ 179.4, 146.8, 146.6, 145.5, 144.4, 133.5, 129.3, 122.0, 
119.2, 114.0, 113.9, 111.0, 107.9, 74.4, 68.4, 55.7, 45.0, 43.8, 34.9, 29.7 ppm. 
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3.1. Indole alkaloids from Vocanga africana 
3.1.1. Voacanga africana 
In the past decades, many investigations were made on plants belonging to the genus 
Voacanga (Apocynaceae) for their biologically active components. In fact, the alkaloids 
are the principal bioactive compounds responsible for its use 
as medicinal plants. 
Voacanga africana is a small tropical tree occurring mainly in 
West Africa. It has white or yellows flowers and its fruits 
occur mainly in pairs, spherical, green with seeds wrapped in 
yellow pulp (Figure 27). 
In Africa it is traditionally used for the treatment of a wide 
range of diseases, such as diarrhea, generalized edema, 
leprosy, convulsions in children and madness. Moreover, bark 
infusions are used for stomac, hernia, cardiac spams, post 
partum pain, and kidney affections. In southeastern Nigeria 
the plant is used in many healing rituals as well to induce hallucinations and trances in 
religious rituals. 
Different compounds were isolated from various organs of Voacanga species. The 
presence of tannins, phenols, flavonoids, terpenes and steroids alkaloids has been 
reported in the seeds, leaves, stem bark and root.74 There is a qualitative and quantitative 
diversity in alkaloid composition and content by plant tissue and species. 
The seeds and root bark are the main source of indole alkaloids (the alkaloids content is 
5-10%), such as tabersonine, an aspidosperma-type alkaloid. The other alkaloids content 
was reported as 4-5% in trunk bark, 0.3-0.45% in leaves and 1.5% in seeds. 
                                                          
74 (a) Tona, L.; Kambu, K.; Ngimbi, N.; Cimanga, K.; Vlietinck, A.J. J. Ethnopharmacol 1998, 61, 57-65; 
(b) Gangoue-Pieboji, J.; Pegnyemb, D.E.; Niyitegeka, D.; Nsangou, A.; Eze, N.; Minyem, C.; Mbing, J.N.; 
Ngassam, P.; Tih, R.G.; Sodengam, B.L.; Bodo, B. Ann. Trop. Med. Parasit. 2006, 100, 237-243; (c) Agbor, 
G.A.; Kuate, D.; Oben, J.E. Pak. J. Biol. Sci. 2007, 10, 537-544. 
Figure 27: Voacanga 
africana 
Isolation and structural characterization of natural products  
 
79 
 
Alkaloids found in Voacanga, such as voacamine and voacangine, have also been found 
in other species of the family Apocynaceae (for example Peschiera fuschiaefolia). In 
table 4 are reported some compounds isolated from different sources of Voacanga.75,76 
Alkaloid Organ Distribution Species/Sources 
Amataine Root Bark V. Chalotina 
(-)-Tabersonine Cell Culture V. africana 
Folicangine Leaves V. africana 
Vincamol Seed V. africana 
Voacafrine Bark V. africana 
Voacangine Trunk Bark V. africana 
Vincamone Seed V. africana 
Vacorine Tree Bark V. africana 
Voacristine Bark V. africana And V. Thousarsii 
Voacryptine Bark and Root Bark V. africana 
Voacamidine Bark and Root Bark V. africana 
Voafolidine Leaf V. africana 
Voafoline Leaf V. africana 
Tabernanthin Root bark V. africana 
Δ14-Vincanol Seed V. africana 
Cuanzine Root bark V. Chalotiana 
Campesterol Seed  V. africana 
Voafrine A And B Cell Culture V. africana 
Vobtusamine Leaves V. Chalotiana 
Voafolidine Leaves V. Thouarsii 
Lupeol Leaves V. Globosa 
Vobasinol Bark  V. schweinfurthii 
Table 4: Some alkaloids isolated from different sources of Voacanga 
                                                          
75 Hussain, H.; Hussain, J.; Al-Harrasi, A.; R. Green, I.; Pharm. Biol .2012, 50,1183–1193. 
 76Koroch, A. R.; Juliani, H. R.; Kulakowski, D.; Arthur, H.; Asante-Dartey, J.; Simon, J. E. ACS Symposium 
Serie s2009, 1021, 363-380. 
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3.1.2. Isolation and structure elucidation of Voacanga alkaloids 
The isolation of interesting products, mainly indole alkaloids, from plants of the 
Voacanga genus prompted us to isolate and to determine the alkaloids structure from V. 
africana (Apocynaceae) seeds. 
The idea of the extraction is to separate the soluble plant secondary metabolites, leaving 
behind the residual plant material (marc). The crude extracts includes complex mixture 
of many plant metabolites, for example alkaloids, glycosides, lignans, flavonoids and 
terpenoids. However, some of the initially obtained extracts may be directly use as 
medicinal agents in the form of fluid extracts and tinctures but some need additional 
processing. 
Different methods77 can be employed to extract active compoundsfrom the plant 
material: 
 Maceration 
 Infusion 
 Digestion 
 Decoction 
 Percolation 
 Hot continuos extraction (Soxhlet extraction) 
 Fermentation 
 Counter-current extraction 
 Sonication  
 Supercritical fluid extraction 
 Phytonic extraction (with hydrofluorocarbon solvents) 
We evaluated the alkaloids composition in the extracts of V. africana seeds employing 
two different methods: extraction at room temperature and Soxhlet extraction.  
                                                          
77 Handa SS, Khanuja SPS, Longo G, Rakesh DD (2008) Extraction Technologies for Medicinal and 
Aromatic Plants, (1stedn), no. 66. Italy: United Nations Industrial Development Organization and the 
International Centre for Science and High Technology. 
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In Soxhlet method the sample, which is reduced to fine particles, is positioned in a porous 
bag or “thimble” composed by a strong filter paper or cellulose, 
which is placed in thimble chamber of the Soxhlet apparatus 
(Figure 28). The extracting solvent is heated in a bottom 
flaskand it vaporizes into the sample thimble. The vapor 
condenses in the condenser and drip back, extracting the crude 
drug by contact. When the liquid content arrives at the siphon 
arm, the liquid contents let out into the bottom flask again and 
the process begins again. The advantage of this extraction 
technique is that large amounts of drug can be extracted with a 
much smaller quantity of solvent. 
The main steps of the alkaloids extraction are indicated in the Scheme 30. A 100 g batch 
of Voacanga seeds yielded 4g of alkaloids mixture by both extraction at room 
temperature and Soxhlet extraction. The total alkaloids extract was separated by column 
chromatography. 
Figure 28: Soxhlet 
apparatous 
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Scheme 30: Isolation of plant natural products 
 
Ten known indole alkaloids 40-47 (Figure 29) were isolated from the seeds of Voacanga 
africana (Apocynaceae) and their chemical structures were determined by 
spectroscopicand mass analysis. 
Ground seeds of 
Voacanga  africana
MeOH extract
crude elueted with 
CH2Cl2 and washed with 
H3PO4 10%
aqueous layer: alkaloids
NH3 5M (pH 10)
thin-layer cromathography (TLC) of crude extract 
column chromatography
extracted with CH2Cl2
organic layer: neutral and acid 
compounds
solvent evaporation
Soxhlet and room 
temperature extraction
with MeOH
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Figure 29: Structures of voacanga alkaloids. 
The mass spectrum (ESI) of lochnericine 40 showed the peak [M+H]+at  m/z 353. 
The 1H-NMR spectrum showed the signals of the protons at position 14 and 15 at  3.51-
3.45 (m, 2H) and  3.14 (1H, d, J= 4 Hz) respectively.The orientation of the C-14, C-15 
epoxide in lochnericine was confirmed by the correlation peaks observed between H-3a, 
H-17a, H-14 and H-15 in the NOESYspectrum of 40. 
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Moreover the spetctroscopic data of lochnericine were compared with those reported in 
literature, and they were in good agreement.78 
For what regard alkaloid 41, the presence of an epoxide ring in the structure of 41 was 
confirmed by two signals at 3.59-3.51 (m, 1H) and 3.25 ppm (lH, dd, J= 5.3 and 3.9 Hz) 
respectively in its 1H-NMR spectrum, that appears in vicinal positions as confirmed by 
1H-1H COSY experiment. The orientation of the C-14, C-15 epoxide in pachysiphine 
was determined by comparison with the 13C data for lochnericine. 
Alkaloid 42, named vobtusine, presented a molecular peak ([M+H]+) at m/z 719, 
accompanied by the other peaks at 701 (M-H2O) and 691 (M-28), 365 and 304. 
Comparison of the 13C-NMR spectral data of 42 with already known Voacanga alkaloids 
suggested a spirocyclic bisindole skeleton having two units of an Aspidosperma 
substructure characteristic for a vobtusine congener. 
1H-NMR spectral data revealed signals assignable to one N-H at  8.92 ppm as a singlet, 
seven aromatic protons in a range of 7.4-6.5 ppm, two methoxy groups at 3.77 (s, 
OCH3) and at  3.67 (s, COOCH3) ppm. Vobtusine was identified based on comparison 
of its spectral data with the one reported in literature. 
Vobasine 43, showed a molecular peak (ESI) at m/z 353 ([M+H]+). The 1H-NMR 
spectrum showed 4 signals in the aromatic region. Mutiplicity (d, d, t, t) confirmed the 
presence of an indole moiety. The signal of the protons at position 4 appeared at 2.63 
ppm as singlet, while the presence of the OMe group was revealed by the presence of a 
signal at 2.61 ppm as a singlet. 13C-NMR data confirmed the presence of two carbonyl 
groups at 189.6 and 171.3 ppm respectively. In addition it was observed the presence 
of a single olefinic signal at  119.4 ppm (C-19). These data were compared with those 
reported in literature and they were in agreement with each other.79 
For what regard compound 44, the mass (ESI) revealed a molecular peak at m/z 385 
([M+H]+). 
                                                          
78 Eles,J.; Kalaus, G.; Greiner, I.; Kajtàr-Peredy, M.;  Szabò, P.;  Keserû, G.M.; Szabò, L.; Szàntay, C. J. 
Org. Chem. 2002, 67, 7255-7260. 
 79 Pereira, P.S.; Franca, S.; Anderson de Oliveira, P.V.; Pereira, S. I. Quim.Nova 2008, 31, 20-24. 
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The 1H-NMR spectrum showed 3 signals in the aromatic region due to the presence of a 
substituent on the indole portion. Mutiplicity of those signals (d, d, dd) with two different 
coupling constants (J= 8.9 and J= 3Hz) confirmed the presence of the substituent at 
position 10 or 11. Moreover, the proton of the OMe group showed a signal at  3.97 ppm 
as a singlet, while the signal of the protons of the COOMe group apperead at  3.67 ppm 
as a singlet. The signal of the proton at position 18 at  1.03 ppm as a doublet confirmed 
the presence of an OH group on H-19, whose signal appeared at  4.32-3.89 as a 
multiplet. These data were compared with those reported in literature and they were in 
agreement with each other. 
Voacangine 45 showed the peak [M+H]+ (ESI) at 369 accompanied by a peak at 391 
[M+Na]+. This value showed a decrease of 16 units if compared with the mass of 
voacristine, suggesting the absence of the OH group on C-19. The 1H-NMR spectrum 
showed 3 signals in the aromatic region due to the presence of a substituent on the indole 
portion. Mutiplicity of those signals (d, d, dd) with two different coupling constants (J= 
8.9 and J= 3Hz) confirmed the presence of the substituent at position 10 or 11. In 
addition the 13C-NMR data revealed a highfield shift of the signal at C-19 (26.7 ppm) 
if compared with the corresponding signal in voacristine (71.2 ppm).  
For compounds 31 and 32 see section 3.1.5 and 3.2.2 respectively, where there is a 
discussion of their structures. 
Voacamine 46 presented (ESI) the peak [M+H]+ at 705 accompanied by a peak at 727 
(M+23) and a peak at 353. This data suggested a bis-indole structure with the peak at 
353 corresponding to the monomeric moiety.  
The junction of the two moieties by a bond between C-11 and C-161 was suggested by 
the presence of two singlet signals of the protons at positions 9 (6.92 ppm) and at 
position 12 (6.74 ppm). A crosspeak is detectable between the signal at  5.15 ppm (H-
161) and a singlet at 9.13 ppm (N-H) and between the signal at 3.78 ppm (H-141) and 
a singlet at 1.98 ppm (H-171). 
The configuration of the double bond at C-191 and C-201 was deduced by a NOE 
observed between H-181 (1.65 ppm) and H-141 (3.78 ppm). These data were similar 
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to those reported in literature. Thus the structure of compound 46 was characterized as 
voacamine, and absolute configuration was postulated on the basis of the[α]D
20value -
53.11 (c 1.1 CHCl3) in accordance with the value reported in literature.80 
The mass spectrum (ESI) of alkaloid 47 showed the peak [M+H]+ at 385. 
The 1H-NMR spectrum showed 3 signals in the aromatic region due to the presence of a 
substituent on the indole portion. Mutiplicity of those signals (d, d, dd) with two different 
coupling constants (J= 8.2 and J= 2.5 Hz) confirmed the presence of the substituent at 
position 10 or 11. Moreover the spectrum showed the signal of the proton of the methoxy 
group at  3.81 ppm as a singlet and the signal of the protons of the carbomethoxy group 
at  3.60 ppm as a singlet. Other characteristic signals appearead at 1.41 and  
ppm due to the presence of an ethyl side chain.  
Even though the absolute configuration of iboga alkaloids is known,81 the absolute 
stereochemistry at C-7 in the hydroxyindolenines derivatives is still unknown. 
A long range coupling was observed between H-15 and H-17 toghether with a NOE 
between H-3 and H-15. The spetctroscopic data of compound 47 were compared with 
those reported in literature, and they were in good agreement with each other. 
  
                                                          
80 Medeiros, W.L.; Vieira, I.J.C.; Mathias, L.; Braz- Filho, R.; Leal, K.Z.; Rodrigues-Filho, E.; Schripsema, 
J. Magn. Reson. Chem. 1999, 37, 676-681. 
81 Blahà,K.; Koblicovà, Z; Trojanek, Tetrahedron Lett.1972, 27, 2763-2766. 
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3.2. (-)-Cytisine: natural sources 
3.2.1. Introduction 
Cytisine (Figure 30) is a member of the lupine alkaloids family, first isolated in 1865 by 
Hussemann and Marmè82 from different plants belonging to 
the Leguminosae (Fabaceae) family and principally from 
the seeds of the common deciduous tree Laburnum 
anagyroides (Cytisus Laburnum, Golden rain acacia) 
(Figure 31). From a chemical point of view, (-)-cytisine is a 
quinolizidine alkaloid with a tricyclic skeleton, containing 
thebispidine framework (B- and C-rings) fused to a 2-
pyridonemoiety (A-ring). It bears two stereogenic centers, 
which were established to be 7R, 9S. 
Thousands of years ago, Indians in America started to consume Laburnum seeds for their 
purgative and emetic effects.83 In Europe, (−)-cytisine was used as a diuretic, a 
respiratory analeptic or an insecticide. Furthermore, during the Second World War, the 
leaves of Laburnum anagyroides were used as tobacco substitute. In addition (-)-cytisine 
have shown analgesic, antioxidant, antispasmotic and insecticidal activities. 
In 1890, the correct molecular formula of cytisine (C11H14N2O) has been assigned.84 
Although it was ﬁrst isolated in the mid-19th century, only in 1932 85 the structure of 
                                                          
82 Husemann, A.; Marmé ,W.Z. Chem.1865, 1, 161. 
83 (a) Tzankova, V.; Danchev, N.Biotechnol. Equip.2007, 21,151; (b) Tutka, P.; Zatoński, W. Pharmacol. 
Rep.2006, 58, 777. 
84 Partheil, A. Ber. Dtsch. Chem. Ges.1890, 23, 3201. 
 85H. R. Ing, J. Chem. Soc., 1932, 2778. 
Figure 31: Laburnum 
anagyroides 
Figure 30: Structure of (-)-cytisine 
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this alkaloid was clarified, after approximately 40 years of many efforts86 focused largely 
on analysis of the products (isolated as salts) derived from electrophilic substitutions and 
degradations/reductions of both cytisine and its methyl or acetyl derivatives. Moreover, 
its absolute configuration was established almost thirty years later 87 by chemical 
transformations by Okuda et al. 
Finally, in the mid-1980s it was totally characterized by spectroscopic analyses. 
(−)-Cytisine has been marketed in Eastern and Central Europe in tablet form under the 
trade name Tabex and used for over 40 years to help people with smoking cessation.  In 
fact, its molecular structure has some similarity to that of nicotine and it has also similar 
pharmacological effect: it was demonstrated that it has a high affinity at nicotinic 
acetylcholine receptors (nAChRs) (Figure 32) with high α4β2 subtype selectivity. 88 
 
 
Figure 32: Top and front view to the 3D structure of the pentameric nicotinic acetylcholine 
receptor 
                                                          
86 Leonard, N. J. Lupin Alkaloids. In The Alkaloids; Manske, R. H. F., Holmes, H. L., Eds.; Academic Press: 
New York, 1953; Vol. 3, pp 119−199. 
87 S. Okuda, K. Tsuda and H. Kataoka, Chem. Ind. (London), 1961, 1751. 
88 (a) Hall, M.; Zerbe, L.; Leonard, S.; Freedman, R.Brain Res. 1993, 600, 127;(b) Papke, R. L.; Heinemann, 
S. F.Mol. Pharmacol. 1994, 45, 142; (c) Anderson, D. J.; Arneric, S. P.Eur. J. Pharmacol. 1994, 253, 261. 
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nAChRs are widely expressed in the vertebrate nervous system, where they act as 
postsynaptic receptors exciting neurons or as presynaptic receptors modulating the 
release of many neurotransmitters. 89 
nAChRs are known to be involved in various central nervous system (CNS) disorders 
including degenerative ones such as Tourette’s syndrome, Parkinson and Alzheimer 
diseases, schizophrenia and some forms of epilepsy90. Moreover, they have also been 
associated with some lung tumors and autoimmune diseases.91 The possibility to use 
nicotinic ligands in the treatment of neurodegenerative disorders has been recognized92 
and encouraged the synthesis of a large number of structural analogues of nicotine, a 
very potent natural nAChRs agonist that is unfortunately characterized by many 
undesirable side effects not easily removed. 
Cytisine possesses high affinity for numerous nAChR subtypes and has also the 
capability to discriminate among some of them. Moreover, it has not received much 
attention as a lead compound for the design of structural analogues able to interact, 
allosterically or directly, with one or more receptor subtypes. In fact, one of its 
disadvantages is its low lipophilicity, which could complicate the crossing of the blood 
brain barrier.93 
The previous considerations stimulated many research groups to carry out a systematic 
structural modification of cytisine, in order to synthesize compounds of potential 
therapeutic interest either at central or peripheral level, with a particular attention for 
new nAChR subtype selective ligands. 
Furthermore, the structural modifications of cytisine should favour the passage through 
the blood brain barrier and decrease the affinity for ganglionic receptors. 
                                                          
89 Jones, S.; Sudweeks, S.; Yakel, J.L. Trends Neurosci. 1999, 22, 555-561. 
90F. Clementi, D. Fornasari, C. Gotti (Eds.), Neuronal Nicotinic Receptors, Handbook of experimental 
pharmacology, vol. 144, Springer Verlag, Berlin 2000, pp. 751-778. 
91 Vernino, S.; Adamaski, J.; Kryzer, T.; Fealey, R. V. Neurology 1998, 50, 1806-/1813. 
92 (a)Williams, M.; Sullivan, J. P.; Arneric, S. P.Drug News Perspect. 1994, 7, 205; (b) Gualtieri, F. 
Chem.Med.Chem. 2007, 2, 746; (c) Jensen, A. A.; Frølund, B.; Liljefors, T.; Krogsgaard-Larsen, P.J. Med. 
Chem.2 005, 48, 4705; (d) Gualtieri, F.Chem.Med.Chem. 2007, 2, 746. (e) Jensen, A. A.; Frølund, B.; 
Liljefors, T.; Krogsgaard-Larsen, P.J. Med. Chem. 2005, 48, 4705. 
93 Reavill, C.; Walther, B.; Stolerman, J.P.; Testa, B. Neuropharmacology 1990, 29, 619- 624. 
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The chemical modifications usually made on cytisine involved the secondary amino 
group and the pyridone ring (for example additions to the conjugated double bonds or 
electrophilic substitutions). In addition, in order to preserve the central nicotinic activity, 
it is generally claimed94 that the cationic character of the molecule should be ensured, 
leaving unchanged the typical distance between the carbonyl dipole and the basic 
nitrogen, which should be involved in a hydrogen bond with a donating group of the 
receptor. 
(−)-Cytisine looked as a lead candidate to develop novel molecules able to interact more 
selectively with the nAChRs of the central nervous system showing insignificant side 
effects.  
  
                                                          
94 Barlow, R.B.; Mc Leod,L.J. J. Pharmacol. 1969, 35, 161-174. 
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3.2.2. Biosynthesis  
In the 1960s the first studies on the biosynthesis of (−)-cytisine were described.95 They 
were later proved by extensive research on the biosynthesis of different quinolizidine 
alkaloids of the lupines family, in particular of that of sparteine. 96 
The lupine alkaloids are synthesized in the green parts of the plants and then they are 
translocated to other organs. In the intact plants, they are accumulated as salts such as 
malates in the epidermal tissues, petioles, leaves, and stems.  
Lupine alkaloids biosynthesis (Scheme 31) starts with the production of cadaverine by 
decarboxylation of lysine97, catalyzed by lysine decarboxylase, an enzyme located in 
chloroplast stroma. 
Subsequently a diamine oxidase catalyzes the oxidative deamination of cadaverine in 
favor of the synthesis of -amino pentanal. An intramolecular imine cyclization of δ-
amino pentanal leads to the formation of Δ1-Piperideine, a key intermediate for the 
formation of the quinolizidine ring system.  
After four minor reactions (Aldol-type reaction, hydrolysis of imine to aldehyde/amine, 
oxidative reaction and again Schiff base formation), the pathway is divided into two 
directions. 
The subway leads to the synthesis of (-)-lupinine by two reductive steps, while  the main 
synthesis stream goes through the Schiff base formation and coupling to the compound 
substrate, from which again the synthetic pathway splits to form (+) lupanine synthesis 
and (-)-sparteine synthesis. From (-)-sparteine, the route by conversion to (+)-cytisine 
synthesis is open. 
  
                                                          
95 (a) Schütte, Von H. R.; Lehfeldt, J. J. Prakt. Chem. 1964, 24, 143; (b) Schütte, H. R.; Lehfeldt, J. Z. 
Naturforsch.1964, 19b, 1085. 
96 Ohmiya, S.; Saito, K.; Murakoshi, I. Lupine Alkaloids. In The Alkaloids; Cordell, G. A., Ed.; Academic 
Press: New York, 1995; 47, 2−114; (b) Saito, K.; Murakoshi, I. In Studies in Natural ProductsChemistry. 
Structure and Chemistry (Part C); Atta-ur-Rahman, Ed.; Elsevier: Oxford, 1995, 15, 519−549. 
97 Nowacki, E. K.; Walter, G. R. Phytochemistry 1975, 14, 165. 
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Scheme 31: Biosynthesis ofcytisine starting from L-lysine 
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3.2.3. Total synthesis of the lupin alkaloid cytisine 
The first total synthesis of (±)-cytisine was reported by van Tamelen in 195598 and this 
was closely followed by Bohlmann’s99 and Govindachari’s100 syntheses in the late 1950s. 
In 2000 two new routes to (-)-cytisine were described by O’Neill101 and Coe102 at Pfizer. 
Then, Gallagher103 and O’Brien104 also completed the syntheses of (-)-cytisine.  
Whereas the first asymmetric synthesis of (-)-cytisine was reported by Danieli105 in 2004 
and was closely followed by the syntheses of (+)-cytisine proposed by Honda106 and 
Gallagher107. All of these different routes are summarized in Figure 33. 
 
Figure 33: Different routes to the tricyclic core of cytisine 
                                                          
98 (a) Van Tamelen, E. E.; Baren, J. S. J. Am. Chem. Soc.1955, 77,4944; (b) van Tamelen, E. E.; Baran, J. 
S. J. Am. Chem. Soc. 1958, 80,4659. 
99 Bohlmann, F.; Englisch, A.; Ottawa, N.; Sander, H.; Weise, W. Chem. Ber. 1956, 89, 792. 
100 Govindachari, T. R.; Rajadurai, S.; Subramanian, M.; Thyagarajan, B. S. J. Chem. Soc.1957, 3839. 
101 O’Neill, B. T.; Yohannes, D.; Bundesmann, M. W.; Arnold, E. P. Org. Lett.2000, 2, 4201. 
102 Coe, J. W. Org. Lett.2000, 2, 4205. 
103 Botuha, C.; Galley, C. M. S.; Gallagher, T. Org. Biomol. Chem.2004, 2, 1825. 
104 Stead, D.; O’Brien, P.; Sanderson, A. J. Org. Lett.2005, 7, 4459. 
105 Danieli, B.; Lesma, G.; Passarella, D.; Sacchetti, A.; Silvani, A.; Virdis, A. Org. Lett.2004, 6, 493. 
106 Honda, T.; Takahashi, R.; Namiki, H. J. Org. Chem.2005, 70, 499. 
107 Gray, D.; Gallagher, T. Angew. Chem., Int. Ed.2006, 45, 2419. 
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In four of the synthetic pathways to cytisine, a pyridine derivative was involved as a 
precursor of the pyridone A-ring of cytisine (Scheme 32). 
 
Scheme 32: Synthesis using a pyridine-derived A-ring 
A key difference between van Tamelen and O’Neill’s route is that the first one used a 
monosubstituted pyridine, whilst the second approach employed a methoxy-substituted 
pyridine, thus avoiding the require for an oxidation step to create the pyridone ring. In 
each of these synthetic stratgies, a cis-3,5-disubstituted piperidine needs to be assembled. 
In the synthetic pathways of cytisine reported by Coe and Gallagher (Scheme 33), a 
different pyridone disconnection was planned in which the B-ring of cytisine would be 
produced by a palladium(0)-mediated intramolecular process. In fact, in Gallagher’s 
second-generation approach (X=H), addition of the enolate directly to the pyridone was 
applied to close the ring. Gallagher’s approach also facilitated the pyridone A-ring of 
cytisine to be intact during the synthesis. Another advantage in the use of these strategies 
for the synthesis of cytisine is that they remove the need for a cis-3,5- disubstituted 
piperidine. 
 
Scheme 33: Synthesis using a glutarimide- or pyridone-derived A-ring 
 
Bohlmann and Govindachari explored the use of a substituted pyridine as a precursor to 
the B-ring of cytisine (Scheme 34). In each synthetic route, hydrogenation of a 3,5-
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disubstituted pyridine (after production of the pyridone A-ring) was performed in order 
to establish the cis stereochemistry essential for the preparation of the bispidine. 
 
Scheme 34: Synthesis using a pyridine-derived B-ring 
 
In 2004, Danieli reported the first synthetic approach to cytisine that has involved the 
construction of the C-ring from a piperidine. This route, besides being enantioselective, 
is the only one route that started with the C-ring, using a piperidine derivative as a 
starting material to complete the entire synthesis (Scheme 35). 
 
Scheme 35: Synthesis using a piperidine-derived C-ring 
These routes are the best way of preparing (-)-cytisine and its analogues for biological 
evaluation. Actually, the O’Neill approach has been used specifically for that purpose, 
even though the synthesis of each analogue of cytisine required a separate total synthesis. 
As a result, there is still a need to elaborate an approach to cytisine that produces a late-
stage intermediate that is characterized by an appropriate functionality for analogue 
preparation. Moreover, an efficient asymmetric synthesis of cytisine is still necessary, 
since each of the three asymmetric routes to (-)- or (+)-cytisine has limits.
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3.2.4.  (-)-Cytisine derivatives: synthesis of N-formyl and N-
methyl derivatives 
(-)-Cytisine and its analogues are of interest as pharmacological tools and as potential 
drugs for the treatment of a wide range of conditions, from alcohol and nicotine 
dependence, eating disorders, to schizophrenia, depression and neurodegenerative 
diseases.  
(-)-Cytisine is now an expensive chemical even if it is commercially available from 
general suppliers. Nevertheless, recently, a variation of known described methods 
permitted its efficient extraction from the seeds of Laburnum anagyroides easily 
available at low cost from seed producers.108 The availability of (−)-cytisine permitted 
its used for the synthesis of a large number of  substituted derivatives109 and of more 
complex structures including natural products, such as N-methyl cytisine and N-formyl 
cytisine. 
Up to now many N-substituted (-)-cytisine derivatives synthesized so far were prepared 
by Sparatore’s group since 1999110 and also few analogues were synthesized by 
modifying the pyridone ring. 
We taken into account the possibility to synthesize N-methyl (caulophylline) and N-
formyl cytisine because they are less toxic than cytisine.  
Like cytisine, N-methylcytisine is selective for 42* nAChR over the other major CNS 
subtype (7), but its functional potency and affinity are lower. 
In literature two different procedures have been reported for the synthesis of N-
methylcytisine starting from cytisine.111,112 In our case the desired N-methyl derivative 
has been prepared as described in Scheme 36: 
                                                          
108 (a) Marrière, E.; Rouden, J.; Tadino, V.; Lasne, M.-C. Org. Lett.2000, 2, 1121; (b) Dixon, A. J.; McGrath, 
M. J.; O’Brien, P.Org. Synth.2006, 83, 141. 
109 Rouden,J.; Lasne,M.C.;  Blanchet,J.; Baudoux, J. Chem. Rev. 2014, 114, 712−778. 
110 Canu Boido, C.; Tasso, B.; Boido,V.; Sparatore, F. Il Farmaco2003, 58, 265-277. 
111 Przybył, A.K.; Kubicki, M. J.Mol. Struct.2011, 985, 157–166. 
112 Frigerio, F.; Haseler, A.C.; Gallagher, T.Synlett. 2010, 729-730. 
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Scheme 36: Synthesis of N-methylcytisine 
In NMR analysis of N-methylcytisine it was observed the absence of NH signal at δ 2.31 
ppm as a broad signal and the presence of a signal at δ 2.20 as a singlet, corresponding 
to the methyl group. Moreover, spectroscopic data for synthetic N-methyl cytisine were 
compared with those reported in literature for this compound, and it was observed that 
they were in good agreement with each other. 
In addition crystallization of the crude material from hexane/CH2Cl2 mixture, leads to 
some colourless prisms that were analyzed by single-crystal X-ray diffraction (Figure 
34).  
 
Figure 34: Asymmetric unit of N-methylcytisine, with the atom-numbering Scheme. Thermal 
ellipsoids of non-H atoms at RT were drawn at the 50 % probability level. The usual colour code 
was employed for atoms (black: C; white: H; blue: N; red: O). 
The absolute configuration cannot be reliably assessed with the employed X-ray 
wavelength in the absence of anomalous scatterers. However, the configurational 
descriptors of the stereogenic centres are either C7 (R) and C9 (S) or C7 (S) and C9 (R). 
This analysis demonstrated that the compound crystallizes in an acentric space group 
with one molecule per asymmetric unit. Figures 35 shows the relative configuration of 
the chiral centres.  
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According to literature data113 and on the base of the [α]D
20 value (-129.4 in CHCl3), we 
were able to confirm the N-methylcytisine absolute configurationas depicted in Figure 
35. 
 
 
Figure 35: Molecular structure of N-Methylcytisine, with the CIP descriptors highlighted 
according to the asymmetric unit in Figure 8. 
Nguyen and co-workerks114 reported a novel general method of transamidation of 
carboxamides with amines using catalytic amounts of readily available, environmentally 
friendly and nontoxic boric acid under solvent-free conditions. 
Transamidation is an attractive tool in synthetic organic chemistry. Numerous efforts 
were made in order to develop more convenient protocols that allow the reactions to take 
place at relatively lower temperatures by utilizing catalysts or activating reagents.115 
These procedures posses some disadvantages, because of they involved either 
energetically favorable systems or the use of expensive activation reagents and/or 
moisture-sensitive. In addition, the scope of these methods is limited to primary amines 
and amides. Nguyen and co-workerks were able to develop a methodology whose  scope 
was demonstrated with (i) aliphatic, aromatic, cyclic, acyclic, primary, and secondary 
amines and (ii) primary, secondary, tertiary amides and phthalimide.  
Moreover they proposed a mechanism for the transamidation reaction using B(OH)3 as 
catalyst. (Scheme 37) 
                                                          
113 Freer, A. F.; Robins, D. J.; Sheldrake, G. N. Acta Crystallogr. 1987, C43, 1119-1122. 
114 Nguyen, T.B.; Sorres,J.;  Quan Tran, M.; Ermolenko, L.; Al-Mourabit A. Org.Lett.2012, 14, 3202-3205.  
115 (a) Starkov, P.; Sheppard, T.D. Org. Biomol. Chem.2011, 9, 1320; (b) Dineen, T. A.; Zajac, M. A.; Myers, 
A. G. J. Am. Chem. Soc.2006, 128, 16406; (c) C-alimsiz, S.; Lipton, M.A. J. Org. Chem. 2005, 70, 6218. 
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Scheme 37: Proposed activation mode of boric acid 
The catalytic cycle could starts with the reaction of amide with boric acid catalyst 
forming adduct A, which could take place via concerted proton transfer and B-O bond 
formation. Subsequently an addition of amine 2 to the adduct A could occur directly at 
the carbonyl (CO) bond leading to the intermediate C. Another option leading to C which 
could be predicted is the attack of amine 2 on the boron atom followed by intramolecular 
rearrangement of the amino group from B to C. Elimination of amine 2’ from tetrahedral 
intermediate C can occur in the same manner. The deamination step from C to E could 
be supported by water as described in the Scheme 37. The catalytic cycle finishes with 
the dissociation of amide 3 from boric acid.  
The function of water in improving the rate of transamidation can also be explained by 
its capacity to enhance the solubility of boric acid and avoid the formation of boric acid 
aggregates, which are less catalytically active than the boric acid. 
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We applied the same reaction condition reported by Nguyen for the synthesis of N-
formylcytisine, as depicted in Scheme 38. 
 
Scheme 38: Synthesis of N-formylcytisine 
It is important to note that ring A in cytisine has a planar conformation, while ring B is 
in a sofa conformation with the bridging C-8 atom pointed out of plane. Moreover ring 
C adopts a chair conformation and the nitrogen atom has a free electron pair in the axial 
position.  
N-Formylcytisine may occur in solution as a mixture of two conformers, in a ca. 1:1 
ratio, which differ for ring C conformation (Figure 36).  
The presence of these conformers in solution was revealed by NMR analysis because of 
the presence of a double set of signals in both 1H and 13C NMR. The spectrum was 
recorded heating from 50°C up to 100 °C, but it was impossible to observe coalescence 
of the signals. This is due to the fact that the energy barrier is too high. 
 
Figure 36: The two possible isomers of N-formylcytisine 
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3.3. Experimental part 
3.3.1. General information  
Thin-layer chromatography (TLC) was performed on Merck precoated 60F254 plates. 
Reactions were monitored by TLC on silica gel, with detection by Uv light ( = 254 nm) 
or by charring with 1% permanganate solution. Flash chromatography was performed 
using Silica gel (240-400 Mesh, Merck). NMR spectra were recordered with Brucker 
300 and 400 MHz spectrometers. Chemical shifts are reported in parts per million () 
downfield from tetramethylsilane (TMS). EI mass spectra were recorded at an ionizing 
voltage of 6 kEv on a VG 70-70 EQ. ESI mass spectra were recorded on FT-ICR 
APEXII. Specific rotations were measured with a P-1030-Jasco polarimeter with 10 cm 
optical path cells and 1 ml capacity (Na lamp,  = 589 nm). 
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Lochnericine  
 
1H-NMR (400 MHz, CDCl3):  8.96 (bs, 1H), 7.29-7.14 (m, 2H), 6.90 (d, J= 7.5 Hz,1H), 
6.82 (t, J= 7.8 Hz,1H), 3.81(s, 3H), 3.51-3.45 (m, 2H), 3.14 (d, J= 4 Hz,1H), 3.01-2.89 
(m, 2H), 2.71-2.42 (m, 4H), 2.12-1.89 (m, 1H), 1.82-1.71 (m, 1H), 1.21-1.11 (m, 1H), 
1.04-0.91 (m, 1H), 0.77 (t, J =7.5 Hz, 3H) ppm. 
13C-NMR (100 MHz, CDCl3): 168.7, 167.8, 142.9, 137.6, 127.8, 121.4, 120.7, 109.5, 
90.7, 67.6, 57.1, 54.9, 53.8, 51.08, 50.7, 50.1, 44.6, 41.0, 24.4, 23.3, 7.2 ppm. 
ESIMS: m/z= 353 [M+H]+ 
[α]D
20= -348 (c 0.7  CHCl3). 
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Pachysiphine  
 
1H-NMR (400 MHz, CDCl3):  8.97 (bs, 1H), 7.15 (d, J= 6.6 Hz, 1H), 7.12 (t, J= 7.5 
Hz, 1H), 6.87 (d, J= 7.3 Hz,1H), 6.80 (t, J= 7.7 Hz,1H), 3.76 (s, 3H), 3.59-3.51 (m, 1H), 
3.25 (dd, J= 5.3 and 3.9 Hz,1H), 3.05 (d, J =3 .8 Hz,1H), 2.96 (bs,1H), 2.90-2.86 (m, 
1H), 2.74-2.61 (m, 2H), 2.70-2.45 (m, 2H), 2.12-2.05 (m, 1H), 1.71 (dd, J= 11.2 and 5 
Hz, 1H), 1.14-0.91 (m, 2H), 0.74 (t, J =8 Hz, 3H) ppm. 
13C-NMR (100 MHz, CDCl3): 168.9, 159.8, 143.1, 137.7, 127.9, 122.4, 121.5, 108.9, 
91.2, 71.1, 56.3, 54.7, 52.1, 51.2, 51.0, 49.6, 44.0, 37.1, 26.6, 23.6, 7.2 ppm. 
ESIMS: m/z=  353 [M+H]+ 
[α]D
20= -247 (c 1.1 EtOH). 
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Vobtusine  
 
1H-NMR (400 MHz, CDCl3):  8.92 (bs, 1H), 7.20-7.10 (m, 2H), 6.92-6.75 (m, 2H), 
6.72-6.68 (m,1H), 6.62-6.60 (m, 2H), 3.77 (s, 3H), 3.67 (s, 3H) ppm. 
13C-NMR (100 MHz, CDCl3): 168.5, 167.1, 144.3, 142.8, 137.5,137.0, 134.1,127.2, 
121.1, 120.5, 118.5, 114.9, 110.9, 109.0, 94.5, 93.7, 87.5, 80.5, 69.0, 65.3, 64.2, 63.6, 
55.7, 55.0, 54.8, 53.8, 52.0, 51.0, 50.9, 48.5, 47.6, 46.2, 45.0, 44.5, 39.6, 37.0, 34.1, 34.5, 
32.4, 31.5, 31.0, 25.4, 27.2 ppm. 
ESIMS: m/z= 719 [M+H]+, 701 [M-H2O], 691 [M-28], 365, 304 
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Vobasine 
 
1H-NMR (400 MHz, CDCl3):  10.4 (bs, 1H), 7.81 (d, J= 9.0 Hz, 1H), 7.50 (d, J= 3.5 
Hz, 1H), 7.29 (t, J= 9.0 Hz,1H), 7.13 (t, J= 3.5 Hz,1H), 5.42 (q, J= 6.0 Hz, 1H), 4.01-
3.82 (m, 2H), 3.72-3.53 (m, 2H), 3.51-3.43 (m, 2H), 3.01-2.98 (m, 1H), 2.88-2.73 (m, 
1H), 2.63 (s,3H), 2.61 (s,3H), 2.51-2.48 (m, 1H), 1.72 (dd, J= 7 and 1.8 Hz, 3H) ppm. 
13C-NMR (100 MHz, CDCl3): 189.6, 171.3, 138.2, 137.7, 134.1, 129.3, 126.4, 121.5, 
120.3, 120.0, 119.4, 11.3, 58.0, 54.9, 50.1, 47.5, 43.8, 42.3, 31.2, 20.3, 12.0 ppm. 
ESIMS: m/z= 353 [M+H]+ 
[α]D
20= -100.1 (c 0.3  CHCl3). 
  
Isolation and structural characterization of natural products  
 
106 
 
Voacristine 
 
1H-NMR (400 MHz, CDCl3):  9.34 (bs, 1H), 7.19 (d, J= 8.9 Hz, 1H), 6.96 (d, J= 3.0 
Hz, 1H), 6.70 (dd, J= 8.9 and 3.0 Hz,1H), 4.32-3.89 (m,1H), 3.97 (s,3H), 3.67 (s,3H), 
3.51-3.36 (m, 2H), 3.21-2.66 (m, 7H), 2.20-1.67 (m, 2H), 1.62-1.48 (m, 2H), 1.03 (d,J= 
6.5 Hz, 3H)  ppm. 
13C-NMR (100 MHz, CDCl3): 175.6, 155.0, 137.5, 131.0, 128.7, 112.1, 111.5, 108.9, 
100.6, 72.3, 59.6, 55.9,  54.0, 52.7, 52.3, 51.4, 39.1, 36.5, 26.1, 23.0, 21.4, 20.3 ppm. 
ESIMS: m/z= 385 [M+H]+ 
[α]D
20= -22.7 (c 0.2  CHCl3). 
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Voacangine 
 
1H-NMR (400 MHz, CD3COCD3): 8.12 (bs, 1H), 7.13 (d, J= 8.5 Hz, 1H), 6.93 (d, J= 
2.8 Hz, 1H), 6.80 (dd, J= 8.9 and 3.0 Hz,1H), 3.83 (s, 3H), 3.72 (s, 3H), 3.45-3.35 (m, 
2H), 3.23-2.63 (m, 7H), 2.20-1.28 (m, 6H), 0.98 (t, J= 7 Hz, 3H) ppm. 
13C-NMR (100 MHz, CD3COCD3): 175.8, 153.9,137.2, 130.5, 128.7, 111.8, 111.0, 
110.1, 100.8, 57.2, 56.2, 55.2, 52.8, 52.1, 51.8, 38.9, 36.5, 31.5, 26.7, 26.1, 22.8, 11.2 
ppm. 
ESIMS: m/z= 369 [M+H]+, 391 [M+Na]+ 
[α]D
20= -32.9 (c 0.3  CHCl3). 
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Voacamine 
 
1H-NMR (400 MHz, CD3COCD3): 9.31 (s, 1H), 9.13 (s, 1H), 7. 76-7.49 (m, 1H), 7.15-
7.08 (m, 1H), 7.02-6.92 (m, 3H), 6.73-6.42 (m, 1H), 5.27 (q, J= 7 Hz, 1H), 5.20 (brd, 
1H), 4.07-3.98 (m, 4H), 3.78-3.48 (m, 8H), 3.23-2.97 (m, 7H), 2.72-2.48 (m, 6H), 2.44 
(s, 3H), 1.98-1.70 (m, 6H), 1.64 (d, J= 7.3 Hz, 3H), 1.27-1.07 (m, 2H), 0.84 (t, J= 6.8 
Hz, 3H) ppm. 
13C-NMR (100 MHz, CD3COCD3): 174.8, 171.1, 151.6, 138.7, 138.5, 137.1, 136.0, 
130.6, 129.9, 129.6, 127.8, 121.4, 118.7, 118.3, 117.5, 111.2, 109.9, 109.8 (d), 99.5, 
60.3, 57.6, 56.1, 54.2, 53.7, 52.8, 52.5, 50.4, 49.9, 43.8, 40.8, 38.6, 37.5, 36.8, 36.4, 34.0, 
32.0, 27.6, 26.5, 22.7, 19.5, 12.5, 10.1 ppm. 
ESIMS: m/z= 705 [M+H]+, 727 [M+23] 
[α]D
20= -53.11 (c 1.1 CHCl3). 
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Voacangine hydroxyindolenine 
 
 
1H-NMR (400 MHz, CDCl3):  7.24 (d, J= 8.2 Hz, 1H), 6.88 (d, J= 2.5 Hz, 1H), 6.81 
(dd, J= 8.4 and 2.5 Hz,1H), 3.81 (s, 3H), 3.60 (s, 3H), 3.48 (ddd,J= 12.5, 12 and 4.5 
Hz,1H), 2.95 (dd, J= 14.5 Hz,1H), 2.73 (s, 2H), 2.72-2.68 (m, 1H), 2.12-2.02 (m, 1H), 
1.94-1.71 (m, 5H), 1.61-1.20 (m, 3H), 0.86 (t, J= 7 Hz, 3H) ppm. 
13C-NMR (100 MHz, CDCl3): 185.2, 172.8, 159.2, 144.7, 144.0, 121.3, 113.2, 108.2, 
88.2, 58.5, 58.2, 55.1, 53.5, 49.0, 48.4, 37.2, 34.5, 34.1, 32.2, 27.0, 26.8, 11.2 ppm. 
ESIMS: m/z= 385 [M+H]+ 
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Synthesis of N-methylcytisine 
 
To a solution of (-)-cytisine (0.500 g, 2.60 mmol) in MeOH (15 mL) and THF (15 mL) 
wasadded formaldehyde (37% aq solution, 1.1 mL, 15.6 mmol) followed by NaCNBH3 
(0.571 g, 9.10 mmol). The reaction mixture was stirred at r.t. for 1.5 h. The solvent was 
removedin vacuo and the reaction mixture was eluited with CH2Cl2 and washed with 
saturated aqueous NH4Cl solution. The organic extracts were combined and the solvent 
was removed in vacuo giving N-methylcytisine  as a colourless oil (0.342 g, 64%). 
1H-NMR (CDCl3, 300 MHz):  7.25 (m, 1H), 6.41 (d, J= 8,8 Hz, 1H), 5.96 (d, J= 6,5 
Hz, 1H), 4.02 (d, J= 15,3 Hz, 1H), 3.87 (dd, J= 15,3 Hz; 6,5 Hz, 1H), 2.91-2.80 (m, 4H), 
2.49-2.41 (m, 1H), 2.32-2.20 (m, 1H), 2.29 (s, 3H), 1.88 (d, J=11 Hz; 1H), 1.77 (d, J=12 
Hz; 1H) ppm. 
13C-NMR (100 MHz, CDCl3): 163.7, 151.3, 138.7, 116.7, 104.8, 62.4, 62.0, 46.1, 35.4, 
29.7, 27.9, 25.3 ppm. 
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Synthesis of N-formyl cytisine 
 
A mixture of cytisine (0.500g, 2.6 mmol), formammide (0.117g, 2.6 mmol), water (0.93 
g, 5.2 mmol) and boric acid (0.016 g, 0.26 mmol) was stirred at 100°C.  
After 48 hours the mixture was diluted with H2O and the aqueous phase was extracted 
with diethyl ether. Then the mixture was washed with saturated aqueous NH4Cl and the 
organic extracts were dried over anhydrous sodium sulfate. The solvent was removed in 
vacuo giving the N-formylcytsineas a colourless oil (0.330 g, 58% overall yield). 
Major rotamer:  
1H-NMR (CDCl3, 500MHz): 7.88 (s, 1H), 7.22 (dd, J = 1.0, 6.9 Hz, 1H),6.52 (d, J = 
6.6 Hz, 1H), 6.02 (dd, J = 6.9, 1.0 Hz, 1H), 4.52-4.43 (m, 1H), 4.12 (d, J = 6.0 Hz, 1H), 
3.90-3.95 (m, 1H), 3.64-3.69 (m,1H), 3.46-3.40 (m, 1H), 3.16 (br. s, 1H), 2.95-2.90 (m, 
1H), 2.55 (br. s, 1H), 2.07-2.11 (m, 2H) ppm. 
13C-NMR (CDCl3, 125 MHz): 163.0, 159.9, 147.1, 139.0, 117.5, 106.1, 52.2, 48.4, 46.9, 
34.2, 27.4, 26.9 ppm. 
Minor rotamer: 
1H-NMR (CDCl3, 500MHz):  7.65 (s, 1H), 7.25 (dd, J = 6.9, 1.0 Hz, 1H,),6.44 (d, J = 
6.9 Hz,1H), 6.02 (dd,J = 6.9, 1.0 Hz, 1H,), 4.52-4.43 (m, 1H),4.12 (d, J = 6.0 Hz, 1H), 
3.90-3.95 (m, 1H), 3.53-3.57 (m,1H), 3.46-3.40 (m, 1H), 3.11 (br. s, 1H), 2.93-2.89 (m, 
1H), 2.55 (br. s, 1H), 2.15-2.19 (m,2H) ppm. 
13C-NMR (CDCl3, 120MHz): 163.1, 161.0, 148.0, 138.6, 118.1, 105.5, 53.0, 48.8, 46.1, 
34.2, 26.7, 26.0 ppm. 
4. Natural products as lead compounds 
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4.1. Synthesis of an analogue of the natural product doliculide 
4.1.1. Introduction 
This project was performed under the umbrella of COST Action CM1407 (Challenging 
Organic Synthesis Inspired By Nature: From Natural Product Chemistry To Drug 
Discovery). It was developed in the laboratory of Prof. Karl-Heinz Altmann (Zurich, 
Switzerland) in order to continue the collaboration between Prof. Karl-Heinz Altmann 
and Prof. Daniele Passarella and to combine our experience in the synthesis of natural 
products.  
Doliculide (Figure 37), a 16-membered depsipeptide, has been isolated in 1994 from the 
Japanese sea hare Dolabella auricularia.116 The great deal of attention in the synthesis 
of this natural product is due to its cytotoxic properties1: it exhibited extraordinarily 
potent cytotoxic activity against HeLaS3 cells with an IC value of 0.001 g/mL.117 
 
 
 
 
Figure 37: Doliculide structure 
Furthermore, doliculide is a very potent actin binder. Actin, a globular multi-functional 
protein,118 is one of the targets in cancer research. It can be present as either a free 
monomer called G-actin (globular) or as part of a linear polymer microfilament called 
F-actin (filamentous), both of which are essential for such important cellular functions 
as the mobility and contraction of cells during cell division. 
The actin cytoskeleton is therefore a target for toxins and the actin equilibrium can be 
disturbed or overridden. The effect of doliculide is essentially the same as of the natural 
products jasplakinolide and phalloidin: it promotes assembly of pure G-actin into F-
                                                          
116 Ruoli B. et al.J. Biol. Chem. 2002, 277, 32165.  
117 Ishiwata, H.; Nemoto, T.; Ojika, M.; Yamada, K. J. Org. Chem.1994, 59, 4710. 
118 R. Dominguez and K. C. Holmes, Annu.Rev. Biophys. 2011, 40, 169. 
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actin. Doliculide causes over-polymerisation into F-actin by binding to the actin 
cytoskeleton at a similar as phalloidin 
(Figure 38).119 
Only a few total syntheses of doliculide have 
been reported to date. The Altmann group, 
has recently reported a new total synthesis of 
doliculide114 which features a longest linear 
sequence of 11 steps and a highly atom efficient strategy. 
In addition, several analogues of doliculide have been synthesised in the Altmann group 
in order to determine which features of the doliculide structure are essential for binding 
to the actin cytoskeleton and causing cytotoxic effects.  
  
                                                          
119 Foerster, F.; Braig, S.; Altmann, K-H.; Chen, T.; Vollmar, A. M.; Bioorg.Med. Chem. 2014, 22, 5117.  
Figure 38: Assembly dynamics 
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4.1.2. Aim of the project and retrosynthetic plan 
As part of these SAR investigations conformational studies were also conducted by 
solution NMR (with free doliculide), which indicated an anti-periplanar conformation 
about the C4-C5 bond. Based on these findings and in order to investigate if restricting 
the conformation about the C4-C5 bond in the preferred conformation deduced from the 
solution NMR studies, the group designed 5-desmethyl analog 51 (Figure 39), which 
incorporates a trans double bond between C4 and C5. Preliminary work towards the 
synthesis of this analog has already been performed in the Altmann group, but the 
synthesis has not been completed. 
 
Figure 39: Structure of doliculide analogue 
The aim of this project was to complete the synthesis of the new doliculide analogue 51. 
Scheme 39 shows the retrosynthetic analysis for the target structure. 
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Scheme 39: Retrosynthesis of the target doliculide analogue. 
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4.2. Result and discussion 
4.2.1.  Synthesis of dipeptide 
Protected dipeptide 56 was prepared from commercially available 3-iodo-D-tyrosine 
(Scheme 40). Ghosh et al. proposed this route120 in the total synthesis of doliculide. 
 
Scheme 40: Synthesis of N-methylated peptide 56 
Commercially available 3-iodo-D-tyrosine was converted into the corresponding ester 
derivative 52, which was transformed into the corresponding N-Boc-protected derivative 
53. Protection of the phenolic group as a TIPS ether followed by N-methylation with 
sodium hydride and methyl iodide in a mixture (10:1) of THF and DMF furnished the 
N-methylated tyrosine derivative 56. 
After cleavage of the N-Boc protecting group, the resulting intermediate 56 was 
condensed with N-Boc-glycine with EDC/HOBt (Scheme 41). Unfortunately a cleavage 
of the TIPS protecting group occur. To avoid this problem, the amide coupling step was 
previously tried by Altmann group using PyBroP as the coupling agent. PyBroP 
successfully coupled the amine and carboxylic acid with no cleavage of the TIPS 
protecting group.  
                                                          
120 Ghosh A. K. and Liu C.Org. Lett. 2001, 4, 635. 
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Scheme 41: Formation of the dipeptide unit 
Selective cleavage of the ester group could be accomplished with LiOH at 0°C (Scheme 
42). The resulting dipeptide acid F was directly used in the following step without further 
purification. 
 
Scheme 42: Preparation of acid F 
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4.2.2. Synthesis of secondary alcohol fragment 
The synthesis of secondary alcohol fragment E starts with crotylation of aldehyde I. The 
crotylation step first required the synthesis of the reagent 61 (Scheme 43), which can be 
prepared from trans-2-butene, Schlosser’s base (generated in situ), triisopropyl borate, 
and (−)-DIPT.121 
 
Scheme 43: Generation of crotylation reagent 61 
This reaction proceeded in a low yield of only 19% with the crude spectrum showing a 
2:1 mixture of DIPT and 61. However, it has been reported in literature that the crude 
reagent with excess DIPT (≤ 0.4 eq.) is routinely used in crotylation reactions without 
purification as the purity seems to have no apparent effect on stereoselectivity. The 
aldehyde I was therefore crotylated using the impure reagent 61 to yield free alcohol 62, 
as is shown in Scheme 44. 62 was in a de of 50 % as shown in Figure 40 and Figure 
41.122 
 
 
Scheme 44: Crotylation of aldehyde 62 
                                                          
121 Roush W. R. et al., J.Am. Chem.Soc. 1990, 112, 6339. 
122 Roush, W. R.; Walts, A. E.; Hoong, L. K. J. Am. Chem. Soc. 1985, 107, 8186.  
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Figure 40: Diastereomericcalculation by 1H-NMR 
 
Figure 41: Diastereomeric calculation by 1H-NMR 
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The predicted Zimmerman-Traxler 6-membered chair-like transition state for this 
crotylation is depicted in Figure 42. This transition state accounts for the stereoselectivity 
of the crotylation. 
 
Figure 42: Intermediate formed in the crotylation reaction 
To yield the secondary alcohol fragment E, H, which was already available in the 
laboratory, was submitted to a selective cleavage of the PMB (4-Methoxybenzyl ether) 
protecting group in the presence of DDQ (2,3-Dichloro-5,6-dicyano-1,4-benzoquinone) 
(Scheme 45). The resulting secondary alcohol E was directly used in the following step 
without further purification. 
 
 
Scheme 45: Deprotection reaction of H 
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4.2.3. Fragment coupling and completation of the synthesis 
The secondary alcohol F was coupled to the dipeptide unit E to form an ester 63 (Scheme 
46).  
 
Scheme 46: Coupling of F and E 
Unfortunately, the product decomposed during the reaction, and this step could not be 
repeated because the time was limited. 
For completion of the analogue, H should be again resynthesized. Next step will be again 
PMB cleavage using DDQ/ H2O to yield a secondary alcohol. This secondary alcohol 
can then be coupled to the dipeptide unit to form an ester. After coupled to the dipeptide 
unit to form an ester. This ester will then be Boc cleaved to allow coupling of D via an 
amide formation. The depsipeptide could then be cyclised by a ring closing metathesis. 
Cleavage of the silyl protecting groups would then give the doliculide analogue 51 
(Scheme 47).  
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Scheme 47: Plan for the completion of the target doliculide analogue 51. 
This compound will be assessed for its effects on actin polymerization and cancer 
cell proliferation in collaboration with the group of Prof. Angelika Vollmar at the 
Ludwig-Maximilians-Universtity in Munich. 
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4.3. Pironetin-dumetorine hybrid compounds 
4.3.1. Introduction 
Microtubules, major structural components in eukaryotic cells, are the target of a large 
and various group of natural product anticancer drugs.  
They are dynamic polymers with a fundamental role in many cellular processes, most 
particularly cell division process, as they are key constituents of the mitotic spindle.123 
Microtubules are composed of tubulin heterodimers, each consisting of two tightly 
bound tubulin subunits called α- and β-tubulin. Tubulin subunits self-assemble in 
longitudinal rows called protofilaments, which organized themselves in parallel 
structures of 13 units forming cylindrical microtubules with a hollow core (Figure 43). 
 
Figure 43: Polymerization of microtubule 
Microtubules characteristics properties are dynamic instability and polarity. 
In fact, the assembly of tubulin heterodimers creates a polarity on the microtubule that 
significantly influences the polymerization rates of the two ends of the microtubule. The 
faster growing end, with -tubulin facing the solvent, is called the plus (+) end whereas 
the slower growingend, with -tubulin facing the solvent, is named the minus (-) end.  
The biological functions of microtubules in cells are determined and regulated in large 
part by their polymerization dynamics. Microtubules are in a constant state of formation 
                                                          
123 The Role of Microtubules in Cell Biology, in: T. Fojo (Ed.), Neurobiology and Oncology, Humana Press, 
Totowa, New Jersey, 2008. 
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and disruption, called dynamic instability.124 It is charachterized by four main 
parameters: a) the rate of shortening; b) the rate of microtubules growth; c) the frequency 
of transition from shortening to growth (named “rescue frequency”); and d) the 
frequency of transition from the growth or paused state to shortening (named 
“catastrophe frequency”). Different factors regutale the dynamic of microtubule 
formation, however the most important is the rate of GTP (guanosine triphosphate) 
hydrolisis.There are two GTP-binding stes on tubulin, a hydrolysable site on the -
subunit and a non-hydrolyzable site on the -subunit.  
Both α- and β-tubulin bind GTP in a reversible way at a site in the -subunit and the 
GTP hydrolyzed guanosine diphosphate (GDP) and orthophosphate (Pi) during 
polymerization.  
This GTP hydrolysis decreases the binding affinity of tubulin for closest molecules, 
thereby favouring depolymerization and resulting in the dynamic behaviour of 
microtubules (Figure 44). 
 
Figure 44: Microtubule dynamics 
Microtubule dynamics are crucial to the process of mitosis: when cells enter mitosis 
during the cell cycle, microtubule reorganized into the mitotic spindle. The processes of 
depolymerizing the interphase microtubule structure and forming the mitotic spindle 
involve highly coordinated microtubule dynamics. Thus, any molecules able to interact 
                                                          
124 Mitchison, T.; Kirschner, M. Nature 1984, 312, 237-242. 
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with microtubules dynamics, will have the ability to influence cell cycle division process 
by inhibition or promotion of microtubule assembly.  
Drugs that inhibit microtubule dynamics are classified as microtubule stabilizer or 
destabilizer, respectively. Both microtubules stabilizing and destabilizing agents have 
been successfully applied in the treatment of several types of cancer.125 
Microtubules stabilizing agents arrest microtubules depolymerisation targeting two 
different sites on -tubulin, the taxoid or the laulimalide/peloruside binding site, while 
microtubules destabilizing agents block microtubules assembly and/or induce 
depolymerisation by binding to the vinca or the colchicine binding site. Either sites are 
localized at the interface between - and - subunits, whose reciprocal orientation is 
modified upon ligand binding.  
Recently, microtubules targeting agents have also been shown to be neuroprotective in 
neurodegenerative diseases, such as Parkinson's and Alzheimer's diseases.126127 
Most of tubulin-binding molecules interact with -tubulin, producing either disruption 
or stabilization of microtubules. A well-known representative of this kind of molecules 
is paclitaxel, the first described tubulin interacting drug that was found to stabilize 
microtubules. 128 
On the contrary, only few compounds have been identified to bind -tubulin. One of 
them is the 5,6-dihydro-α-pyrone pironetin (Figure 45), a natural potent inhibitor of 
tubulin assembly that has been found to arrest cell cycle progression at G2/M phase. 
Thus, it constitutes a pharmacologically interesting compound.  
  
                                                          
125 Dumontet, C.; Jordan, M.A. Nat. Rev. Drug Discov. 2010, 9, 790-803. 
126 (a) Brunden, K.R.; Trojanowski, J.Q.; Smith, A.B. et al. Bioorg. Med. Chem. 2014, 22, 5040-5049; (b) 
Ballatore, C.; Brunden, K.R.; Huryn, D.M. et al. J. Med. Chem. 2012, 55, 8979-8996. 
127 Cappelletti,G.; Cartelli, D.; Christodoulou, M.S.; Passarella, D. Curr. Pharm.Des. 2016, 22. 
128 Fu, Y.; Li, S.; Zu, Y.; Yang, G.; Yang, Z.; Luo, M.; Jiang, S.; Wink, M.; Efferth, T. Curr. Med. Chem. 
2009, 16, 3966-3985. 
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Figure 45: Pironetin and its groups essential for the biological activity  
Some structure-activity relationships studies129 on natural pironetin (Figure 46) 
displayed that the presence of the conjugated C2-C3 double bond and of the hydroxyl 
group at C-9 together with the hydroxyl group at C-7, either free or methylated, are 
essential for its biological activity. There are no data available about the importance of 
the remaining structural features. 
 
Figure 46: Schematic model of the covalent union of pironetin to its binding site at the -tubulin 
surface 
It has been proposed that the Lys-352 residue of the -tubulin chain adds in a Michael 
fashion to the conjugated double bond of pironetin therefore forming a covalent bond 
with C-3 of the dihydropyrone ring. In addition, Asn-258 residue of -tubulin holds the 
pironetin molecule through two hydrogen bonds to the pyrone carbonyl C-1 and the 
methoxy oxygen atoms C-9. 
                                                          
129 (a) Kondoh, M.; Usui, T.; Kobayashi, S.; Tsuchiya, K.; Nishikawa, K.; Nishikiori, T.; Mayumi, T.; Osada, 
H. Cancer Lett. 1998, 126 , 29-32; (b) Kondoh, M.; Usui, T.;Nishikiori, T.;Mayumi, T.; Osada, H. Biochem. 
J. 1999, 340, 411-416; (c) Watanabe, H.; Watanabe, H.; Usui, T.; Kondoh, M.; Osada, H.; Kitahara, T. J. 
Antibiot.2000, 53, 540-545; (d) Usui, T.; Watanabe, H.; Nakayama, H.; Tada, Y.; Kanoh, N.; Kondoh, M.; 
Asao, T.; Takio, K.; Watanabe, H.; Nishikawa, K.; Kitahara, T.; Osada, H. Chem. Biol.2004, 11, 799-806. 
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4.3.2. Docking studies of pironetin 
Docking studies have been performed in order to evaluate the interactions modes of 
pironetin with -tubulin. Figure 47 shows the formation of hydrogen bonds between the 
conjugated pyrone ring of pironetin and Lys-352, Cys-315 residues of the -tubulin 
chain. The hydroxyl group of pironetin interacts with Met-313 and Thr-257 residues 
according its orientation.  
There are also non-polar interactions between the alkylic chain of pironetin and the Leu-
254, Val 260 and Pro-261 residues. 
 
 
 
Figure 47: Binding pocket of pironetin (on the left)  and interactions of pironetin with -tubulin 
(on the right)  
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4.3.3. Aim of the project and retrosynthetic plan 
In this context, we were fascinated by the pironetin and dumetorine structures and we 
planned the synthesis of hybrid compounds (Figure 48), as new tubulin binders, bearing 
a piperidine ring instead of oxygen in position 9 (OMe), that has been recognised as a 
previleged structure in medicinal chemistry.130 
Moreover, these hybrid compounds should 
contain a conjugated double bond C8-C9 and a 
hydroxyl group at C2’, either free or methylated, 
according to structure activity studies on natural 
pironetin that showed those groups are essential 
for biological activity. 
These compounds are characterized by the 
presence of three stereogenic centers so we were 
able to prepare eight stereoisomers with the aim of evaluating their influence on tubulin–
microtubule polymerization processes.  
The key steps for the synthesis of the desired compounds are the allylation mediated by 
enantiopure DIP-Cl (diisopinocampheyl chloroborane) and the ring closing metathesis 
according to the synthetic plan previously described for the preparation of dumetorine.131 
Scheme 48 reports the retrosynthetic plan for the preparation of the eight pure 
stereoisomers with the aim to study the direct interaction with tubulin. In this way, we 
aimed to find new scaffolds in order to investigate the chemical space of the tubulin 
                                                          
130 Watson, P.S.; Jiang, B.; Scott, B. Org. Lett. 2000, 2, 3679–3681. 
131 (a) Riva, E.; Rencurosi, A.; Gagliardini, S.; Passarella, D.; Martinelli, M. Chem. Eur.J. 2011, 17, 6221-
6226; (b) Passarella, D.; Riva, S.; Grieco, G.; Cavallo, F.; Checa, B.; Arioli, F.; Riva, E.; Comi, D.; Danieli, 
B. Tetrahedron: Asymmetry 2009, 20, 192-197. 
 
Figure 48: Design of hybrid compounds 
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binders132 and to develop new drugs active against cancer, Parkinson’s133 and 
Alzheimer’s diseases.134 
 
Scheme 48: Retrosynthetic plan for all hybrid compounds 
  
                                                          
132 Canela, M.; Perez-Perez, M.; Noppen, S.; Saez-Calvo, G.; Diaz, J.; Camarasa, M.; Liekens, S.; Priego, 
E. J. Med.Chem.2014, 57, 3924-3938. 
133 Cartelli, D.; Casagrande, F.; Busceti, C. L.; Bucci, D.; Molinaro, G.; Traficante, A.; Passarella, D.; 
Giavini, E.; Pezzoli, G.; Battaglia, G.; Cappelletti, G. Sci. Rep. 2013, 3, 1837-1846. 
134 Zhang, B.; Carroll, J.; Trojanowski, J. Q.; Yao, Y.; Iba, M.; Potuzak, J. S.; Hogan, A.M.L.; Xie, S. X.; 
Ballatore, C.; Smith, A. B.; Lee, V. M. Y.; Brunden, K. R. J.Neurosci. 2012, 32, 3601-3611. 
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4.3.4. Hybrid compounds docking 
For these compounds, only a rigid docking has been performed thanks to the 
collaboration with Prof. M. Sironi and Dr. S. Pieraccini of Dipartimento di Chimica at 
Università degli studi di Milano. These studies demonstrate that the binding modes and 
the orientation of hybrids are similar to those observed in the rigid docking of natural 
pironetin (Figure 49).  
The pyrone ring is directed towards the entrance of the pocket while the piperidine ring 
occupies the position of the alkyl chain of pironetin.  
It is important to note that these compounds are able to form more hydrogen bonds with 
-tubulin compared to pironetin, with a consequent increase of the interaction with 
tubulin. 
 
 
Figure 49: Some interactions modes of hybrids compound and -tubulin. Hydrogen bonds 
between the pyrn ring andresidues Lys-352, Phe-351, Cys-315. 
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4.4. Result and discussion 
4.4.1. Synthesis of hybrid compounds 
Commercially available racemic 2-(piperidin-2-yl) ethanol 64 was converted into the 
corresponding N-Boc-protected derivative 65 (Scheme 49). Oxidation of alcohol 65 
under Swern condition provided aldehyde 66. 
 
Scheme 49: Synthesis of aldehyde 66 
Subsequent reaction is based on the reactivity and versatility of aldehyde 66 (Scheme 
50), previously used in both racemic and enantiopure forms.135 
 
Scheme 50: Stereoselective allylation of aldehyde 66 
                                                          
135 Perdicchia, D.; Christodoulou, M. S.; Fumagalli, G.; Calogero, F.; Marucci, C.; Passarella, D. Int. J. Mol. 
Sci.2016, 17, 17. 
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Brown's asymmetric allylation with the B-allyl diisopinocampheylborane,136 allowed 
formation of allylic alchols 70a–73a with total stereocontrol at C2′ (numbering system 
of the target compound) thus providing two enantiopure diastereoisomers (on the basis 
of HPLC traces).137 
Using (–)-DIP-Cl (Scheme 50) we were able to obtain 70a and 71a characterized by the 
S configuration at position 2′ whereas the use of (+)-DIP-Cl (Scheme 50) lead to 
compounds 72a and 73a. On the basis of previously reported spectroscopic data 138,139 
and by performing the same reaction on small scale using, as substrates, the pure 
enantiomers of aldehyde 66, we were able to confirm the assignment of the structures. 
In particular, the reaction of (S)-66 with (–)-DIP-Cl furnished 70a as a single product 
revealing that the configuration of the newly formed stereogenic center is dictated by the 
chirality of DIP-Cl. In the same manner, reaction of (R)-66 with (–)-DIP-Cl gave 71a 
whereas the use of (+)-DIP-Cl with (S)-66 and (R)-66 provided 72a and 73a respectively. 
Enantiomerically pure compounds 70a–73a were submitted to methylation reaction 
(Scheme 50) and subsequent ozonolysis oxidation provided corresponding aldehydes 
74-77 in 40–50 % yield. (Scheme 51) 
 
Scheme 51: Synthesis of aldehydes 74-77 
                                                          
136 Ramachandran, P. V.;Chen, G. M.; Brown, H. C. Tetrahedron Lett.1997, 38, 2417–2420. 
137 Angoli, M.; Barilli, A.; Lesma, G.; Passarella, D.; Riva, S.; Silvani, A.; Danieli, B. J. Org. Chem.2003, 
68, 9525–9527. 
138 Passarella, D.; Barilli, A.; Belinghieri, F.; Fassi, P.; Riva, S.; Sacchetti, A.;Silvani, A.; Danieli,B. 
Tetrahedron: Asymmetry, 2005, 16, 2225–2229. 
139 Passarella, D.; Angoli, M.; Giardini, A.; Lesma, G.; Silvani, A.; Danieli, B. Org. Lett.2002, 4, 2925-
2928. 
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One more Brown's asymmetric allylation reaction afforded compounds 78a–85a as pure 
single stereoisomers (Scheme 52). 
 
Scheme 52: Stereoselctive allylation of aldehydes and acylation reaction 
Acylation of compounds 78a-85a with acryloyl chloride led to the formation of 78b-
85b. Subsequent ring closing metathesis in the presence of Hoveyda–Grubbs-II catalyst 
(Scheme 53) gave compounds 86a–93a with 70–80 % yield and then they were 
submitted to Boc cleavage with TFA in CH2Cl2 (via b in Scheme 53). 
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Scheme 53: Synthesis of target compounds 86b-93b 
Finally, target compounds 86b–93b were obtained as ammonium trifluoroacetate salts 
and they were submitted to biological evaluations with the aim of illustrating 
theirinfluence on the tubulins-microtubules polymerization. 
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4.4.2. Biological evaluation 
The ability of compounds 86b–93b to influence tubulin polymerization was evaluated 
by sedimentation assays (Figure 50) thanks to the collaboration with Prof. G.Cappelletti 
of the Dipartimento di Biologia at Università degli studi di Milano.  
Thiocolchicine (10 μM) was used as a reference compound that, as expected, acts by 
inhibiting the aggregation of tubulin. We also compared the activities of 86–93 against 
that of previously reported pironetin analog 94.140 
 
 
 
 
 
Figure 50: Biological results 
From this analysis we observed that the new compounds appear to moderately impact 
microtubule formation. 
In particular 86b, 88b and 89b significantly increase the ratio between microtubules and 
tubulin dimers, whereas agents 90b, 91b and 93b inhibit microtubule assembly in a 
fashion similar to that previously reported for 94. 
                                                          
140 Alberto Marco, J.; Garcia-Pla, J.; Carda, M.; Murga, J.; Falomir, E.; Trigili, C.; Notararigo, S.; Fernando 
Diaz, J.; Barasoain, I. Eur. J. Med. Chem.2011, 46, 1630–1637. 
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4.5. Bivalent compounds toward -tubulin interaction 
4.5.1. Introduction 
 
In the last years, our research group explored the possibilities offered by the concept of 
multivalency141 for the design of new antitubulin agents.142 The theory of multivalency 
is based on the consideration that in Nature the activity and selectivity of several lead 
compounds are improved through the creation of their homo- or heterodimers.143 As a 
result, the concept of multivalency can be applied as a successful approach for designing 
bivalent compounds.  
In particular microtubule-targeting bivalent hybrids represent an emerging class of 
molecules that may be a valuable tool to increase the activity and selectivity of 
monomeric drugs. Thus, bifunctional drugs, characterized by two components able to 
bind to different sites inducing a multiple effect and increasing their pharmacological 
activity, represent a specif class of microtubules targeting agents. 
According to Meunier144 hybrid molecules can be divided into three categories (Figure 
51): 
a) Both parts of the hybrids act on the same target (not necessarily on the same site) 
b) Each parts acts on a different target:  the hybrids are like dual prodrugs if the 
linker is cleaved in the biologycal system. 
c) The parts of the hybrid molecule may act at the same time on two connected and 
closely related binding sites of the same target.  
 
                                                          
141 Synthetic Multivalent Molecules; Choi, Seok-Ki, Ed.; Wiley Interscience: USA, 2004. 
142 Passarella, D.; Giardini, A.; Peretto, B.; Fontana, G.; Sacchetti, A.; Silvani, Al.; Ronchi, C.; Cappelletti, 
G.; Cartelli, D.; Borlak, J.; Danieli, B. Bioorg. Med. Chem.2008, 16, 6269–6285. 
143 Berube, G. Curr. Med. Chem. 2006, 13, 131. 
144 Meunier, B. Acc. Chem. Res. 2007,41, 69. 
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Figure 51: Categories of hybrid molecules according to their mode of action. 
Bifunctional compounds are able to interfere with protein-protein interaction soffering a 
powerful means of influencing the function of selected proteins within the cell. 
Protein-protein interactions have a central role in cellular processes. In fact, anomalous 
or inappropriate interactions posses the potential to induce pathological conditions while 
the modulation of such protein-protein interactions by organic molecules offers 
possibilities for the treatment of human disease. 
On the base of recent results regarding the crystallographic structure of tubulin in 
complex with thiocolchicine,145 we moved our attention toward the preparation of 
bivalent hybrid compounds linking our pironetin-dumetorine hybrid compounds and a 
drug able to bind -tubulin by a linker (Figure 52).  
 
 
 
 
 
 
Figure 52: General structure of bivalent derivatives 
  
                                                          
145 Marangon, J.; Christodoulou M. S.; Casagrande, F.V.M.; Tiana, G.; Dalla Via, L.; Aliverti, A.; 
Passarella, D.; Cappelletti, G.; Ricagno, S. Biochem.Biophys.Res.Comm. 2016, 479, 48-53. 
binder 
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4.5.2. Aim of the work  
The first attempt for the synthesis of bivalent compound was to connect one of our hybrid 
compounds and deacetylthiocolchicine by a linker containing 10 carbon atoms (Figure 
53).  
 
Figure 53: Structure of our first bivalent molecule. In blue deacetylthiocolchicine, in red sebacic 
acid and in green 86b as hybrid compound. 
As active compounds, we chose deacetylthiocolchicine because it is a potent inhibitor of 
tubulin polymerization that it is able to bind tubulin more rapidly than colchicine.146 
Hydrolysis of (+)-thiocolchicine with 20% HCl yielded (+)-deacetylthiocolchicine 
(Figure 54),147 that can attack a suitable spacer binding to the amino group present in 
position 7 as acetamide. 
 
Figure 54: Deacetylthiocolchicine 
Ideally, homo- and hetero-bifunctional tubulin binders should be able to simultaneously 
occupy two binding sites on the microtubules assembly. To do this, the three-
                                                          
146 Kang, G. J.; Getahunt, Z.; Muzaffar, A.; Brossi, A.; Hamel, E. J. Biol. Chem. 1990, 265, 10255. 
147 Velluz, L.; Muller, G. Bull. Soc. Chim. Fr.1955, 194. 
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dimensional structure of a microtubule section was considered. From this analysis it was 
observed that the distances between the targeted sites within the same protofilament has 
to be around 40 Å, a distance that could be covered by a linker of about 50 atoms. 
Future work will be the preparation of a new series of bivalent molecules that will 
comprise different pironetin-dumetorine hybrids and various β-tubulin binders. The 
chemical nature and length of the linkers between the two moieties will be varied with 
the aim of optimising the biological activity. The binding affinities of the prepared 
analogues will be measured experimentally by fluorescence quenching and compared 
with the suggestions deriving from computational studies. 
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4.5.3. Synthetic strategy 
As depicted in Figure 55, two disconnections have been envisioned, in the 
correspondence of the amide bonds, obtainable via two condensation reactions. 
 
Figure 55: Disconnectionson our drug-hybrid conjugate 
The first step consist in the preparation of (+)-deacetylthiocolchicine starting from (+)-
thiocolchicine (Scheme 54).148 
 
 
Scheme 54: Syntheis of (+)-deacetylthiocolchicine 
Compound 96 was submitted to a condensation reaction with sebacic acid using 
BOPCl/Et3N as activating system in CH2Cl2 at room temperature (Scheme 55). 
 
                                                          
148 Shi, Q.; Verdier-Pinard, P.; Brossi, A.; Hamel, E.; Lee, K.H. Bioorg. Med. Chem., 1997, 5, 2277-2282. 
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Scheme 55: Condensation between sebacic acid and compound 98 
Then we made a second condensation between 98 and hybrid copound 86b using again 
BOPCl/Et3N. NMR and mass analysis of the purified compound confirmed the structure 
of 99 (Scheme 56). 
 
Scheme 56: Synthesis of bivalent compound  
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4.5.4. Biological evaluation and future work 
From biological evaluation (Figure 56), we observed that compound 99 is able to inhibit 
tubulin polymerization process and this result encouraged us to develop new bivalent 
compound toward -tubulin interaction.   
 
Figure 56: Desac (deacetylthiocolchicine the blu portion of bivalent compound), 86b (the green 
portion of bivalent compound), 99 (bivalent compound). 
Furthermore we evaluated the effect of compound 99 on HeLa cells and on HepG2 
cancer cell line. As reported in table 1, compound 99 is able to inhibit the growth of 
cancer cells but less than deacetylthiocolchicine. 
Composti HeLa (GI50) HepG2 (GI50) 
Desacetilthiocolc. 
 
0.0145 μM 0.0141 μM 
86b 
 
> 30 μM > 30 μM 
99 
 
0.117 μM 0.41 μM 
 
Table 5: Desac (deacetylthiocolchicine the blu portion of bivalent compound), 86b (the green 
portion of bivalent compound), 99 (bivalent compound). 
0
2
4
6
8
MTs/Dimers
DMSO Desac 86b 99 
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4.6. Experimental part 
4.6.1. General information 
All reactions that are sensitive to air were performed under an argon atmosphere in 
heatgun dried glassware. The solvents used in reactions were purchased from Fluka 
(dried over molecular sieves). Solvents used for extractions, thin layer chromatography 
(TLC) or silica gel chromatography were purchased as commercial grade and distilled. 
Commercially available substances were used without prior purification unless 
otherwise specified. 
TLC were performed on aluminium sheets coated with silica gel (silica gel F254) the 
spots were visualised either with UV light (254 nm), or by spraying with appropriate 
TLC stains. Purification by flash chromatography was performed using Fluka silica gel.  
Solvents were evaporated with a Büchi Rotavapor together with a Büchi waterbath at 40 
°C and at an appropriate pressure. Pure compounds were dried under high vacuum.  
1H-NMR and 13C-NMR spectra were recorded on a Bruker AV-400, or an AV-500 
spectrometer at room temperature. CDCl3 was used as a solvent unless otherwise 
specified, and the chemical shifts are referenced to the residual solvent peak (for CDCl3: 
1H, = 7.26 ppm and 13C = 77.00 ppm) All 13C spectra were measured with complete 
proton decoupling. The following abbreviations were used for the report of the NMR 
spectra: J: nucleus decoupling constant in Hz, s: singlet, d: doublet, t: triplet, q: quartet, 
m: multiplet. A Jasco FT/IR-6200 spectrometer was used for the acquisition of infrared 
resonance spectra. Frequencies are given in cm -1.  
High resolution mass spectra (HRMS) were aquired on an IonSpec (Varian) Ultima 
spectrometer. Melting points of pure solid products were measured on a Büchi B-540 
melting point apparatus using open glass capillaries.  
Optical rotation values were determined using an Anton Paar MCP 300 polarimeter. The 
wavelength of light used was 589 nM. The concentration of the sample used is given in 
g 100 cm-3. Optical rotation values were recorded at 20 °C. 
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4.6.2. Doliculide fragments synthesis 
Synthesis of compound 52 
 
Acetyl chloride (4.7 mL, 66.4 mmol) was dissolved in MeOH (60 mL). 3-iodo-D-
tyrosine (3.01 g, 9.7 mmol) was added to the solution as a solid. The reaction was stirred 
under reflux at 65 ºC for 18 h. The solution was concentrated under reduced pressure to 
yield a white-yellow solid (3.14 g, quantitative yield). This solid was used directly in the 
next reaction. 
TLC: Rf = 0.26 (DCM/MeOH 19:1).  
*Product has poor solubility and was not purified, full characterization was not made. 
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Synthesis of compound 53 
 
Compound 52 (3.14g, 9.7 mmol) was dissolved in ethanol (75 mL). Sodium bicarbonate 
(8.2 g, 97.7 mmol), and Boc2O (2.28g, 10.4 mmol) were added and the solution was 
stirred at r.t. overnight. The solution was filtered and the filtrate was concentrated under 
reduced pressure to give a brown oil. The crude was purified by silica gel 
chromatography (hexane/EtOAc 2:1) to yield 53 as a white foam (3.15 g, 77%). 
TLC: Rf = 0.40 (hexane/EtOAc 4:1) 
1H-NMR (400 MHz, CDCl3): δ 7.42 (s, 1H), 6.98 (dd, J = 8.2, 1.9 Hz, 1H), 6.86 (d, J = 
8.2 Hz, 1H), 5.69 (s, 1H), 5.02 (bs, 1H), 4.57- 4.45  (m, 1H), 3.72 (s, 3H), 3.08-2.85 (m, 
2H), 1.43 (s, 9H).  
IR: ?̃?= 3335, 2981, 1715, 1685, 1510, 1396, 1290, 1252, 1153, 1126, 1153, 1126, 1050, 
1004, 822, 567.  
HRMS (ESI+): m/z calculated for C15H20INO5 [M+H]+, 422.0459, measured: 422.0459. 
[𝑎]𝐷
20= -47.57 (c 0.35, CHCl3).  
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Synthesis of compound 54 
 
TIPSCl (1.8 mL, 8.43 mmol) and imidazole (1.19 g, 17.56 mmol) in dry DMF (11 mL) 
were stirred together. 53 (2.96 g, 7.02 mmol) was added in dry DMF (35 mL). The 
reaction mixture was stirred at r.t. for 4 nights. The solution was diluted with EtOAc 
(300 mL) and washed with water (2 x 1250 mL). The organic phase was dried over dried 
over anhydrous MgSO4 and concentrated under reduced pressure to obtain the crude 
material as a yellow oily residue. The crude material was purified by silica gel 
chromatography (hexane/EtOAc 9:1 → 8:2) to yield 54 as a very sticky colourless oil 
(4.05 g, 99%).  
TLC: Rf = 0.55 (hexane/EtOAc 4:1).  
1H-NMR (400 MHz, CDCl3): δ 7.51 (d, J = 1.6 Hz, 1H), 6.94 (dd, J = 8.3, 2.2 Hz, 1H), 
6.74 (d, J = 8.3 Hz, 1H), 4.91 (d, J = 8 Hz, 1H), 4.56 – 4.45 (m, 1H), 3.69 (s, 3H), 2.95-
2.78 (m, 2H), 1.43 (s, 9H), 1.30-1.15 (m, 3H), 1.14 (d, J = 7.3 Hz, 18H).  
IR (film): ?̃? ̃= 2947, 2867, 1719, 1483, 1365, 1286, 1168, 1016, 917 875, 681, 651cm-1.  
HRMS: (ESI/MALDI +): m/z calculated for C24H40INO5Si [M+Na]+ 600.1613, 
measured: 600.1611 [𝑎]𝐷
20= - 36.71 (c 2.86, CHCl3). 
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Synthesis of compound 55 
 
 
 
Compound 54 (2 g, 3.5 mmol) was dried by evaporation with toluene (high vacuum) 
before dissolving in a 10:1 mixture of THF: DMF (31 mL), then were added NaH 60% 
in oil (166 mg, 4.1 mmol) and MeI (1 mL, 17 mmol). The solution was heated at 60 °C 
for 20 h. After this period the mixture was cooled and then diluted with Et2O. The 
solution was washed with satured aqueous NH4Cl, 20% Na2S2O3 and brine. The organic 
layer was evaporated, dried over anhydrous Na2SO4 and concentrated to give the product 
55. Purification of the residue by flash chromatography (toluene/AcOEt 19:1 and 1% 
TEA) afforded 1.72 g (84 %) of 55 as a white solid.  
TLC: Rf = 0.36 (toluene/EtOAc 19:1, 1% TEA). 
1H-NMR (400 MHz, CDCl3): δ 7.58/7.57 (s, 1H), 6.98 (dd, J = 8.3, 2.2 Hz, 1H), 6.73 
(d, J = 8.3 Hz, 1H), 4.85 – 4.74 (m, 1H), 4.51-4.42 (m, 1H), 3.74/3.72 (s, 3H), 3.23-3.10 
(m, 1H), 2.96-2.83 (m, 1H), 2.71/2.69 (s, 3H), 1.46-1.23 (m, 12 H), 1.12/1.08 (d, J = 7.3 
Hz, 18H). 
13C-NMR (101 MHz, CDCl3): δ 171.9/171.6, 154.4/154.3, 139.3/139.9, 131.8/131.6, 
130.1/129.8, 118.0/117.9, 80.6/80.2, 61.72, 59.70, 52.33, 34.26, 33.77, 32.75, 32.31, 
28.39, 18.23, 13.32  
IR (film): ?̃? = 2946, 2867, 2360, 2341, 1746, 1696, 1286, 1167, 1145, 920, 882 cm-1. 
HRMS: (ESI +): m/z calculated for C25H43INO5Si [M + Na]+ 592.1950, measured: 
592.1956. Melting point=78-80 °C. [𝑎]𝐷
20 = +14.46 (c 1.68, CHCl3). 
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Synthesis of compound 56 
 
To a stirred solution of 55 (1.50g, 2.5 mmol) at 0°C, TFA (4mL) was added. The solution 
was warmed to 23 °C and stirred for 1 h. After this period the mixture was washed with 
5% NaHCO3 and brine. The organic layer was separated, dried over anhydrous Mg2SO4 
and concentrated to give 56 as a sticky oil (1.7g, 97%). No Purification. 
TLC: Rf = 0.50 (Hex/AcOEt 1:1, 1% TEA).  
1H-NMR (400 MHz, CDCl3): δ 7.57 (d, J= 2.1 Hz, 1H), 7.06 (dd, J = 8.3, 2.1 Hz, 1H), 
6.77 (d, J = 8.3 Hz, 1H), 4.01-3.91 (m, 1H), 3.69 (s, 3H), 3.95-3.92 (m, 1H), 3.18-3.08 
(m,1H), 2.72 (s, 3H), 1.38-1.21 (m, 3H), 1.12 (d, J = 7.3 Hz, 18H).  
13C-NMR (101 MHz, CDCl3): δ 168.0, 155.5, 140.13, 130.27, 127.85, 118.45, 90.80, 
62.52, 53.14, 34.63, 32.22, 18.19, 13.19 
IR (film): ?̃?= 3383, 2947, 2867, 2364, 2342, 1749, 1670, 1488, 1288, 1200, 1180, 1133, 
1038, 916, 881cm-1.  
HRMS: (ESI/MALDI +): m/z calculated for C20H35INO3Si [M+Na]+ 492.1425, 
measured: 492.1417 [𝑎]𝐷
20 = - 8.04 (c 0.64, CHCl3). 
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Synthesis of compound 58 
 
To the amine 56 (0.100 g, 0.2 mmol) and Boc-Gly (50 mg, 0.28mmol) in DMF at 0°C 
were added EDC (44 mg, 0.28 mmol) and HOBt (50 mg, 0.32mmol). The resulting 
solution was warmed to room temperature and stirred for 20 h. After this period the 
solution was quenched saturated aqueous solution NH4Cl, diluted with AcOEt, washed 
with 5% HCl, 5% NaHCO3 and brine. The organic layer was separated, dried over 
anhydrous Mg2SO4 and concentrated. Purification of the residue by flash 
chromatography (hexane/AcOEt 1:1) give 58 (30 mg, 20%). There is no TIPS protective 
group. 
TLC: Rf= 0.55 (Hex/AcOEt 1:1, TEA 1%).  
1H-NMR: Complicated to interpret due to the presence of rotational isomers.  
IR (film) : ?̃?= 3350, 2955, 2923, 2853, 2368, 2362, 2357, 2341, 2336, 1740, 1735, 1706, 
1700, 1685, 1653, 1647, 1521, 1507, 1482, 1457, 1366, 1288, 1252, 1236, 1217, 1159, 
1052, 1037, 1025, 759, 751  
HRMS (ESI +): Calculated for C18H25IN2O6 [M + H]+, 493.0830, found 493.0829. [𝑎]𝐷
20 
= 13.5 (c 0.10, CHCl3) 
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Synthesis of compound F 
 
To a solution of dipeptide ester 58 (20 mg, 0.03 mmol) in a mixture (2:1) of THF and 
H2O (1 mL) was added LiOH (3 mg, 0.075 mmol) at 0°C. The reaction mixture was 
continued stirring at 0°C for one hour. The reaction was acidified to pH 3.5 with aqueos 
NaHSO4 saturated solution. The mixture was then extracted with Et2O (x 2) and the 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo to 
afford a yellow oil, which was used immediately in the next reaction.Full 
characterization was not made as the product was used immediately for the next reaction. 
TLC: Rf = 0.25 (AcOEt/hexane 1:1) 
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Synthesis of compound 61 
 
To a dry 3 necked flask, t-BuOK (3.162 g, 28.18 mmol, glovebox) and anhydrous THF 
(13.5 mL) were added. This solution was cooled to -78 °C. Trans-2-butene (2.42 g, 43.14 
mmol) was condensed into the reaction flask from a balloon. During this addition, the 
solution became cloudy. Over 50 mins, n-BuLi (17.54 mL, 28.08 mmol) was added to 
the solution via a syringe pump. The solution turned a bright yellow colour. The solution 
was the warmed to -50 °C for 20 mins. The solution was then cooled to -78 °C and 
triisopropyl borate (6.47 mL, 28.075 mmol) was added over 50 min. The solution was 
then stirred at -72.5 °C for 15 min. The solution was then transferred to a separating 
funnel containing 1M HCl (53 mL). The organic layer was then extracted, using some 
sat. NaCl to aid separation. The aqueous layer was controlled to be pH 1 (if not used HCl 
1 M). ((S,S)-DIPT) (5.87 mL, 28.08 mmol) in Et2O (9.5 mL) was then added to the acidic 
solution, which was then shaken vigorously for 10 min. The phases were separated, and 
the aqueous phase was extracted with ether (3 x). The combined organic layers were 
dried over anhydrous MgSO4 for two h and concentrated under reduced pressure before 
drying under vacuum. A crude NMR was taken and was indicative of a 2:1 DIPT: 
product ratio. The reaction yielded 2.5 g of 61 (19%) in 7.5 g of sticky clear oily residue. 
This residue was dissolved in toluene (24 mL) and stored in the freezer under argon.*Full 
characterisation was not made as the reagent is not pure and is highly sensitive to water 
and air. 
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Synthesis of compound 62 
 
Molecular sieves (3 mg) were added to dry toluene (0.3 mL). Crude 61 in toluene was 
added (0.3, 0.06 mmol) and the solution was cooled to -78 °C. I (15 mg, 0.06 mmol) was 
dissolved in toluene (0.01 mL) and added dropwise to the solution. The solution was 
stirred for 4 h at -78 °C. The reaction was quenched with 1 M NaOH. The aqueous layer 
was extracted with ether (3 x). The combined organic layers were washed with NaHCO3 
(2 x) and brine, dried over anhydrous MgSO4 and concentrated under reduced pressure. 
The crude material was purified by silica gel chromatography (hexane/EtOAc 10:1) to 
yield 62 as a slightly yellow oily residue (6 mg, 33%).  
TLC: Rf= 0.30 (Hex/AcOEt 10:1). 
1H-NMR: (400 MHz, CDCl3) δ 7.35 – 7.20 (m, 2H), 6.97 – 6.78 (m, 2H), 5.88-5.69 (m, 
1H), 5.10 (d, J = 0.7 Hz, 1H), 5.08 – 5.02 (m, 1H), 4.49 (d, J = 2 Hz, 2H), 3.80 (s, 3H), 
3.72-.66 (m, 1H), 3.51 – 3.38 (m, 1H), 2.43 (bs, 1H), 2.22-2.11 (m, 1H), 2.03-1.92 (m, 
1H), 1.62 – 1.43 (m, 2H), 1.00 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 
6.8 Hz, 3H).  
13C-NMR (101 MHz, CDCl3): δ 159.2, 140.7, 130.8, 129.5, 120.0, 115.6, 113.8, 81.6, 
71.8, 71.5, 55.2, 44.4, 33.6, 30.6, 19.1, 17.8, 16.0.  
IR (film) : ?̃?= 3673, 2958, 2917, 1613, 1514, 1464, 1396, 1240, 1175, 1065, 1035, 909, 
818cm-1.  
HRMS (ESI +): m/z calculated for C18H28O3 [M + Na]+ 315.1931, measured: 315.1933. 
[𝑎]𝐷
20 = -23.71 (c 0.165, CHCl3).  
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Synthesis of compound E 
 
 
To a solution of H in CH2Cl2 (1.6 mL) and 0.16 mL pH 7.2 buffer solution was added 
DDQ (16 mg, 0.07 mmol). The reaction mixture was stirred at 0°C for 35 min, when the 
reaction was quenched with saturated aqueous NaHCO3 (1 mL). The aqueous layer was 
extracted with CH2Cl2 (3×2 mL) and the combined organic layers washed with water (2 
mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo. 
Purification of the residue by flash chromatography (hexane/AcOEt 9:1) afforded 10 mg 
(73 %) of E as a colorless oil. Full characterization was not made as the product was 
used immediately for the next reaction. 
TLC: Rf = 0.54 (AcOEt/hexane 9:1) 
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4.6.3. Pironetin-dumetorine hybrid compounds 
Synthesis of compound 65  
 
 
Racemic-2-(piperidin-2-yl)ethanol (2g, 15.4 mmol) was dissolved in dioxane (30 mL) at 
room temperature and then NaOH (15 mL) and H2O (15 mL) were added. (Boc)2O (3.36 
g, 15.4 mmol) was added to the solution cooled at 0°C. Next the solution was acidified 
with KHSO4 until pH 2 and then extracted with EtOAc. The organic layer was washed 
with water, dried over anhydrous Na2SO4, and filtered. The solvent was evaporated 
under vacuum, and the residue was purified by column chromatography on silica gel 
(hexane /EtOAc, 7:3) to give 65 (2.5 g) as a colourless oil (70% overall yield).  
1H-NMR (400 MHz, CDCl3,): δ 4.72-4.60 (m, 1H), 3.96-3.91 (d, J= 13.72 Hz, 1H), 
3.62-3.56 (m, 1H), 3.39-3.31 (m, 1H), 2.65 (t, J = 12.83 Hz, 1H), 1.88 (d, J = 12.53 Hz, 
1H), 1.74-1.32 (m, 16H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 156.5, 80.0, 58.5, 45.5, 39.4, 32.2, 29.1, 28.4, 25.5, 19.2 
ppm. 
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Synthesis of compounds 66 
 
 
(COCl)2 (0.45 mL, 5.3 mmol) was dissolved under nitrogen atmosphere in anhydrous 
CH2Cl2 (21.8 mL) the cooled at -78 °C. A solution of DMSO (0.93 mL, 13 mmol) in 
anhydrous CH2Cl2 (5.2 mL) was then added dropwise to the reaction mixture. The 
solution was stirred for 10 minutes at -78 °C and then a solution of 65 (1 g, 4.4 mmol) 
in anhydrous CH2Cl2 (10.4 mL), was added to the mixture. The solution was stirred for 
2 hours and then TEA (7.3 mL, 22 mmol) was added. The reaction was left overnight at 
room temperature, then quenched with H2O (35 mL) and HCl 1 N (18 mL) and extracted 
with CH2Cl2. The organic layer was washed with brine, dried over anhydrous Na2SO4, 
and filtered. 
The solvent was evaporated under vacuum, and the residue was purified by column 
chromatography on silica gel (hexane /EtOAc, 7:3) to give 66 (0.860 g) as a colourless 
oil (87% overall yield).  
1H-NMR (400 MHz, CDCl3,): δ 9.71 (s, 1H), 4,78 (br s, J=5.8 Hz, 1H), 3.98 (d, J=13.4 
Hz,1H), 2.76-2.67 (m, 2H), 2.55-2.49 (m, 1H), 1.71-1.41 (m, 6H), 1.42 (s, 9H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 199.1, 152.9, 78.2, 44.2, 42.8, 37.5, 27.9, 27.1, 23.2, 
16.8 ppm. 
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General procedure for synthesis of compounds 70a-73a 
 
 
 
 
 
 
 
 
Allylmagnesium bromide (commercial 1M solution in Et2O, 2.86 mL, 2.86 mmol) was 
added dropwise under nitrogen atmosphere to a solution of (-)-DIP-Cl (1.06 g, 3.3 mmol) 
in dry THF (13.5 mL) at -78°C. The reaction mixture was allowed to warm to 0 °C and 
stirred at that temperature for 1 h. The solution was then allowed to stand until 
magnesium chloride precipitated. The supernatant solution was then carefully 
transferred to another flask. After cooling this flask at 78C, a solution of aldehyde 66 
(0.500 g, 2.20 mmol) in dry THF (6.5 mL) was added dropwise. The resulting solution 
was further stirred at the same temperature for 1 h and then 16 h at room temperature. 
The reaction was quenched with NaH2PO4 buffer solution at pH 7 (13.5 mL), MeOH 
(13.5 mL) and 30% H2O2 (6.7 mL). After stirring for 30 minutes, the mixture was washed 
with saturated aqueous NaHCO3 and extracted with Et2O. The combined organic phases 
were dried over anhydrous Na2SO4, and filtered. The solvent was evaporated under 
vacuum, and the residue was purified by column chromatography on silica gel (hexane 
/EtOAc, 8:2) to give 70a (0.311 g) and 71a (0.234 g) as a yellow oil (51% overall yield). 
In order to obtain the other two diastereoisomer 72a and 73a the reaction is performed 
in the same way except for the use of (+)-DIP-Cl. 
70a: 1H-NMR (400 MHz, CDCl3,): δ 1.35-1.59 (m, 6H), 1.42 (s, 9H,), 1.73-1.76 (m, 
1H), 2.01 (dt, J = 12.5, 1.8 Hz, 1H), 2.16-2.23 (m, 1H), 2.27-2.33 (m, 1H), 2.66 (dt, J = 
12.7, 2.0 Hz, 1H), 3.39 (br s, 1H), 3.95 (br s, 1H), 4.47 (br s, 1H), 5.05 (d, J = 9.7 Hz, 
1H), 5.08 (d, J = 17.4 Hz, 1H), 5.81-5.91 (m, 1H) ppm.  
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13C-NMR (100 MHz, CDCl3): δ = 19.4, 25.3, 28.6, 29.2 , 36.9, 39.3, 41.1, 46.2, 67.1, 
80.2, 116.6, 135.5, 167.1 ppm. 
IR: (neat) = 1674 cm-1. [α]D
20= -33 (c 1, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C15H28NO3: 270.21; Found: 270.72. 
73a: [α]D
20= +35 (c 0.8, CHCl3). ESIMS m/z [M+H+]+ calcd for C15H28NO3: 270.21; 
Found: 270.56. 
71a: 1H-NMR (400 MHz, CDCl3): δ 1.35-1.59 (m, 6H), 1.42 (s, 9H), 1.77-1.82 (m, 1H), 
2.14-2.21 (m, 1H), 2.27-2.32 (m, 1H), 2.79 (dt, J = 12.8, 0.2 Hz, 1H), 3.65 (tt, J = 7.5, 
2.4 Hz, 1H), 3.88-3.93 (m, 1H), 4.32 (br s, 1H), 5.08 (d, J = 9.8 Hz, 1H), 5.10 (d, J = 
17.3 Hz, 1H), 5.75-5.85 (m, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 18.9 , 25.5, 28.4, 28.9, 37.0, 38.8, 41.8, 48.0, 71.3, 79.6, 
117.4, 135.06, 155.29 ppm. 
IR: (neat) = 1674 cm-1[α]D
20 = +15 (c 0.9, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C15H28NO3: 270.21; Found: 270.78. 
72a:[α]D
20= -13.8 (c 13.3, CHCl3). ESIMS m/z [M+H+]+ calcd for C15H28NO3: 269.20; 
Found: 269.84. 
  
Natural products as lead compounds 
 
159 
 
General procedure for synthesis of compounds70b-73b 
 
Alcohol 70a (0.319 g, 1.18 mmol) was dissolved in anhydrous THF (7 mL) and the 
solution was added dropwise to a suspensionof sodium hydride (0.095 g, 3.90 mmol) in 
dry THF (3 mL) cooled at -78°C and it was stirred for 1 h. Then methyl iodide (0.3 mL, 
4.70 mmol) was added and the reaction mixture was stirred 1 h at -78 °C and 16 h at 
room temperature. The mixture was quenched with cold water (10 mL) and the aqueous 
layer was extracted with Et2O. The organic layer was dried with Na2SO4 and the solvent 
was removed under vacuum. The residue was purified by column chromatography on 
silica gel (hexane/EtOAc, 8:2) to give 70b (0.235g,74%) as yellow oil. In order to obtain 
the other compounds 71b, 72b and 73b the reaction was performed in the same way. 
70b:1H-NMR (400 MHz, CDCl3): δ 1.37-1.64 (m, 6H), 1.46 (s, 9H), 1.83-1.90 (m, 1H), 
2.21-2.33 (m, 2H), 2.70 (t, J = 13.2 Hz, 1H), 3.11-3.17 (m, 1H), 3.35 (s, 3H), 3.97 (br s, 
1H), 4.44 (br s, 1H), 5.08 (d, J = 17.1 Hz, 1H), 5.10 (d, J = 9.2 Hz, 1H), 5.73-5.83 (m, 
1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.4, 25.7,  25.7, 28.5, 29.5, 34.5, 37.7, 47.6, 56.9, 77.9, 
79.1, 117.3, 134.5, 155.1 ppm. 
IR: (neat) = 1677 cm-1.[α]D
20= -36 (c 3.64, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C16H30NO3: 284.22; Found: 284.45. 
73b:[α]D
20= +33 (c 0.5, CHCl3). ESIMS m/z [M+H+]+ calcd for C16H30NO3: 284.21; 
Found: 284.55. 
71b:1H-NMR (400 MHz, CDCl3): δ 1.33-1.59 (m, 6H,(CH2)3), 1.43 (s, 9H, Boc), 1.88-
1.96 (m, 1H), 2.28 (dddd, J = 12.3, 12.3, 6.4, 1.2 Hz,1H), 2.35 (dddd, J = 12.3, 12.3, 6.4, 
1.2 Hz), 2.78 (t, J = 13,3 Hz, 1H), 3.14-3.19 (m, 1H), 3.29 (s, 3H), 3.96 (m, 1H), 4.33 
(br s, 1H), 5.03-5.09 (m, 2H), 5.75-5.84 (m, 1H) ppm.  
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13C-NMR (100 MHz, CDCl3): δ 23.6, 24.9, 30.2, 33.7, 35.1, 39.2, 44.7, 47.9, 53.9, 73.9, 
80.8, 118.5, 132.4, 153.9 ppm. 
IR: (neat) = 1677 cm-1.[α]D
20= +23.4 (c 2.7, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C16H30NO3: 284.21; Found: 284.78. 
72b: [α]D
20= -19 (c 0.9 CHCl3). ESIMS m/z [M+H+]+ calcd for C16H30NO3: 284.22; 
Found: 284.89. 
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General procedure for synthesis of compounds 74-77 
 
 
Olefin 70b (0.470 g, 1.66 mmol) was dissolved in dry CH2Cl2 (19 mL) and cooled to 
78C. A stream of ozone-oxygen was bubbled through the solution until persistence of 
the bluish color. Dry N2 was then bubbled through the solution for 10 min at the same 
temperature. After addition of PPh3 (0.870 g, 3.32 mmol), the reaction mixture was 
stirred for 2 h at room temperature. After the completion of the reaction the solvent was 
removed under vacuum. The residue was purified by column chromatography on silica 
gel (hexane/EtOAc, 7:3) to give 74 (0.202 g,43%) as orange oil. In order to obtain the 
other compounds 75, 76 and 77 the reaction was performed in the same way. 
74:1H-NMR (400 MHz, CDCl3): δ 1.37-1.65 (m, 6H), 1.46 (s, 9H), 1.88 (ddd, J = 14.0, 
9.3, 4.4 Hz, 1H), 2.63 (ddd, J = 6.3, 4.3, 2.1 Hz, 2H), 2.75 (t, J = 12.7 Hz, 1H), 3.36 (s, 
3H), 3.59-3.65 (m, 1H), 3.98 (br s, 1H), 4.43 (br s, 1H), 9.81 (t, J = 2.1 Hz, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.1, 25.6, 28.5, 29.0, 33.6, 38.8, 48.0, 56.6, 74.4, 76.2, 
79.5, 155.0, 201.4 ppm.  
IR: (neat) = 1679, 1719 cm-1.[α]D
20= -21.3 (c 3.45, CHCl3). ESIMS m/z [M+H+]+ calcd 
for C15H28NO4: 286.20; Found: 286.57. 
77: [α]D
20= +19.1 (c 0.5, CHCl3). ESIMS m/z [M+H+]+ calcd for C15H28NO4: 286.20; 
Found: 286.97. 
75: 1H-NMR (400 MHz, CDCl3): δ 1.37-1.66 (m, 6H), 1.44 (s, 9H), 2.09-2.19 (m, 1H), 
2.59 (ddd, J = 16.4, 7.5, 2.8 Hz,1H), 2.75-2.82 (m, 2H), 3.32 (s, 3H), 3.64 (ddd, J = 12.4, 
7.7, 5.1 Hz, 1H), 4.00-4.02 (m, 1H), 4.34 (br s, 1H), 9.78 (s, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.2, 25.7 , 28.6, 29.1, 33.7, 38.8, 48.0, 56.8, 60.5, 74.3, 
79.7, 155.0, 201.6 ppm. 
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IR: (neat) = 1678, 1719 cm-1.[α]D
20= 28.8 (c 2.65, CHCl3). ESIMS m/z [M+H+]+ calcd 
for C15H28NO4: 286.20; Found: 286.77. 
76:[α]D
20= -26.54 (c 0.5, CHCl3). ESIMS m/z [M+H+]+ calcd for C15H28NO4: 286.20 ; 
Found: 286.79. 
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General procedure for synthesis of compounds 78a-85a 
 
Allylmagnesium bromide (commercial 1M solution in Et2O, 0.87 mL, 0.87 mmol) was 
added dropwise under nitrogen atmosphere to a solution of (-)-DIP-Cl (0.323 g, 1.01  
mmol) in dry THF (5 mL) at -78°C. The reaction mixture was allowed to warm to 0 °C 
and stirred at that temperature for 1 h. The solution was then allowed to stand until 
magnesium chloride precipitated. The supernatant solution was then carefully 
transferred to another flask. After cooling this flask at 78C, a solution of aldehyde 74 
(0.190 g, 0.67 mmol) in dry THF (2.5 mL) was added dropwise. The resulting solution 
was further stirred at the same temperature for 1 h and then 16 h at room temperature. 
The reaction was quenched with NaH2PO4 buffer solution at pH 7 (5.1 mL), MeOH (5.1 
mL) and 30% H2O2 (2.5 mL). After stirring for 30 minutes, the mixture was washed with 
saturated aqueous NaHCO3 and extracted with Et2O. The combined organic phases were 
dried over anhydrous Na2SO4, and filtered. The solvent was evaporated under vacuum, 
and the residue was purified by column chromatography on silica gel (Hexane /EtOAc, 
7:3) to give 78a (0.179 g, 82%) as a yellow oil. In order to obtain the other 
diastereoisomer the reaction is performed in the same way except for the use of (+)-DIP-
Cl. 
78a: 1H-NMR (400 MHz, CDCl3): δ 1.34-1.63 (m, 8H), 1.45 (s, 9H), 1.74-1.76 (m, 2H), 
2.22 (t, J = 6.6 Hz, 2H), 2.72-2.78 (m, 1H), 3.35-3.41 (m, 1H), 3.36 (s, 3H), 3.78-3.84 
(m, 1H),3.95 (br s, 1H), 4.33 (br s, 1H), 5.07-5.12 (m, 2H), 5.83 (ddt, J = 17.5, 10.5, 7.1 
Hz, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.3, 25.7, 28.4, 28.6, 34.5, 38.9, 40.7, 42.4, 48.0 , 56.5, 
68.31, 70.3, 79.6, 117.7, 135.0, 155.1 ppm. 
IR: (neat) = 1687 cm-1.[α]D
20= - 21.4 (c 0.7, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C18H34NO4: 328.25; Found: 328.67.  
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85a: [α]D
20= + 24.3 (c 0.1, CHCl3). ESIMS m/z [M+H+]+ calcd for C18H34NO4: 328.25; 
Found: 328.43. 
79a:1H-NMR (400 MHz, CDCl3): δ 1.37-1.66 (m, 8H), 1.45 (s, 9H), 1.77-1.84 (m, 1H), 
2.14-2.19 (m, 1H), 2.23 (t, J = 6.1 Hz, 2H), 2.80 (t, J = 13.2 Hz,1H), 3.29-3.40 (m, 1H), 
3.34 (s, 3H), 3.81-3.87 (m, 1H),4.01 (br s, 1H), 4.30 (br s, 1H), 5.07-5.12 (m, 2H), 5.82-
5.97 (m, 1H)  ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.2, 25.7, 28.6, 29.5, 33.7, 39.1, 41.0, 42.2, 47.3, 56.2, 
68.3, 71.2, 79.8, 117.4, 135.1, 155.3 ppm. 
IR: (neat) = 1687 cm-1.[α]D
20 = -9.2 (c 0.3, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C18H34NO4: 328.25; Found: 328.15. 
84a : [α]D
20= +10.5 (c 0.04, CHCl3). ESIMS m/z [M+H+]+ calcd for C18H34NO4: 328.25; 
Found: 328.12. 
80a:1H-NMR (400 MHz, CDCl3): δ 1.33-1.66 (m, 8H), 1.45 (s, 9H), 1.76-1.84 (m, 1H), 
2.15-2.19 (m, 1H), 2.23-2.25 (m, 2H), 2.80 (t, J = 13.8 Hz,1H), 3.30-3.39 (m, 1H), 3.33 
(s, 3H), 3.81-3.85 (m, 1H),4.01 (br s, 1H), 4.30 (br s, 1H), 5.06-5.13 (m, 2H), 5.87 (ddt, 
J = 17.3, 10.2, 7.1 Hz, 1H) ppm. 
13C-NMR (100 MHz, CDCl3): δ 19.3, 25.8, 28.6, 29.4, 34.4, 38.9, 40.8, 42.3, 47.8, 57.1, 
68.1, 71.05, 79.7, 117.5, 135.1, 155.0 ppm. 
IR: (neat) = 1687 cm-1.[α]D
20= +17.8 (c 0.1, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C18H34NO4: 328.25; Found: 328.24. 
83a: [α]D
20= -15.7 (c 0.07, CHCl3). ESIMS m/z [M+H+]+ calcd for C18H34NO4: 328.25; 
Found: 328.18. 
81a:1H-NMR (400 MHz, CDCl3): δ 1.31-1.66 (m, 15H),1.69- 1.84 (m, 3H), 2.16-2.29 
(m, 2H), 2.64-2.82 (m, 1H), 3.33-3.47 (m, 5H), 3.89-4.02 (m, 3H), 4.27-4.42 (s, 1H), 
5.04-5.15 (m, 2H), 5.75-5.91 (m, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.3, 25.8, 28.7, 29.3, 34.2, 38.9, 40.6, 42.5, 48.01, 
57.3, 68.2, 70.3, 79.5, 117.7, 135.0, 155.1 ppm. 
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[α]D
20 = +22.4 (c 1.4, CHCl3). ESIMS m/z [M+H+]+ calcd for C18H34NO4: 328.25; Found: 
328.45. 
82a: [α]D
20= -21.6 (c 0.02, CHCl3). ESIMS m/z [M+H+]+ calcd for C18H34NO4: 328.25; 
Found: 328.29. 
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General procedure for synthesis of compounds 78b-85b 
 
Acryloyl chloride (014 mL, 1.71 mmol) and TEA (0.48 mL, 3.42 mmol) were added 
sequentially to a cooled solution (0°C) of compound 78a (0.140 g, 0.42 mmol) dissolved 
in dry CH2Cl2 (0.73 mL). The reaction was stirred for 4 h at room temperature, then it 
was quenched with water (3 mL) and satd. aqueos NaCl (3 mL). the aqueous layer was 
extracted with CH2Cl2. The organic layer were dried with Na2SO4 and filtered. The 
solvent was evaporated under vacuum, and the residue was purified by column 
chromatography on silica gel (Hexane /EtOAc, 6:4) to give 78b (0.118 g, 72%) as yellow 
oil.  
78b:1H-NMR (400 MHz, CDCl3): δ 0.86-0.97 (m, 2H), 1.45 (s, 9H), 1.51-1.72 (m, 6H), 
1.88-1.98 (m, 2H), 2.33-2.45 (m, 2H), 2.70 (t, J = 13.6 Hz, 1H), 3.09-3.15 (m, 1H), 3.30 
(s, 3H), 3.95 (br s, 1H), 4.44 (br s, 1H), 5.06-5.12 (m, 3H), 5.72-5.82 (m, 1H), 5.82 (dd, 
J = 10.6, 1.5 Hz, 1H), 6.10 (dd, J = 17.3, 10.4 Hz, 1H), 6.39 (dd, J = 17.3, 1.5 Hz, 1H) 
ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.2, 25.7, 28.5, 29.6, 34.6, 37.2, 38.7, 39.1, 47.0, 56.4, 
70.6, 75.4, 78.9, 118.1, 128.6, 130.6, 133.3, 154.4, 165.6 ppm. 
IR: (neat) = 1677, 1719 cm-1.[α]D
20= -7.66 (c 0.7, CHCl3). ESIMS m/z [M+H+]+ calcd 
for C21H36NO5: 382.26; Found: 382.64. 
85b: [α]D
20= +9.1 (c 0.03, CHCl3). ESIMS m/z [M+H+]+ calcd for C21H36NO5: 382.26; 
Found: 382.55. 
79b: 1H-NMR (400 MHz, CDCl3): δ 0.82-0.94 (m, 2H), 1.35-1.59 (m, 6H), 1.45 (s, 9H), 
1.86-1.97 (m, 2H), 2.30-2.44 (m, 2H), 2.79 (t, 1H, J = 12.6 Hz), 3.21 (tt, 1H, J = 12.3, 
6.2 Hz), 3.26 (s, 3H), 3.97 (br s, 1H), 4.35 (br s, 1H), 5.05-5.10 (m, 2H), 5.12-5.18 (m, 
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1H), 5.72-5.82 (m, 2H), 5.79 (dd, J = 10.4, 1.5 Hz, 1H), 6.10 (dd, J = 17.3, 10.4 Hz, 1H), 
6.38 (dd, J = 17.3, 1.5 Hz, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.0, 25.6, 28.5, 28.7, 29.3, 33.5, 37.5, 39.3, 47.3, 56.8, 
70.8, 75.7, 79.1, 118.2, 128.4, 130.5, 133.4, 154.7, 165.8 ppm.  
IR: (neat) = 1677, 1719 cm-1.[α]D
20= +20.4 (c 0.5, CHCl3). ESIMS m/z [M+H+]+ calcd 
for C21H36NO5: 382.26; Found: 382.87. 
84b: [α]D
20= -15.4 (c 0.005, CHCl3). ESIMS m/z [M+H+]+ calcd for C21H36NO5: 382.26; 
Found: 382.18. 
80b:1H-NMR (400 MHz, CDCl3): δ 0.89-0.94 (m, 2H), 1.46 (s, 9H), 1.44-2.00 (m, 8H), 
2.30-2.45 (m, 2H), 2.76-2.82 (m,  1H), 3.21 (tt, J = 12.3, 6.2 Hz, 1H), 3.26 (s, 3H), 3.97 
(br s, 1H), 4.35 (br s, 1H), 5.05-5.10 (m, 2H), 5.12-5.18 (m, 1H), 5.71-5.82 (m, 2H), 6.10 
(dd, J = 17.3, 10.4 Hz, 1H), 6.39 (ddd, J = 17.3, 2.9, 1.5 Hz, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 18.9, 25.6, 28.6, 28.9, 33.2, 37.0, 38.5, 39.0, 47.4, 55.7, 
70.9, 75.3, 79.2, 117.9, 128.8, 130.4, 133.5, 154.8, 165.6 ppm. 
IR: (neat) = 1677, 1719 cm-1. [α]D
20= +12.3 (c 0.5, CHCl3). ESIMS m/z [M+H+]+ calcd 
for C21H36NO5: 382.26; Found: 382.54. 
83b: [α]D
20= -16.5 (c 0.002, CHCl3). ESIMS m/z [M+H+]+ calcd for C21H36NO5: 382.26; 
Found: 382.25. 
81b:1H-NMR (300 MHz, CDCl3): δ 1.20-1.65 (m, 19H),1.65-1.86 (m, 1H),  2.29–2.44 
(m, 2H), 2.66-2.81 (m, 1H), 3.05-3.17 (m, 1H), 3.31 (s, 3H), 3.89-4.03 (m, 1H), 4.26-
4.50 (m, 1H), 5.01-5.28 (m, 2H), 5.69-5.85 (m, 2H), 6.03-6.17 (m, 1H), 6.33-6.45 (m, 
1H) ppm. 
13C-NMR (100 MHz, CDCl3): δ 18.9, 25.5, 28.4, 28.7, 29.5, 34.7, 38.6, 39.1, 47.6, 57.1, 
70.6, 75.6, 79.1, 117.9, 128.6, 130.4, 133.1, 165.5 ppm. 
[α]D
20 = +11.4 (c 0.8, CHCl3). ESIMS m/z [M+H+]+ calcd for C21H36NO5: 382.26; Found: 
382.91. 
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82b: [α]D
20= -9.4 (c 0.01, CHCl3). ESIMS m/z [M+H+]+ calcd for C21H36NO5: 382.26; 
Found: 382.59. 
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General procedure for synthesis of compounds 86a-93a 
 
A solution of Hoveyda-Grubbs-II catalyst (0.014 g, 0.02 mmol) in dry CH2Cl2  (3.2 mL) 
was added dropwise to a solution of compound 78b (0.085 g, 0.22 mmol) dissolved in 
dry CH2Cl2 (9.4 mL). The reaction was stirred for 3.5 h at room temperature, then the 
solvent was removed under vacuum. The residue was purified by column 
chromatography on silica gel (Hexane /EtOAc, 6:4) to give 86a (0.059 g, 75%)as dark 
oil. 
86a:1H-NMR (400 MHz, CDCl3): δ 1.38-1.71 (m, 6H),1.46 (s, 9H), 1.84-1.92 (m, 2H), 
1.99-2.07 (m, 2H), 2.31-2.41 (m, 2H), 2.73 (t, J = 13.3 Hz, 1H), 3.32 (s, 3H), 3.32-
3.37(m, 1H), 3.96 (br s, 1H), 4.43 (br s, 1H), 4.59 (dt, J = 11.4, 6.2 Hz, 1H), 6.02 (d, J = 
9.9 Hz, 1H), 6.88 (m, 1H) ppm. 
13C-NMR (100 MHz, CDCl3): δ 19.6, 25.8, 28.7, 28.9, 29.94, 30.2, 34.6, 40.6, 56.6, 
58.0, 74.9, 75.5, 79.7, 121.7, 146.3, 155.3, 164.7 ppm. 
IR: (neat) = 1677, 1721 cm-1.[α]D
20 = -50.2 (c 0.6, CHCl3). ESIMS m/z [M+H+]+ calcd 
for C19H32NO5: 354.23; Found: 354.78. 
93a: [α]D
20= +47.6 (c 0.002, CHCl3). ESIMS m/z [M+H+]+ calcd for C19H32NO5: 354.23; 
Found: 354.65. 
87a:1H-NMR (400 MHz, CDCl3): δ 1.36-1.58 (m, 7H),1.44 (s, 9H), 1.91-2.15 (m, 3H), 
2.32-2.38 (m, 2H), 2.76-2.82 (m, 1H), 3.24-3.31(m, 1H), 3.28 (s, 3H), 3.96 (br s, 1H), 
4.35 (br s, 1H), 4.55-4.62 (m, 1H), 6.00 (d, J = 9.8 Hz, 1H), 6.86 (ddd, J = 9.2, 4.5 Hz, 
1H)ppm.  
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13C-NMR (100 MHz, CDCl3): δ 19.3 (t), 25.7 (t), 28.7 (t), 29.5 (q), 29.9 (t), 30.2(t), 34.4 
(t), 40.7 (t), 54.0 (q), 57.7  (d), 74.8 (d), 75.0 (d), 79.5 (s), 121.6 (d), 145.2 (d), 155.1 (s), 
164.4 (s)ppm. 
IR: (neat) = 1677, 1721 cm-1. [α]D
20= -15.8 (c 0.7, CHCl3). ESIMS m/z [M+H+]+ calcd 
for C19H32NO5: 354.23; Found: 354.24. 
92a: [α]D
20= +11.1 (c 0.023, CHCl3). ESIMS m/z [M+H+]+ calcd for C19H32NO5: 354.23; 
Found: 354.72. 
88a:1H-NMR (400 MHz, CDCl3): δ 1.37-1.59 (m, 7H),1.46 (s, 9H), 1.92-2.17 (m, 3H), 
2.32-2.40 (m, 2H), 2.74-2.83 (m, 1H), 3.23-3.27(m, 1H), 3.29 (s, 3H), 3.98 (br s, 1H), 
4.36 (br s, 1H), 4.61 (td, J = 15.4, 6.5 Hz, 1H), 6.01 (d, J = 9.8 Hz, 1H), 6.87 (td, J = 9.2, 
4.2 Hz, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 19.1 (t), 25.6 (t), 28.5 (q), 28.7 (t), 28.9 (t), 29.4 (t), 
33.0 (t), 38.0 (t), 47.5 (d), 55.9 (q), 75.2 (d), 75.4 (d), 79.3 (s), 121.4 (d), 145.0 (d), 155.0 
(s), 164.4 (s) ppm. 
IR: (neat) = 1677, 1721 cm-1. [α]D
20 = -15.8 (c 0.4, CHCl3). ESIMS m/z [M+H+]+ calcd 
for C19H32NO5: 354.23; Found: 354.19. 
91a: [α]D
20= +13.3 (c 0.001, CHCl3). ESIMS m/z [M+H+]+ calcd for C19H32NO5: 354.23; 
Found: 354.47. 
89a:1H NMR (400 MHz, CDCl3): δ 1.19-1.77 (m, 17H),1.78-1.94 (m, 2H),  1.95-2.11 
(m, 1H), 2.29-2.48 (m, 2H), 2.67-2.83 (m, 1H), 3.38 (s, 3H), 3.40-3.52 (m, 1H), 3.88-
4.05 (m, 1H), 4.56-4.72 (m, 1H), 6.02 (dt, 1H, J= 9.8, 1.6 Hz), 6.84-6.92 (m, 1H) ppm.  
13CNMR (100 MHz, CDCl3): δ19.2, 25.7, 28.6, 28.7, 29.8, 30.2, 34.5, 40.7, 56.6, 57.7, 
74.8, 75.0, 79.5, 121.6, 145.0, 155.0, 164.4 ppm. 
[α]D
20 = +6.8 (c 0. 038, CHCl3). ESIMS m/z [M+H+]+ calcd for C19H32NO5: 354.23; 
Found: 354.17. 
90a: [α]D
20= -4.7 (c 0.006, CHCl3). ESIMS m/z [M+H+]+ calcd for C19H32NO5: 354.23; 
Found: 354.69.   
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General procedure for synthesis of compounds 86b-93b 
 
To a stirred solution of compound 86a (0.352 g, 1 mmol) in CH2Cl2 (2 mL) was added 
TFA (2 mL) at 0°C. The reaction mixture was stirred for 30 min. at room temperature. 
Upon completation the reaction was quenched with NH4OH 5M at pH 9.The organic 
layer was dried with Na2SO4 and concentrated under reduced pressure to give 86b 
(0.233g, 92%) as colorless oil. 
86b: 1H-NMR (400 MHz, CDCl3): δ 2.43-2.01 (m, 10H),2.32-2.38 (m, 3H), 2.80-2.85 
(m, 1H), 3.02 (br s, 1H), 3.34 (br s, 1H), 3.36 (s, 3H), 3.65-3.72(m, 1H), 4.57-4.65 (m, 
1H), 6.01 (dd, J = 10.3, 1.6 Hz, 1H), 6.88 (ddd, J = 9.5, 5.2, 3.1 Hz, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ = 23.0, 23.2, 30.0, 37.7, 38.6, 40.3, 44.9, 54.2, 57.2, 
74.1, 74.8, 121.2, 145.3, 164.1 ppm.   
IR: (neat) = 1730 cm-1. [α]D
20= +21.7 (c 0.009, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C14H24NO3:  254.18; Found: 254.57. 
93b: [α]D
20= -21.8 (c 0.2, CHCl3). ESIMS m/z [M+H+]+ calcd for C14H24NO3: 254.18; 
Found: 254.23. 
87b:1H-NMR (400 MHz, CDCl3): δ 1.33-1.80 (m, 8H),1.86-1.93 (m, 1H), 2.29-2.38 (m, 
2H), 2.62-2.72 (m, 2H), 3.09-3.15 (m, 1H), 3.33 (s, 3H), 3.57-3.67(m, 1H), 4.02 (br s, 
1H), 4.57-4.64 (m, 1H), 6.00 (dd, J = 9.8, 1.9 Hz, 1H), 6.84-6.88 (m, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 22.0, 22.3, 29.1, 30.0, 37.7, 40.0, 45.1, 55.8, 62.1, 74.8, 
75.0, 120.9, 145.8, 160.5 ppm.  
IR: (neat) = 1730 cm-1. [α]D
20= + 6.3 (c 0.001, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C14H24NO3:  254.18; Found: 254.93. 
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92b: [α]D
20= -9.8 (c 0.5, CHCl3). ESIMS m/z [M+H+]+ calcd for C14H24NO3:  254.18; 
Found: 254.27. 
88b: 1H-NMR (400 MHz, CDCl3): δ 1.33-1.80 (m, 9H),2.12 (ddd, J = 7.2, 7.2, 5.7 Hz, 
2H), 2.31-2.38 (m, 2H), 2.70 (dt, J = 14.6, 2.6 Hz, 1H), 2.84-2.88 (m, 1H,), 3.16-3.19 
(m, 1H), 3.32 (s, 3H), 3.60-3.67(m, 1H), 4.30 (br s, 1H), 4.50-4.57 (m, 1H), 6.00 (d, J = 
9.8 Hz, 1H), 6.87 (ddd, J = 9.4, 5.1, 3.2 Hz, 1H) ppm. 
13C-NMR (100 MHz, CDCl3): δ 23.9, 24.5, 29.7, 31.6, 38.2, 39.3, 46.1, 54.0, 56.3, 74.1, 
75.0, 121.4, 145., 164.4 ppm.  
IR: (neat) = 1730 cm-1. [α]D
20= +24.8 (c 0.005, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C14H24NO3:  254.18; Found: 254.14. 
91b:[α]D
20= -21.2 (c 0.8, CHCl3). ESIMS m/z [M+H+]+ calcd for C14H24NO3:  254.18; 
Found: 254.11. 
89b:1H-NMR (400 MHz, CDCl3): δ 1.31-1.80 (m, 8H),2.11 (ddd, J = 12.9, 9.6, 6.0 Hz, 
1H), 2.31-2.40 (m, 2H), 2.61-2.67 (m, 2H), 3.06-3.09 (m, 1H, H-CH-N), 3.26 (br s, 1H), 
3.31 (s, 3H), 3.57-3.63(m, 1H), 4.53 (ddd, J = 12.5, 10.6, 5.3 Hz, 1H), 6.01 (d, J = 9.9 
Hz, 1H), 6.87 (ddd, J = 12.9, 9.6, 6.0 Hz, 1H) ppm.  
13C-NMR (100 MHz, CDCl3): δ 24.6 (t), 25.7 (t), 29.7 (t), 32.7 (t), 38.3 (t), 40.5 (t), 46.9 
(t), 55.8 (d), 56.0 (q), 75.0 (d), 75.5 (d), 121.3 (d), 145.1 (d), 164.2 (s) ppm.  
IR (neat) = 1730 cm-1.[α]D
20= + 12.7 (c 0.001, CHCl3). ESIMS m/z [M+H+]+ calcd for 
C14H24NO3:  254.18; Found: 254.10. 
90b: [α]D
20= -13.9 (c 1.0, CHCl3). ESIMS m/z [M+H+]+ calcd for C14H24NO3:  254.18; 
Found: 254.22. 
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4.6.4. Bivalent compounds 
Synthesis of compound 96 
 
 
A solution of tiocolchicine 95 (0.500 g, 1.2 mmol) in MeOH (20 mL) and 2 N HC1 (9.5 
mL) was heated at 85-90 °C with stirring for 3 days. Then the reaction mixture was 
cooled and the solutionwas neutralized with saturated NaHCO3 solution,extracted with 
CH2CI2, and washed with brine. Theextract was dried over Na2SO4 and the solvent was 
removed under vacuum. The residue was purified by column chromatography on silica 
gel (CH2CI2 /MeOH, 9:1) and crystallization fromCH2Cl2/MeOH to give 0.320 g of pure 
96 in an 70% yield. 
1H-NMR (400 MHz, CDCl3): δ 7.63 (s, 1H), 7.42 (d, J = 10.5 Hz, 1H), 7.22 (d, J = 10.5 
Hz, 1H), 6.54 (s, 1H), 4.01 (s, 6H), 3.73-3.63 (m, 1H), 3.66 (s, 3H), 2.43 (s, 3H), 2.51-
2.38 (m, 4H).  
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Synthesis of compound 98 
 
A solution of deacetylthiocolchicine 96 (0.500 g, 1.34 mmol), sebacic acid (0.271 g, 1.34 
mmol), BOP-Cl (0.409g, 1.68 mmol) and Et3N (220L) in CH2CI2 (10mL) was stirring 
for 2 days at room temperature.The mixture was quenched with HCl 1N and the aqueous 
layer was extracted with CH2Cl2. The organic layer was dried with Na2SO4 and the 
solvent was removed under vacuum. The residue was purified by column 
chromatography on silica gel (EtOAc/ MeOH, 30:1) to give 98 (0.212 g, 28 %) as yellow 
oil. 
1H-NMR (400 MHz, CDCl3): δ 7.58 (s, 1H), 7.34 (d, J = 9 Hz, 1H), 7.10 (d, J = 9 Hz, 
1H), 6.95 (d, J = 5 Hz, 1H), 6.52 (s, 1H), 4.75-4.63 (m, 1H), 3.91 (s, 3H), 3.88 (s, 3H), 
3.62 (s, 3H), 2.56-2.40 (m, 1H), 2.40 (s, 3H), 2.40-2.23 (m, 4H), 2.23-2.15 (m, 2H), 
1.92-1.78 (m, 1H), 1.68-1.49 (m, 4H), 1.38-1.18 (m, 8H). 
ESIMS m/z [M+H+]+ 558. 
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Synthesis of compound 99  
 
 
A solution of N-sebacoyl-N-deacetylthiocolchine (0.030 g, 0.05 mmol), hybrid 86b 
(0.020 g, 0.05 mmol), BOP-Cl (0.016 g, 0.06 mmol) and Et3N (15 L) in CH2CI2 (1mL) 
was stirring for 2 days at room temperature. The mixture was quenched with HCl 1N 
and the aqueous layer was extracted with CH2Cl2. The organic layer was dried with 
Na2SO4 and the solvent was removed under vacuum. The residue was purified by column 
chromatography on silica gel (CH2CI2 /MeOH, 98:2) to give 99 (0.023 g, 53%)as dark 
yellow oil. 
1H-NMR (400 MHz, CDCl3): δ 7.46 (s, 1H), 7.40 (d, J = 8.7 Hz, 1H), 7.16 (d, J = 8.7 
Hz, 1H), 6.93-6.90 (m, 1H), 6.56 (s, 1H), 6.06-6.02 (m, 1H), 5.01 (bs, 1H), 4.78-4.51 
(m, 2H), 4.18-4.02 (m, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.70 (s, 3H), 3.34 (s, 3H), 3.21-
3.05 (m, 1H), 2.98-2.91 (m, 1H), 2.61-2.52 (m, 2H), 2.47 (s, 1H), 2.46-2.18 (m, 11H), 
1.72-1.51 (m, 5H), 1.48-1.18 (m, 17H). 
[α]D
20= -115.9 (c 0.465, CHCl3). ESIMS m/z [M+H+]+ 794.04  
  
4.7. Biological assay 
Tubulin was purified from bovine brain purchased from a local slaughterhouse, 
conserved before use in ice-cold PBS and used as soon as possible. According to Castoldi 
and Popov,149 pure tubulin was obtained by two cycles of polymerization–
depolymerization in a high-molarity PIPES buffer (1 M K-PIPES, pH 6.9, 2 mM EGTA, 
1 mM MgCl2), and protein concentration was determined by the MicroBCA assay kit 
(Pierce). To test the effects on tubulin assembly, stereoisomers were dissolved in 
dimethyl sulfoxide (DMSO), added at 50 μM to a reaction mixture composed of 20 μM 
tubulin, 10 % glycerol, 1 mM GTP in BRB80 buffer (80 mM K-PIPES, pH 6.9, 2 mM 
EGTA and 1 mM MgCl2) and incubated for 30 min at 37 °C. As control conditions were 
used either unmodified thiocolchicine (10 μM) or DMSO alone were employed. At the 
end of polymerization, unpolymerized and polymerized fractions of tubulin were 
separated by centrifugation at 16500 × g for 30 min at 25 °C. The collected microtubules 
were resuspended in SDS-PAGE sample buffer (2 % w/v SDS, 10 % v/v glycerol, 5 % 
v/v -mercaptoethanol, 0.001 % w/v bromophenol blue, and 62.5 mM Tris, pH 6.8) and 
the unpolymerized tubulin was diluted 3:1 with 4 X SDS PAGE sample buffer. Equal 
proportions of each fraction were resolved by a 7.5 % SDS-gel and stained with 
Coomassie blue. Densitometric analyses of stained gels were performed by using ImageJ 
software (National Institute of Health), and data were elaborated using STATISTICA 
(StatSoft Inc., Tulsa, OK). Significant differences were assessed by one-way ANOVA 
with Fisher LSD post hoc test. Experiments were done in triplicate and data are 
expressed as means ±SEM. 
                                                          
149 Castoldi, M.; Popov, A. V. Protein Expression Purif. 2003, 32, 83–88 
4.8. Docking Studies 
Pironetin derivatives were docked in the pironetin binding site in the crystal structure of 
tubulin (1JFF.pdb)150 using AutoDock 4.2 software. Pironetin binding site has been 
identified according to Usui et al.,151 thus the grid box for ligand-protein interaction 
potential evaluation has been centered on Asn258. A cubic box has been employed, with 
50 points per side and a grid spacing of 0.375 Å. A Lamarkian genetic algorithm was 
used for the docking simulations, performing 100 independent runs per molecule. In each 
run, a population of 50 individuals evolved along 27.000 generations and a maximum 
number of 25 million energy evaluations was performed. The best fit (lowest docked 
energy) solutions of the 100 independent runs were stored for subsequent analysis. 
Docked structures have been rendered using VMD. 
                                                          
150 Lowe,J.; Li, H.; Downing, K. H.; Nogales, E.  J. Mol. Biol. 2001, 313, 1045–1057. 
151 Usui, T.; Watanabe, H.; Natayama, H.; Tada, Y.; Kanoh, N.; Asao, T.; Takio, K.; Nishikawa, K.; 
Kitahara, T.; H. Osada Chem. Biol. 2004, 11, 799–806. 
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All tissues of multicellular adult organism are constituted by mature and specialized cells 
and its specific stem cells that are responsible for tissue renewal and repair of damaged 
tissue.  
Stem cells have four distinct properties respect to the other cells in the body:  
1. self-renewal 
2. undifferentiated and unspecialised 
3. differentiation potential into specialised cells of a specif tissue 
4. potential to proliferate extensively while remaining undifferentiated 
The combination of these four characteristics makes stem cells unique. In addition, all 
these properties are often referred to as “stemness”.152 
Even if the cells in adult tissues are various, all cells originate from a single egg after 
fertilization of an ovule by a spermatozoid. Egg fertilization leads to the creation of 
totipotent stem cells, which are the precursors of every tissues of embryo, allantois, 
amniotic sac and placenta. After about four days, these totipotent stem cells go through 
several mitotic divisions to form identical cells and, after this point, they gradually lose 
their high proliferative potential and initiate to specialize, until they become nullipotent 
(Figure 57). 
 
Figure 57: Diverse degree of differentiation potential of stem cells 
The integrity of adult tissues is preserved by the constant replacement of cells that 
cyclally differentiate and die. Thus, in most adult tissues there are groups of progenitor 
cells that multiply and differentiate into specialized tissues of origin and, at the same 
                                                          
152 Mikkers,H.; Frisèn, J. The EMBO Journal 2005, 24, 2715–2719. 
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time, maintain a reserve of undifferentiated cells. These adult progenitor cells are called 
somatic stem cells or adult tissue-specific stem cells. 
Stem cells can divide in two different manners (Figure 58):  
 symmetrically: two daughter cells share the same stem cell feature. It happens 
when their number (stem cell pool) needs to be extended, such as during 
embryonic development and after tissue damage. 
 asymmetrically: one of the progeny continue to be undifferentiated, renewing 
the pool of stem cells, while the other daughter cells can proliferate and 
differentiate into specialized cells to produce new tissue mass. 
 
 
Figure 58: Stem cells asymmetrical and symmetrical division 
A subset of cancer initiating cells have been identified in cancers of the hematopoietic 
system, breast, and brain.153 
This kind of cells have the ability to self-renew and differentiation into a variety of 
mature cells and the proliferative ability to drive continued expansion of the population 
of malignant cells. Consequently, the properties of cancer-initiating cells and normal 
stem cells are closely parallel. Malignant cells with these features have been termed 
“cancer stem cells” to reflect their stem-like properties. 
The cancer stem cells theory proposes that these cancer cells are responsible for tumor 
initiation, progression, maintenance, metastasis and recurrence.  
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Figure 59 shows the situations that are possible for tumors in which cancer stem cells 
play a central role.  
In panel A is shown a primary tumor generated from mutation of a normal stem cell or 
progenitor cell that may create a cancer stem cell. In the second panel, during 
chemotherapy treatment, most of cells in a primary tumor may be destroyed, but if the 
cancer stem cells are not eliminated, the tumor may regrow and cause a relapse. In panel 
C, cancer stem cells arising from a primary tumor may migrate creating metastasis. 
Based on these scenarios it is evident that it is possible to have a recurrence of the tumor 
if cancer stem cells have not been completely destroyed during the treatment.  
It is well known that different cancers are particularly resistant to conventional chemo-
and radiotherapy that usually kill the majority of cancer cells. This clinical response 
could reflect the targeting of the bulk of non-stem cell population. On the other hand, 
several specific key intracellular signaling pathways are involeved in CSCs self-renewal 
and proliferation processes that seem to be promising therapeutic targets. 
For these reasons therapeutic strategies that specifically target cancer stem cells should 
eliminate tumors more effectively than current treatments and reduce the risk of relapse 
and metastasis. 154 
 
Figure 59: Situations involving cancer stem cells 
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In order to develop efficient treatments that can induce a long-lasting clinical response 
preventing tumor relapse it is important to develop drugs that can specifically target and 
eliminate CSCs.155156 
An ideal therapeutic strategy may be sensitize CSCs to radio- and chemotherapy by 
inhibiting their stem properties and then by promoting a direct cytotoxicity. Due to the 
fact that the CSCs population is driven by embryonic signaling pathways, the targeting 
of these pathways could lead to an efficient therapy: in this direction, several drugs for 
the inhibition of embryonic signaling pathways are now underdevelopment. 
Natural products are efficient tools for the exploration of the chemical space because 
they embrace so many varied pharmacophores of wide structural diversity. Recent 
progress have permitted a revival of interest in natural products for the drug discovery 
pipeline.157 
Many natural products have been reported that influence cellular pathways important for 
stem cells and cancer stem-like cells, but have not yet been tested in these cell types 
specifically. Thus, there are many natural compounds to be explored in cancer stem cell 
biology. 
Natural products could have considerable importance in stem cell biology for both 
protection of normal tissue against the side effects of cancer radio- and chemotherapy 
and for tissue regeneration (Figure 60). Well-known anticancer drugs kill the bulk of 
differentiated cancer cells, but leave quiescent and undifferentiated cancer stem-like 
cells untouched. This population of cancer stem-like cells could be responsible for tumor 
relapse even after chemotherapy. In the past few years the results obtained with natural 
products were promising, as several molecules have been described to attack cancer 
stem-like cells. In addition, many of these natural products improve the efficacy of 
chemo- and radiotherapy, making them ideal partners for combination therapy 
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treatments. The field of treating cancer stem-like cells with natural products is still at the 
beginning, but it can be predictable to develop into a rapidly growing area of research. 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: Therapeutical potential of natural products towards stem cells 
In a review recently published from our research group, 158 we summarize the natural 
products that demonstrate activity against CSCs (forty-nine different natural products 
are reported in Figure 61).  
Some of these natural products, grouped into several structural classes (such as 
flavonoids, polyketides, terpenes, alkaloids and many others), are here described.  
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Figure 61: Natural compounds that target CSCs 
 
Flavonoids 
Icaritin (100), a prenylflavonoid isolated from plants of the genus Epimedium, possesses 
many biological and pharmacological activities, such as stimulation of neuronal and 
cardiac differentiation, growth inhibition of human prostate carcinoma PC-3 cells, 
neuroprotective effects and estrogen-like properties.159 Icaritin is able to inhibit the 
growth of breast CSCs and/or progenitor-like cells in a different way from the well-
known antiestrogen tamoxifen. 
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Icaritin induces continued activation of ERK signaling, cell cycle arrest and apoptosis.  
Wogonin (101),160 obtained from extraction of an herbal material of Scutellaria 
baicalensis, is used for the treatment of different types of cancer of diverse organs. The 
inhibition of CSCs growth is possible by a pharmaceutical composition, which is formed 
by wogonin, a pharmaceutically acceptable carrier and also a therapeutic agent such as 
a cytotoxic agent. Wogonin can also be used in combination with radiotherapy or 
immunotherapy. The expression of ABCG2, ALDHA1 and catenin was revealed after 
the treatment with the extract of S. Baicalensis. 
Apigeninidin (102) and luteolinidin (115), which are two constituents of the 3-
deoxyanthocyanidin subclass of flavonoids, are isolated from Sorghum bicolor.161 These 
molecules have been reported to have a cytotoxic activity towards various cancer cell 
lines, such as liver, colon and leukemia. 
Phenolic extract of the sweet sorghum pith and dermal layer were analyzed and revealed 
the presence also of flavonoids, stilbenoids and phenolic acids which possess effective 
in vitro and in vivo anticancer activities. 
The majority of 3-deoxyanthocyanidins is in the dermal layer extract than in the pith 
one. As a result, the dermal layer extract shows a potent in vitro anti-cancer activity 
against the colon cancer cell line: HCT116 and colon CSCs. In addition, luteolinidin 
inhibits colon CSCs proliferation more than apigeninidin.  
Epigallocathechin-3-gallate (110), the most abundant catechin in green tea, is able to 
inhibit self-renewal capacity and the migration of nasopharyngeal CSCs by attenuating 
NF-κB p65 activity. 
Broussoflavonol B (113)162 was isolated from the plant Broussonetia papyrifera 
(Moraceae), which contains different types of flavonoids some of which showed strong 
antimicrobial, antifungal, antioxidant properties and tyrosinase inhibition.  Recently 
broussoflavonol B has been reported to inhibit the growth of ER-positive breast cancer 
cells and also of ER-negative breast cancer stem-like cells. It induces the differentiation 
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of these cells and this could be one of the mechanisms used to limit the growth of ER-
negative breast cancer stem like cells.  
Ugonins J and K (103-104), identified as the main two cyclohexylmethyl flavonoids 
constituents of the rhizomes of H. zeylanica, inhibit propagation of breast CSCs in 
mammosphere cultures and in tumor xenografts. 
Recently, activation of p53, which in turn led to reduction of NANOG, was found to 
mediate the suppressive effect of ugonin J for the propagation of breast CSCs. 
Overexpression of NANOG arrests the suppressive effect of ugonin J. Rhizomes of H. 
zeylanica can be utilized as a complementary medicine for reducing CSC-mediated 
breast cancer relapse.  
Casticin (105) is the main active compound of Fructus Viticis Simplicifoliae, which is 
used in traditional Chinese medicine for the treatment of different types of tumors. This 
compound inhibits self-renewal of glioma stem-like cells, but the effects of casticin on 
lung cancer stem-like cells and its mechanisms of action remain unknown. 
Pomiferin (106), extracted from the fruit of the Maclura pomifera, shows in vitro 
antitumor effects on various types of tumor cell lines from kidney, prostate, breast, lung 
and colon.163 Compound 106 acts on gliomas stem cells by down-regulating stemness-
associated genes20 and could be used as a therapeutic agent in the future.  
Compound 2 (112)164 is a new gamboge derivative able to inhibit proliferation of both 
CSCs and non-CSCs derived from neck and head squamous cell carcinoma. Gamboge 
is a natural anti-cancer medicine that possesses pharmacological effects different from 
those of traditional chemotherapeutical drugs. Compound 2 acts on CSCs by suppressing 
the activation of EGF/EGFR signal pathway leading to down-regulation of multiple stem 
cell-related proteins. For these reasons, it could be a candidate for use in long-term and 
recurrent cancer drug therapies. 
Silibinin (116), a flavonolignan isolated from the milk thistle Silybum marianum, 
demonstrated pro-apoptotic, anti-proliferative and anti-inflammatory activities.  
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Silibinin could interfere with kinetics of CSC by shifting CSC cell division to an 
asymmetric type via the targeting of the various signals associated with the survival and 
multiplication of colon CSC pool.165 
Alkaloids 
Three different alkaloids have been reported to be active against different CSC lines. 
Harmine (114) inhibits the self-renewal and promotes the differentiation of glioblastoma 
stem-like cells. It is able to decrease the tumorigenicity of glioblastoma CSCs (this 
feature was confirmed in vivo).166 Glioblastoma CSCs are also the targets of the well-
known cyclopamine (107) alkaloid that is able to limit significantly drug resistance of 
CD34+ leukemic cells to cytarabine. 
Recently it was demonstrated that cyclopamine- and paclitaxel-squalene conjugates self-
assemble to generate hetero-nanoparticles that have shown combined activities in the 
treatment of ovarian and glioblastoma CSCs.167 
Berberine (111) is an alkaloid isolated from Coptis chinensis, Hydrastis canadensis and 
other species of the family Berberidaceae.26 It shows anti-inflammatory and anti-
bacterial properties, and has been formulated into liposomes for targeted delivery to the 
mitochondria of breast CSCs. These liposomes are able to cross the CSC membrane, 
inhibit the ABC transporters (ABCC1, ABCC2, ABCC3 and ABCG2) and selectively 
accumulate in the mitochondria. Moreover, the pro-apoptotic protein BAX was 
activated, while the anti-apoptotic protein BCL-2 was inhibited, resulting in cell 
apoptosis. 
Terpenoidic derivatives 
Seven different terpene or terpenoid compounds have been reported to arrest the 
proliferation of various types of CSC. Retinoic acids (all-trans) (108) are potent 
differentiating agents. These natural products induce in vitro differentiation of stem-like 
glioma cells and, consequently, are able to induce therapy-sensitizing effects, to impair 
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the secretion of angiogenic cytokines and disrupt stem-like glioma cells motility. The 
anti-cancer effects of all trans retinoic acids are associated with downregulation of 
Wnt/β-catenin signaling.  
Methyl antcinate A (109) is an ergostane-type triterpenoid extracted from the fruiting 
bodies of Antrodia camphorate. It may be a powerful anti-metastasis agent and could 
amplify the expression of p53, which is a tumor supressor able to block the self-renewal 
capability  of breast CSCs.168 Compound 109 is able to suppress the expression of Hsp27 
in breast CSC-like cells and to inhibit their self-renewal capability. 
Another natural product isolated from Antrodia camphorate is Antroquinonol B (117).169 
This compound could inhibit the survival of various cancer cells including breast, 
hepatic, lung and prostate cancer. These different types of cancer can be treated with a 
medicinal formulation composed by antroquinonol B, antroquinonol C and the 
pharmaceutically accepted carriers, for example water, diluents and many others. The 
inhibitory effects on CSCs could be increased through a co-administration of the 
chemotherapy drugs, such as cisplatin or taxol, and the A.camphorata extracts. 
Triptolide (118), the major active substance in Tripterygium wilfordii Hook f., is a 
diterpenoid triepoxide currently being tested in a phase I trial for its safety. It possesses 
pro-apoptotic, anti-inflammatory, and tumor-repressing effects when inhibiting NFAT, 
topoisomerase, proteasome activity, NF-B signaling and heat-shock response.  
Withaferin A (119), a bioactive compound extracted from the plant Withania somniferia, 
has been recently demonstrated to be used as a possible anti-cancer compound showing 
the ability to prevent tumor growth, angiogenesis and metastasis.170 
It is able to suppress tumor growth, target cells expressing CSC markers and to inhibit 
Notch1 and its downstream signaling genes (Hes1 and Hey1) that play a key role in self-
renewal and maintenance of CSCs. These features have been confirmed through the 
treatment of mice bearing human orthotopic ovarian tumors. 
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Gamma tocotrienol (124) is one of the four isoforms of tocotrienols, which are 
components of the vitamin E family. It inhibits prostate cancer cell invasion and makes 
the cells sensitive to docetaxel induced apoptosis. These features suggest that gamma 
tocotrienol may be an efficient therapeutic agent against advanced stage prostate cancer. 
Tocotrienol has been shown to regulate different signaling pathways, such as PI3K and 
NF-B, but the exact mechanisms underlying its antitumor effects are not known. 
Gamma tocotrienol treatment downregulates protein expression of prostate CSC markers 
CD44 and CD133 in prostate cancer cells and it is able to suppress their spheroid 
formation capacity and also interferes with their ability to form tumors in vivo.  
Atractylenolide I (123), a constituent of the sesquiterpene lactone class, is isolated from 
Rhizoma Atractylodis Macrocephalae.171 This compound acts in inhibiting cancer cell 
proliferation and in inducing apoptosis through inactivation of the Notch pathway. 
Atractylenolide I treatment led to the reduction of expressions of Jagged1, Notch1 and 
its downstream effector Hes1/ Hey1.  In addition, 123 is able to inhibit the self-renewal 
capacity of gastric stem-like cells by suppression of their sphere formation capacity and 
cell viability. 
Polyketides 
The macrocyclic tanespimycin (120) is a derivative of the antibiotic geldanamycin. It 
eliminates lymphoma CSCs both in vitro and in vivo by disrupting the transcriptional 
function of HIF1a, a client protein of HSP90. Tanespimycin selectively induced 
apoptosis and led to elimination of the colony-formation capacity of mouse lymphoma 
CSCs and human AML CSCs. However, low concentrations of tanespimycin failed to 
eliminate highly proliferative lymphoma and AML cells (non CSCs), in which the AKT-
GSK3 signaling pathway is constitutively active. The heat shock transcription factor 
HSF1 is highly expressed in non CSCs, but it is weakly expressed in lymphoma CSCs. 
Nevertheless, siRNA-mediated attenuation of HSF1 abrogated the colony-formation 
ability of both lymphoma and AML CSCs.172 Another macrocyclic compound, 
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telomestatin (129), has been demonstrated to make less effective the maintenance of 
glioma stem cells (GSCs) by inducing apoptosis in vitro and in vivo. Telomestatin 
treatment also inhibited the migration potential of GSCs.  
Mithramycin (121), a polyauroleic acid isolated from Streptomyces, is another useful 
antibiotic. This compound was initially evaluated as an anticancer agent in patients with 
cancer during the 1960s and 1970s.  The use of mithramycin was discontinued due to its 
excessive toxicity. Recently, mithramycin showed efficacy in repressing ABCG2 and in 
inhibiting stem cell signaling in thoracic malignancies.173 
Brefeldin A (122) is a lactone antibiotic first isolated from the fungus Eupenicillium 
brefeldianum. It inhibits the transport of secreted and membrane proteins from 
endoplasmic reticulum (ER) to Golgi apparatus, leading to disruption of Golgi function, 
accumulation of unfolded and incompletely processed proteins in ER and, finally, the 
induction of ER stress. Brefeldin A shows various effects including reducing CSCs 
activities, inducing anoikis and inhibiting the migration capacity of the human breast 
cancer MDA-MB-231 cells.174 Western blotting analysis showed that these effects of 
brefeldin A might be mediated by the down regulation of the breast CSC marker CD44 
and the anti-apoptotic proteins Bcl-2 and Mcl-1, in addition to the reversal of epithelial-
mesenchymal transition. 
Salinomycin (133) is an antibiotic isolated from Streptomyces albus. The activity of 
salinomycin is probably due to the interference with the Wnt/β-catenin signaling 
pathway, with the ABC drug transporters and other CSC pathways. Salinomycin is able 
to eliminate effectively CSCs and to induce partial clinical regression of heavily pre-
treated and therapy-resistant cancers, as demonstrated by pre-clinical trials using human 
xenografts in mice and a few pilot clinical studies. The ability of salinomycin to kill both 
CSCs and therapy-resistant cancer cells identify the compound as a promising and potent 
antitumor drug.  
Galiellalactone (134) is a hexaketide metabolite produced by the fungus Galiella rufa 
that possesses promising features for the development of anti-prostate cancer drugs. It is 
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a highly potent and selective inhibitor of IL-6 signaling through STAT3, and is believed 
to inhibit STAT3 signaling by blocking the binding of activated STAT3 to DNA. The 
effects of galiellalactone on ALDH-expressing prostate cancer cells have been studied 
to explore the expression of ALDH as a marker for cancer stem cell-like cells in human 
prostate cancer cell lines. Galiellalactone treatment decreased the proportion of ALDH+ 
prostate cancer cells and induced their apoptosis. The gene expression of ALDH1A1 was 
downregulated in vivo in galiellalactone-treated DU145 xenografts.175 
Cinnamic acid derivatives 
Six different compounds sharing a polyphenolic structure have been used to inhibit 
different types of CSC. Among these, curcumin (125) has been reported to be effective 
against different types of tumors: colon (in combination with dasatinib), breast and brain 
(in combination with paclitaxel). A difluorinated derivative was shown to be active 
against colon cancer stem-like cells.176 Resveratrol (126), a controverted sirtuin 
activator, has been reported to inhibit pancreatic CSC characteristics in both humans and 
KrasG12D transgenic mice when inhibiting pluripotency-maintaining factors and 
epithelial–mesenchymal transition.177 
Honokiol (127), used in traditional Chinese medicine for the treatment of various 
disorders, possesses a biphenolic backbone. It has been demonstrated to be a potent 
inhibitor of colon cancer growth and it is also able to target CSCs by inhibiting the -
secretase complex and the Notch signaling pathway. Recently honokiol has been  
demonstrated to eliminate oral CSCs by the inhibition of their EMT, suppression of 
Wnt/𝛽-catenin signaling and apoptosis induction.178 
6-Shogaol (128) and pterostilbene (130) are natural products that act by increasing the 
sensitivity of basal CSCs to chemotherapeutic drugs and the anticancer activity of 
paclitaxel.  
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6-shogaol and pterostilbene decrease the expression of the surface antigen CD44 on 
basal CSCs and promote -catenin phosphorylation through the inhibition of the 
Hedgehog/Akt/GSK3pathway.  
Rooperol (131), the aglycone of hypoxoside, is the major phenolic constituent of the 
African potato, Hypoxis hemerocallidea (Fish. & C.A. Mey). In the last decade, it has 
been demonstrated that the hypoxoside derivative has pro-apoptotic effect on different 
types of cancer cell lines.76 Rooperol-induced cell death involves cell cycle arrest and 
increases the expression levels of p21Waf1/Cip1 and active caspase-3. This compound kills 
pluripotent cancer stem-like cells in a selective fashion.  
Auraptene (132) is a coumarin derivative extracted from the fruits of edible plants 
belonging to the Rutaceae family. Genovese and Epifano performed studies179 in order 
to elucidate the mechanisms of action and the pharmacological effects of this natural 
product. They showed that auraptene inhibits the formation and growth of colonospheres 
of the FOLFOX-resistant colon cancer HT-29 cells in vitro at a concentration of 10 M. 
The corresponding parental cells were also treated with auraptene. The inhibition in the 
growth and colonospheres formation in FOLFOX-resistant HT-29 was related to a 
concomitant decrease in phospho-epidermal growth factor receptor. These results 
suggest that auraptene could prevent the re-emergence of CSCs. 
Miscellaneous 
Rocaglamide (135) and silvestrol (136), which are flavagline compounds isolated from 
the plant genus Aglaia, demonstrated toxic effect toward leukemia cells. A recent 
study180 demonstrated that rocaglamide and silvestrol preferentially kill phenotypically 
and functionally defined leukemia stem cells, while sparing normal stem and progenitor 
cells. These compounds are significantly more toxic to leukemia cells as single agent or 
in combination with other anti-cancer drugs than clinically available translational 
inhibitors.  
The plant compound isothiocynate sulforaphane (142) is present in high concentration 
in Brassica oleracea and other cruciferous vegetables. This natural product showed 
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interesting activity against three different types of CSCs. One of the first contributions 
in this field reported the inhibitory activity of sulforaphane against breast CSCs and the 
downregulation of the Wnt/β-catenin self-renewal pathway.181 More recently, 
sulforaphane has been reported to regulate the self-renewal of pancreatic CSCs through 
the modulation of the Sonic Hh–GLi pathway182 and to inhibit downstream targets of 
GLi transcription by suppressing the expression of pluripotency-maintaining factors 
(Nanog and Oct-4), and PDGFR and Cyclin D1. As a result, sulforaphane has been 
highlighted as an inexpensive, safe and effective alternative for the management of 
pancreatic cancer.  
Plant extracts 
Berberis libanotica, specifically its roots, has been used in traditional herbal Lebanese 
medicine for rheumatic and neuralgic diseases. 
Berberis are characterized by the presence of different type of secondary metabolites 
with important biological activities. Berberis extracts was found to induce cell cycle 
arrest at the G0-G1 inter phase. In fact, a high increase in the G0-G1 peak was seen in 
response to treatment with the berberis extract, suggesting an arrest at the G0-G1 phase. 
Since other studies have been demonstrated that the anti-proliferative effect of alkaloid-
rich plant extracts is due to G2-M arrest rather than G0-G1 arrest, as in the berberis 
extract, more studies should be done at the molecular level in order to clarify the altered 
pathways in response to berberis treatment.  
Bitter melon (Momordica charantia) is a tropical and subtropical vine, widely grown in 
Africa and Asia.  
Methanolic extracts of bitter melon revelaed great efficacy on both colon cancer stem 
and progenitors cells.183 
In particular, extracts are able to inhibit the growth of colon CSCs in vitro by inducing 
autophagy. 
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We concluded that the natural products here reported could become lead compounds for 
the design of new analogues due to their structural and chemical diversity. The 
development of a single “magic bullet” that will eliminate CSCs and therefore prevent 
the development of metastasis, drug resistance, and relapse is an attractive purpose. 
6. Conclusions  
During my three years of PhD, I’ve been focusing my attention on the study of natural 
products as building blocks and lead compounds for active pharmaceutical ingredients 
production. The research activity regarded seven different topics that could be grouped 
in four main fields: 
 Natural products and large scale production of Active Pharmaceutical Ingriedients 
(API) 
 Industrial synthesis of vincamine 
 Synthesis of lignan derivatives 
 Synthesis of cytisine derivatives 
 Isolation and structural characterization of natural products  
 Isolation and structural elucidation of natural products from Voacanga 
africana 
 Natural products as lead compounds 
 Synthesis of doliculide analogue 
 Pironetin-dumetorine hybrid compounds 
 Natural products and cancer stem cells 
These topics have in common the natural products as critical point, underling the 
importance of Nature as a source for medicinal products.  
It is clear that nature will continue to provide interesting inspirations for the discovery, 
design and synthesis of new drug leads. 
7. Acknowledgments 
This research work was performed thanks to a scholarship financed by Linnea SA, a 
high-quality manufacturer of botanical exracts and pharmaceutical ingredients of natural 
origin for use in the pharmaceutical, nutraceutical and cosmetic industries.  
I want to thanks COST Action CM1407 (Challenging Organic Synthesis Inspired By 
Nature: From Natural Product Chemistry To Drug Discovery) for the financial support 
for international collaboration with Prof. Karl-Heinz-Altmann (ETH-Zurich).
 
